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Abstract: These guidelines incorporate the recent advances in chronic cough 
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pathophysiology, diagnosis and treatment. The concept of cough 
hypersensitivity has allowed an umbrella term that explains the exquisite 
sensitivity of patients to external stimuli such a cold air, perfumes, 
smoke and bleach.  Thus adults with chronic cough now have a firm 
physical explanation for their symptoms based on vagal afferent 
hypersensitivity.  Different treatable traits exist with cough variant 
asthma / eosinophilic bronchitis responding to anti inflammatory 
treatment and non acid reflux being treated with promotility agents 
rather the anti acid drugs. An alternative antitussive strategy is to 
reduce hypersensitivity by neuromodulation.  Low dose morphine is 
highly effective in a subset of patients with  cough resistant to other 
treatments.  Gabapentin and pregabalin are also advocated but in clinical 
experience they are limited by adverse events.  Perhaps the most 
promising future developments in pharmacotherapy are drugs which 
tackle neuronal hypersensitivity by blocking excitability of afferent 
nerves by inhibiting targets such as the ATP receptor (P2X3). Finally 
cough suppression therapy when performed by competent practitioners 
can be highly effective. 
Children are not small adults and a pursuit of an underlying cause for 
cough is advocated.  Thus in toddlers inhalation of a foreign body is 
common.  Persistent bacterial bronchitis is a common and previously 
unrecognized cause of wet cough in children.  Antibiotics, (which, dose, 
and duration need to be determined) can be curative. Paediatric specific 
algorithm should be used.  .  
 





























































Dear Martin and James,
Please find attached the next iteration of the cough guidelines. The text and appendices have been 
altered according to the methodologist’s requirements. I hope this is now acceptable.

































































The full comments of the reviewers were the following:
Reviewer: 1
Comments to the Author
These guidelines present recommendations for the diagnosis and treatment of chronic cough.
The document would benefit from clearer presentation of the recommendations. Some of the 
document narrative uses words indicative of recommendations "recommend" or "suggest", which 
may be conflated with graded recommendation statements.
We thank the reviewer for pointing out possible confusion. The text has now been altered using 
phrases previously used to express the panel’s opinion in the recent bronchiectasis and pneumonia 
guidelines. The words recommended and suggest are reserved for the graded recommendation 
statements.
Each of the research questions should be stated as a PICO, identifying all pieces: Population, 
intervention, comparison, and outcomes. In the text and appendix, the comparison is not disclosed; 
however, that would be helpful for the reader/user to understand.
Text and appendix amended as suggested.
Could the following information be included in the methods section or the abstract: number of 
graded recommendations.
Both the text and abstract amended as suggested.
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Cough is a vital protective reflex preventing aspiration and enhancing airway clearance. 
Pathologically excessive and protracted cough is however a common and disabling complaint 
affecting perhaps 5 to 10 percent of the adult population[1]. When severe, it causes a major 
decrement in the quality of life with comorbidity such as incontinence, cough syncope and 
dysphonia leading to social isolation, depression, and difficulties in relationships[2].
Whilst a wide range of diseases may be associated with chronic cough it has become increasingly 
clear that the majority of adult patients presenting with chronic cough as the primary complaint 
have a common clinical presentation[3]. They often complain of exquisite sensitivity to inhalation of 
environmental irritants such as perfumes, bleaches, and cold air which result in sensations of 
tickling/irritation in the throat and an urge to cough; features suggestive of heightened sensitivity of 
the neuronal pathways mediating cough[4]. There is also a unique epidemiology with two thirds of 
patients being female and the peak prevalence in their fifties and sixties. These observations have 
led to the concept of cough hypersensitivity syndrome as a diagnosis[5]. In children chronic cough 
presents in a markedly different fashion with different aetiology. They are not miniature adults[6]. 
This guideline aims to improve diagnostic accuracy and promote evidence-based therapy for both 
paediatric and adult patients in both primary and secondary care. The guideline is intended for use 
by all health care professionals looking after patients with chronic cough. The guideline has been 
developed by a multidisciplinary international panel of clinicians and scientists with a published 
record of expertise in the field. Input on patient views and preferences was sought via the European 
Lung Foundation who provided an advisory group of patient representatives who expressed their 
preferences via teleconferences, attendance at the ERS Congress, and in writing. They contributed to 
formulating and prioritising the key questions. 
Guideline scope and structure
This guideline follows the hybrid model of the ERS Guidelines Working Group and Science Council[7], 
which combines the scientific rigor of the GRADE framework for key questions of uncertainty with a 
narrative component to reflect the expert consensus of the guideline task force. The narrative covers 
clinically important aspects of chronic cough while the eight key questions systematically explore the 
evidence in areas of clinically important controversy.  
Full details of the methodological process and the analysis of the individual questions can be found 
in the online supplement. Table 1 provides a summary of the eight questions (two diagnostic and six 
therapeutic questions), the level of evidence, and the recommendations arising from the systematic 
review. All other propositions should be regarded as narrative statements.





























































Definition of chronic cough
To define a chronic cough on the basis of longevity is clearly an arbitrary paradigm. Early studies 
used three months based on the MRC definition of chronic bronchitis[8]. More recent guidelines 
have adopted eight weeks in adults[9] and four weeks in children[10]. Inclusion criteria for studies of 
novel antitussives require a cough refractory to treatment to be present for over a year. Whilst some 
patients cough on a daily basis over many years for others the disease has a relapsing and remitting 
course making a definition based purely on a temporal basis difficult to sustain. The diagnosis of 
chronic cough should be made on a global clinical assessment taking into account the other features 
of the phenotypes of cough detailed below. The failure to recognise that the patient is suffering 
from the syndrome of chronic cough may lead to misdiagnosis with the patient labelled as suffering 
from recurrent chest infections, treatment resistant asthma, or exacerbations of COPD.
The commonly used definition of chronic cough in children is 4 weeks, although cough in children 
lasting 3 to 8 weeks has been termed prolonged acute cough[10, 11]. Irrespective of the exact 
duration, chronic cough in children is different from that in adults due to differences in the airway 
morphology, a higher degree of vulnerability to noxious insults, reduced control of the cough reflex 
and differences in maturation of the neurological and immunological system in the different 
paediatric age groups[6]. Chronic cough in children is best seen as a symptom of an underlying 
disease. 
Epidemiology
Cough is a common medical problem and the socioeconomic burden is substantial[12]. However, 
there is no precise data on the burden of chronic cough, probably because chronic cough was 
previously perceived not as a clinical entity but as the consequent symptom from other respiratory 
conditions. There is no agreed definition of chronic cough for use in epidemiological studies[8]. 
A meta-analysis estimated the global prevalence of chronic cough in the general adult population as 
about 10%[1]. It was more prevalent in Europe, America and Oceania than in Asia and Africa. 
Notably, the prevalence of chronic cough in adults is associated with a number of characteristics [13-
16]. In a recent international survey of 10,032 adult patients attending specialist cough clinics, two-
thirds were females and the most common age for presentation was in the sixth decade [3]. The 
distinct demographic pattern is thought to be related to sex differences in central processing of 
cough sensation. The most commonly associated conditions are irritable bowel syndrome, obesity 
and a variety of neuropathic syndromes. Iatrogenic chronic cough from drug treatments is 
frequently unrecognised.
About 35 % of preschool children report cough at any given time in a month[17]; however, so far, no 
studies have systematically compared the prevalence of chronic cough in children worldwide. 
Reports of chronic cough in populations vary between 1% in India[18], 9% in Eastern Europe[19] and 
5-12 % in China with increases in areas with higher air pollution[20]. Subjective perception and 





























































parental reporting of symptoms further biases prevalence reports[21]. Studies comparing 
prevalence rates worldwide are warranted.
Impact on patients
Chronic cough is highly disruptive to the individual affected and those around them. The most 
common reasons why patients with cough seek medical attention include concern about a serious 
underlying illness, vomiting, exhaustion, sleep disruption, social embarrassment, difficulty speaking 
on the telephone, urinary incontinence and annoyance to family, friends and workmates[22].
The consequence of chronic cough is a wide range of complications of coughing[23].  Most impactful 
on Health-Related Quality of Life (HRQOL) are stress urinary incontinence, interference with speech 
and depression[24].  However, there are many others that can be equally bothersome, such as 
syncope. Individuals report, on average, eight adverse symptoms associated with cough[22].  
Stress urinary incontinence is particularly impactful, as cough affects females disproportionately 
compared to males. Female patients with cough and urinary incontinence have worse HRQOL 
compared to those without incontinence[24].  In a quarter of patients, the incontinence is severe but 
rarely discussed. Thus incontinence should be enquired about during a consultation. 
The impact of cough can be assessed and quantified formally with validated HRQOL tools, such as 
the Leicester Cough Questionnaire (LCQ) or the Cough-specific Quality of Life Questionnaire 
(CQLQ)[25, 26]. A strength of cough HRQOL tools is that they can be used to demonstrate the 
efficacy of anti-tussive therapy that is clinically meaningful. In the clinic simply asking “score your 
cough out of 10” is perhaps the easiest subjective measure of treatment success[27] and should be 
asked at each consultation.
In children, the caregiver’s worries about the underlying reason for the cough are a major driver to 
seek medical attention[28]. Paediatric cough is best considered as a symptom of an underlying 
disease. Therefore, the burden of disease is influenced by the quality of the health care system as 
well as health care independent factors such as age range[29-31], gender, and indoor and outdoor 
air pollution[32].
Aetiology and mechanisms
Cough is a vital protective reflex preventing aspiration into the lung. Patients with a poor cough 
reflex such as those who suffer from neurological conditions succumb to recurrent episodes of 
aspiration[33] frequently misdiagnosed as “chest infections”. Cough is a vagal reflex evoked by 
stimulation of afferents carried by the tenth cranial nerve, with their receptive fields primarily in the 
larynx and conducting airways, but also potentially in the alveolar septa and parenchyma of the lung 
(e.g. pulmonary embolism, heart failure, altitude sickness), the pharynx and oesophagus, and even 





























































the ear, with vagal afferents projecting to the auricular canal from the superior vagal (jugular) 
ganglia (Arnolds reflex)[34].
Noxious stimuli (e.g. gastric fluid, protons, cigarette smoke, particulates, hyper or hypotonicity) are 
detected through receptors and ion channels (e.g. TRPV1, TRPA1, TRPV4, ASIC, P2X3) localized to 
vagal afferent nerve terminations in the airways mucosa[35]. The vagal afferent nerves regulating 
cough are polymodal i.e. responding to a variety of different chemical and mechanical stimuli. 
Cellular stress releasing ATP appears to be an important stimulus[36]. Afferent neuronal traffic is 
relayed via vagal axons to the brainstem via at are least two different biochemical pathways[37]. 
Cortical influences modulate the reflex, with women having a greater area of the somatosensory 
cortex devoted to cough. The system is characterised by marked redundancy, plasticity and 
adaption. The neurobiology of cough has recently been comprehensively reviewed[38].
Cough may be caused by excessive stimulation of a normal cough reflex such as occurs following 
inhalation of a foreign body or noxious vapours. However, most patients presenting with a chronic 
cough have features of cough reflex hypersensitivity, responding to exposure to low levels of 
thermal, chemical, or mechanical stimulation[5]. The cough hypersensitivity syndrome has been 
adopted as an overarching diagnosis with the different phenotypes dependent on the type and 
location of the inflammation seen.  Both central and peripheral mechanisms have been postulated 
for cough reflex hypersensitivity[39].
The aetiological mechanisms for cough hypersensitivity remain controversial and are dealt with in 
greater depth below. In the airways, T2 inflammation occurs in approximately a quarter of patients 
although this may be through stimulation of the innate immune system rather than atopy[40]. This 
gives rise to the phenotypes of cough variant asthma and eosinophilic bronchitis[41]. Reflux, 
particularly nonacid gaseous airway reflux, and oesophageal dysmotility are common features[42]. 
Central mechanisms for cough hypersensitivity have also been postulated, with circumstantial 
supportive evidence generated using fMRI[43]. It is suggested that there is an underlying 
neuropathic process responsible for cough hypersensitivity[44], a view that is supported by the 
development of cough in certain forms of hereditary somatosensory neuropathy[45].
Phenotypes of chronic cough
Asthmatic Cough / Eosinophilic Bronchitis
Asthma is a clinical diagnosis. There is no agreed single diagnostic test to diagnose or exclude asthma 
and because of its heterogeneous presentation opinions differ on how to describe the syndrome in 
patients with chronic cough. Eosinophilic inflammation may be a useful biomarker of asthmatic 
cough and may have utility in directing therapeutics. All adults and children with chronic cough may 
be assessed for eosinophilic inflammation. Sputum eosinophilia is perhaps the most accurate 
indicator, but is not routinely available, time-consuming, and requires expert interpretation. Exhaled 
nitric oxide can be used as a surrogate marker of eosinophilic airway inflammation and steroid 
responsiveness in classic asthma, but its role in asthma and chronic cough is questioned below. A 
meta-analysis of observational studies showed exhaled nitric oxide to have a relatively high 
specificity of 0.85 in predicting asthma among adult patients with chronic cough[46]; however, there 





























































is still no consensus on the cut-off level for the diagnosis. Blood eosinophilia is a simple and readily 
available measure, but is characterised by diurnal and seasonal variability[47] so multiple 
assessments should be made[48]. An eosinophil count of greater than 0.3 cells/µL may be taken to 
indicate eosinophilic airway inflammation[49, 50].
Three subgroups of asthmatic cough have been recognised. Classic asthma is characterised by 
airflow variability and bronchial hyperresponsiveness. Spirometry is thus an obligatory investigation. 
Cough variant asthma (CVA) ) was originally described as those patients with asthma and cough as 
the sole symptom and where treatment with bronchodilators improved coughing 
 [51]. Opinions vary as to whether this should be sought by performing bronchial provocation test. 
Some centres see this as an important part of the workup, whereas others find it adds little to the 
patient pathway. The third form of asthmatic cough is eosinophilic bronchitis (EB) without 
bronchoconstriction or hyperresponsiveness. The lack of these latter two features has been 
suggested to indicate that EB is a separate condition – Non-Asthmatic Eosinophilic Bronchitis[52]. 
However, in chronic cough communication with patients and other health care professionals may be 
enhanced if it is considered as part of an asthmatic spectrum, particularly as all three subgroups can 
respond to anti-inflammatory asthma therapy. The vital importance of establishing or refuting the 
diagnosis of asthmatic cough lies in the therapeutics (discussed in questions below) as it may be 
considered as a treatable trait. 
Reflux cough
The role of reflux, oesophageal dysmotility, and aspiration in chronic cough is controversial.  Its 
prevalence has been estimated from 0 to almost 100%.  Early studies using the criteria of acid reflux 
found a low incidence and poor temporal relationship[53]. A systematic review[54] found no 
significant benefits over placebo of PPIs in patients without acid reflux and only modest benefits 
even in patients with acid reflux. It was suggested that non-acid reflux, both liquid and gaseous, may 
be an aetiological factor[55].  However no technology reliably detects such reflux and the diagnosis 
relies on the clinical history supported by validated questionnaires such as the Hull Airway Reflux 
Questionnaire (HARQ)[56] (see issc.info for multi lingual versions) or Reflux Symptom Index[57].  The 
picture is complicated by the observation that there is a high prevalence of oesophageal dysmotility 
in patients with chronic cough[42] and thus oesophago-pharyngeal reflux rather than GORD/GERD 
may be the problem.  
Many of the signs and symptoms associated with chronic cough are explicable by reflux and 
aspiration.  Voice change, nasal symptoms and dysgeusia are common[58].  Frequent “chest 
infections” bronchitis, and even frank bronchiectasis may be the consequence rather than the cause 
of cough through repeated aspiration. Unsurprisingly following aspiration of contents from the GI 
tract there is an inflammatory response.  This might be neutrophilic or eosinophilic giving rise to 
asthmatic cough and mucus hypersecretion[59].
Postnasal drip syndrome/Upper airways cough syndrome





























































The 2006 American College of Chest Physicians (ACCP) cough management guidelines suggested the 
term upper airways cough syndrome (UACS) to describe the variety of signs and symptoms 
previously referred to by other synonyms including postnasal drip syndrome, rhinitis and 
rhinosinusitis[60]. The revised nomenclature however did not resolve ongoing controversy regarding 
the existence of this syndrome and the mechanism(s) by which it may induce chronic cough.
 A first-generation antihistamine and decongestant were recommended as the treatment, in the 
absence of adequate randomised controlled trial (RCT) evidence.  The first-generation 
antihistamines however are thought to be antitussive through their action as centrally penetrant 
anticholinergics[61].
However UACS could be accepted as an aetiology of chronic cough in some patients by acting as a 
trigger for cough hypersensitivity although the mechanism remains obscure. The absence of 
evidence for localised treatment might suggest that upper airway symptoms merely reflect 
generalised airway inflammation consequent to asthma or airway reflux.
Iatrogenic cough
Chronic cough occurs in approximately 15% of patients taking angiotensin-converting enzyme 
inhibitors (ACEI). ACEI increases the sensitivity of the cough reflex in most subjects[62] and it is 
probable that additional factors are required to produce clinical impact. Since the reflex is reset 
there may be no close temporal relation to drug administration or withdrawal and the cough[63]. No 
patient with a cough or who develops one should be given ACEI. Angiotensin II antagonists do not 
affect the cough reflex.
Drugs such as bisphosphonates or calcium channel antagonists may worsen pre-existing reflux 
disease causing increased cough. Prostanoid eye drops such as latanoprost may descend the lacrimal 
duct irritating the pharynx[64].
Chronic cough in children
Chronic cough in children differs from that in adults in terms of common aetiologies and 
management and is increasingly defined as cough that lasts more than 4 weeks. Regardless of 
setting and age, children with chronic cough should be evaluated carefully using children-specific 
protocols[65]. 
During childhood, the respiratory tract and nervous system undergo a series of anatomical and 
physiological maturation processes that influence the cough reflex. Additionally, immunological 
responses undergo developmental and memorial processes that make infection and congenital 
abnormalities the predominant causes of cough in children[66]. Thus, tracheomalacia, protracted 
bacterial bronchitis (PBB), and bronchiectasis occur, in addition to common aetiologies such as 
asthma and post-infectious cough[67]. PBB is not a new entity and PBB-like conditions were being 
reported in the 1980s[68]. An ERS task force has recently advanced a reliable definition of PBB for 
day-to-day clinical practice when all three of the following criteria are fulfilled: 1) Presence of 





























































continuous chronic (>4 weeks’ duration) wet or productive cough; 2) absence of symptoms or signs 
(i.e. specific cough pointers) suggestive of other causes of wet or productive cough; and 3) cough 
resolved following a 2–4-week course of an appropriate oral antibiotic[69]. PBB may be a precursor 
of bronchiectasis[70]. 
Initial assessment for chronic cough in children includes a detailed history and thorough physical 
examination to identify possible specific causes due to an underlying disease.  A sudden onset of 
cough in an otherwise healthy preschool child may suggest foreign body aspiration and requires 
bronchoscopy.  A chest x-ray as well as spirometry in collaborative children is essential. If specific 
cause for the chronic cough is suspected, further investigations are necessary. In case no specific 
pointers are detected and chest x-ray and spirometry are normal then the guideline panel 
considered that we suggest another period of observation of up to four weeks was indicated.  In 
case of persistence of cough differentiate between dry and wet cough[71].  Exposure to airborne 
irritants (e.g. tobacco exposure, combustions, traffic related exposure etc.), allergen exposure or 
postinfectious cough may be a reason for dry chronic cough. In case of wet cough, sputum cultures 
should be attempted.
Habit/tic cough is another aetiology found particularly in children, manifesting the core clinical 
features of tics including suppressibility, distractibility, suggestibility, variability, and the presence of 
a premonitory sensation whether the cough is single or one of many tic. The formerly called 
psychosomatic cough should now be labelled somatic cough disorder and this diagnosis should only 
be made after an extensive evaluation that includes ruling out tic disorders and uncommon causes 
of chronic cough[72].
Psycho-morbidity is present in all patients with chronic cough with a variety of aetiologies, and tends 
to decrease following successful treatment[73]. There are limited criteria for the diagnosis of 
psychogenic (or somatic) cough and features of psychogenic cough reported in the literature are not 
unique to psychogenic cough[72]. Somatic cough disorder has been commonly used to describe 
cough without obvious aetiology. However, recent research has revealed neurobiological 
phenomena are responsible for psychogenic cough[43]. The presence of depression and/or anxiety 
cannot be used to diagnose psychogenic cough because, as in adults, patients with a persistently 
troublesome chronic cough can develop these psychologic symptoms when their coughs remain 
untreatable. Non-pharmacological trials of hypnosis or suggestion therapy or combinations of 
reassurance, counselling, or referral to a psychologist and/or psychiatrist have been suggested in 
management, but such strategies lack an evidence base.
Chronic refractory cough
A proportion of patients with chronic cough, particularly among adults, have persistent cough 
despite thorough investigation and treatment according to published practice guidelines. Terms such 
as idiopathic chronic cough, unexplained chronic cough and chronic refractory cough have been 
utilized to describe this clinical condition[74]. Successful trials of drugs with neuromodulatory effects 
such as opiates, gabapentin, and P2X3 antagonists suggest that aberrant neurophysiology is likely to 
underlying this condition. Here the term chronic refractory cough is used to indicate that the cough 
is refractory to conventional treatment of cough-associated conditions or traits.





























































Chronic cough in other diseases
Most chronic respiratory disease is associated with cough.  Physical distortion of the airway such as 
occurs in lung cancer or the bronchorrhea of cystic fibrosis and chronic bronchitis produces cough by 
mechanical effects.  However cough hypersensitivity through cell damage and inflammation 
underlies much of the increased cough seen in other pathologies.  The different pathological 
processes in individual conditions contribute to the disease specific, heterogeneous, aetiology of 
cough in other lung disease.
As an example, cough in interstitial lung diseases (ILDs) is common with a prevalence of 30 to 90%. 
Patients with ILD often respond poorly to general anti-tussive therapy. In an open label study of 
idiopathic pulmonary fibrosis (IPF) pirfenidone reduced 24-hr objective cough counts and improved 
cough-related QoL[75]. Reformulated sodium cromoglicate improved 24-hr objective cough by 31% 
in patient with IPF whereas there was no effect in chronic idiopathic cough[76]. It seems likely that 
each individual respiratory condition will have its own profile dependent on the tussigenic factors 
expressed in that disease. 
Chronic cough, tobacco and nicotine
Smoking is the major remediable cause of chronic cough and is inextricably linked to chronic 
obstructive pulmonary disease (COPD). Epidemiological studies have demonstrated a relationship 
between cumulative smoking exposure and chronic cough[77]. Furthermore, smoking history and 
current cigarette consumption are predictors of objectively-measured cough frequency[78]. A 
natural inference therefore would be to ascribe a protussive effect to tobacco smoke and its 
components. Research in otherwise healthy smokers and nonsmokers, however, has provided 
additional insights, some of which contradict general assumption.
Multiple studies of otherwise healthy smokers have demonstrated suppressed cough reflex 
sensitivity to inhaled capsaicin[79, 80]. The development of electronic cigarettes (e-cigs) provided a 
mechanism of non-combustible delivery of nicotine to the lungs. One tobacco cigarette equivalent 
induced significant suppression of cough reflex sensitivity[81]. These data are consistent with 
previous clinical observations of transient increase in cough within the first month after smoking 
cessation[82]. All patients should quit smoking and they should be warned there may be a transient 
increase in coughing. For those unable to quit because of excessive coughing e-cigs may be a 
supportive therapy[83].
Assessing cough in the clinic
Initial assessment





























































The history, examination, and investigations for patients with chronic cough are performed to 
exclude treatable traits of the disease for which directed therapy can be offered.  The guideline 
panel placed higher value on We suggest it is better to control of any on-going pathology such as 
reflux or airway eosinophilia before currently available neuro-modulatory treatments are 
considered. A detailed history and examination should be directed to exclude malignancy, infection, 
foreign body inhalation or the use of an angiotensin converting enzyme (ACE) inhibitor. The impact 
of cough should be assessed either by recording simple measures such a cough score out of 10 or 
VAS or by more detailed, validated measures of cough quality of life (LCQ or CQLQ).  Validated 
questionnaires may help to detect features of airway reflux (HARQ and RSI) and airway 
hypersensitivity[84]. 
Initial evaluation should include spirometry and a recent chest x-ray (CXR) (Good Practice 
Statement). 
Chest CT
Question 1: Should chest CT scan be routinely performed on chronic cough patients with normal 
chest X-ray and physical examination?
We suggest that clinicians do not routinely perform a chest CT scan in patients with chronic cough 
who have normal chest x-ray and physical examination (conditional recommendation, very low 
quality evidence).
Some prospective and retrospective cohorts identified CT findings in a range of 6.5% to 58% of 
patients with cough and normal CXR; however the causal relationship was either not specified or 
considered as unlikely related to cough [85-87]. There is a concern about potential cancer risk from 
CT radiation exposure [88, 89]. Thus the potential radiation risk needs to be weighed against 
possible diagnostic yields, particularly in susceptible populations such as children and females.
Further investigations to identify treatable traits in chronic cough
Further investigations for asthma, EB, reflux and oesophageal dysmotility, and rhinosinusitis should 
be considered depending on the clinical history. 
Asthma and eosinophilic inflammation
Objective evidence of classic asthmatic cough conventionally requires some evidence of variable 
airflow obstruction such as peak flow variability, or reversibility to salbutamol of more than 12-15%. 
However, these investigations have a very low negative predictive value particularly in patients with 
normal lung function[86].  Further investigation of bronchial hyper-responsiveness (BHR) using 
either methacholine or histamine inhalational challenge is advocated by some although its utility in 
diagnosis is questioned. Evidence for ongoing airway eosinophilic inflammation can be sought by 
performing differential cell counts on samples from sputum induction or bronchoalveolar lavage. In 
such cases, elevated eosinophils (>3%) in the airways in the absence of BHR would suggests EB, 
which has been reported in up to 13% of patients attending cough clinics[41]. However, most 
centres do not have such facilities available, hence a non-invasive alternative is the use of fractional 
exhaled nitric oxide (FeNO) in breath or blood eosinophilia as a surrogate marker to assess airway 
eosinophilia. The clinical usefulness of FeNO or blood eosinophils in aiding diagnosis or predicting 
treatment response in patients with chronic cough has not yet been systematically evaluated[90]. 





























































Question 2: Should FeNO/blood eosinophils be used to predict treatment response to 
corticosteroids/anti-leukotrienes in chronic cough?
There is a need for convenient and practical tests for predicting anti-inflammatory treatment 
responses in patients with chronic cough. However, there is a still lack of quality evidence. Placebo-
controlled trials are warranted to assess their utility and also consensus is required on threshold 
levels in patients with chronic cough. 
One RCT [91] in adult non-smoking patients with chronic cough shows that baseline FeNO levels 
(greater than 30ppb or lower than 20 ppb) did not predict response to anti-leukotrienes. Cough 
frequency and quality of life were similar between high and low FeNO groups at the end of 
treatment. Observational studies suggested that non-responders to ICS may have significant lower 
levels of FeNO at baseline [92, 93], but the findings were not consistent[94]. Randomised placebo-
controlled trials are required to validate the utility or otherwise of FeNO as a predictor of treatment 
response in chronic cough patients.  Currently, there is no study examining the predictive utility of 
blood eosinophils in patients with chronic cough. 
Given the uncertainty of diagnostic testing, a therapeutic trial may be indicated for asthmatic cough. 
In adults oral prednisolone for one week may cause a dramatic decrease in cough[95]. Inhaled 
corticosteroids (ICS) may be used when oral is contraindicated and is preferable in children.  
However it may be less effective since inflammation in CVA and EB is located in different parts of the 
airway from that seen in classic asthma[96], and may be driven by other pathways such as the innate 
immune system[97]. This also may explain the greater efficacy of systemic leukotriene antagonists 
such as montelukast in asthmatic cough[98].
Reflux and dysmotility
In the absence of peptic symptoms 24-hour pH monitoring for the investigation of reflux disease is 
not helpful. However abnormal oesophageal physiology is very common in patients with chronic 
cough and may be detected with poor sensitivity by a barium swallow. More accurately, high 
resolution oesophageal manometry provides diagnostic information as to the site and mechanism of 
dysmotility in the majority of patients[42].
The upper airways
In patients who report upper airway symptoms fibre optic laryngoscopy may be performed. The 
larynx is commonly found to be red and inflamed. However, the test has poor sensitivity and 
specificity. In select patients, laryngoscopy may be useful in identifying inducible laryngeal 
obstruction (ILO) associated with cough, and this may help plan the need for future cough control 
therapy[99]. Rhinoscopy may be helpful in identifying polyps and clearing mucus from blocked 
sinuses in patients with recurrent sinus and nasal inflammation, but routine laryngoscopy, 
rhinoscopy or CT sinuses is not advised recommended as nasal findings are not directly associated 
with cough[100, 101].
Chronic cough in children





























































Chronic cough in children should be approached using paediatric-specific cough management 
protocols or algorithms and basing the management on the aetiology of the cough. The most 
common recognized aetiologies for chronic cough in children are post-infectious or natural 
resolution, asthma and PBB.  Refer to the flow diagram on page x.
Treatment of chronic cough
Even after a thorough clinical assessment it may be impossible to identify which of the treatable 
traits is most likely to underlie the patient’s chronic cough. Individuals may vary in their response to 
the different modalities of treatment. The guideline panel considered We therefore recommend that 
it was preferable to undertake sequential therapeutic trials should be undertaken of each agent in 
turn and if no responses waeres observed therapy should be stopped. The length of the trial 
depends on the pharmacology. Response to morphine occurs within one week. ICS may take a 
month. If successful, the guideline panel believes that we recommend the treatment may be 
continued for several months to allow for resolution of neuronal hypersensitivity (Good Practice 
Statement). Treatment may be then withdrawn to determine whether remission has occurred.  The 
reader is referred to table 1 for commentary on the recommendations below. 
Anti-asthmatic drugs
Question 3:  Should anti-asthmatic drugs (anti-inflammatory or bronchodilator drugs) be used to 
treat patients with chronic cough?
We suggest a short-term ICS trial (2-4 weeks) in adult patients with chronic cough (conditional 
recommendation, low quality evidence).
Ten RCTs were identified for chronic cough, but with considerable heterogeneity in patient 
characteristics, intervention, measured outcomes and treatments responses. Two studies of chronic 
cough patients (unselected by airway hyper-responsiveness or sputum eosinophilia) found 
significant benefits from a 2-week high dose ICS treatment over placebo in reducing cough 
severity[102] and subjective cough frequency. However, in a study of patients with chronic cough 
and at least one additional respiratory symptom but with normal lung function, an 8-week medium 
dose ICS treatment did not produce a significant improvement in cough severity score over placebo. 
In two studies of patients with non-asthmatic chronic cough (defined by negative methacholine 
airway-hyper-responsiveness), ICS treatment was not superior to placebo in improving cough 
outcomes[103, 104]. In studies of patients with chronic bronchitis or chronic obstructive pulmonary 
disease (COPD), ICS treatment did not significantly improve subjective cough scores compared to 
placebo[105-108]. 
Although the original definition of CVA demonstrated improvement of coughing in a small number of 
asthmatic subjects with bronchodilator therapy, we do not recommend the use of a lone 
bronchodilator therapy as maintenance treatment for cough in asthmatic patients. The current GINA 
2019 guideline recommend the use of low dose ICS-formoterol or low dose ICS. Effectiveness of 
these treatment regimes in CVA and asthmatic cough still requires further evaluation.





























































We suggest a short-term ICS trial in children with chronic dry cough (2-4 weeks) (conditional 
recommendation, low quality evidence). 
Two RCTs were identified. A trial of 50 children aged 1-10 years with persistent nocturnal cough 
found that there is a modest but significant benefit in objective cough frequency from a 2-week 
course of high dose ICS over placebo[109]. Another study of 43 children aged 6-17 years with 
recurrent cough (two episodes of cough, each lasting two weeks in the past 12 months) found no 
significant effects of ICS in cough outcomes at 4-5 weeks; there was no association between ICS 
treatment response and airway hyper-responsiveness in hypertonic saline challenge[110].
We suggest a short-term anti-leukotriene trial (2-4 weeks) in adult patients with chronic cough, 
particularly in those with asthmatic cough (conditional recommendation, low quality evidence).
Three RCTs were identified. Two clinical trials[111, 112] of adults with cough variant asthma (defined 
by clinical history, absence of other common diseases, and presence of methacholine hyper-
responsiveness) found significant benefits of oral anti-leukotriene (for 2-4 weeks) over placebo in 
subjective cough frequency or severity scores. However, a single trial of adults with atopic cough 
(defined as chronic cough with increased capsaicin cough sensitivity and atopic constitution but 
without bronchial hyper-responsiveness) did not find any significant benefits of 2-weeks 
montelukast over placebo in subjective cough score[113]. Adverse drug event was reported in one 
study, without any significant event related to the treatment[112]. There are no trials conducted in 
unselected chronic cough patients.
No RCTs are available for children.  Mild, transient neuropsychiatric adverse events are common 
(>10%) in children[114].
We suggest a short-term trial (2-4 weeks) of ICS and long-acting bronchodilator combination in 
adults with chronic cough and fixed airflow obstruction (conditional recommendation, moderate 
quality evidence).
A single RCT[108] of COPD patients with chronic bronchitis, smoking history and at least one episode 
of COPD symptom exacerbation in the previous year found that the combination of 50 μg salmeterol 
and 500 μg fluticasone twice daily produced a significant improvement in cough severity score 
compared to placebo (scale: 0-4) (mean difference: −0.09; 95% CI: −0.17 to −0.01), whereas 
salmeterol or fluticasone monotherapy did not. The treatment was well-tolerated, except for an 
increased incidence of oropharyngeal candidiasis (8% in the combination treatment group vs. 2% in 
the placebo group).
Anti-acids
Question 4: Should anti-acid drugs (PPIs and H2 antagonists) be used to treat patients with chronic 
cough?
We suggest that clinicians do not routinely prescribe anti-acid drugs in adult patients with chronic 
cough (conditional recommendation, low quality evidence).
Anti-acid drugs are unlikely to be useful in improving cough outcomes, unless patients have peptic 
symptoms or evidence of acid reflux. Systematic reviews have found no significant benefits from PPI 





























































over placebo in adult patients without acid reflux and possible modest effect in those with acid 
reflux [54]. Faruqi et al. found no significant benefits of esomeprazole 20 mg twice daily therapy 
over placebo in subjective cough frequency, cough severity, or cough-specific quality of life scores at 
8 weeks. There was a trend towards greater improvement in the PPI treatment arm in patients with 
dyspepsia[115]. In a study of chronic cough patients with rare or no heartburn, there were no 
benefits from a long-term high-dose PPI therapy (esomeprazole 40 mg twice daily for 12 weeks) in 
cough-specific quality of life or cough scores [116]. Whilst PPI is frequently considered safe 
observational studies reported potential risks of iron deficiency, vitamin B12 deficiency, 
hypomagnesemia, Clostridium difficile–associated diarrhoea, osteoporosis-related bone fracture, 
dementia, or pneumonia[117, 118].  However, direct evidence about the safety issues is lacking in 
chronic cough population. There is not enough evidence to draw a specific recommendation for PPI 
use in children.
Drugs with promotility activity
Question 5: Should drugs with promotility activity be used to treat patients with chronic cough?
 There is currently insufficient evidence to recommend the routine use of macrolide therapy in 
chronic cough. A one month trial of macrolides can be considered in the cough of chronic bronchitis 
refractory to other therapy, taking into account local guidelines on antimicrobial stewardship.  
(conditional recommendation, low quality evidence). 
No RCTs have been undertaken with pro-motility agents, such as baclofen, metoclopramide or 
domperidone, in patients with chronic cough. There are three RCTs with macrolides with pro-
motility activity in adult patients with chronic cough. One study of patients with COPD GOLD stage ≥ 
2 and chronic productive cough demonstrated a significant benefit of a 12-week low dose 
azithromycin (250 mg three times a week) over placebo for improving cough-specific quality of life 
(LCQ; MD 1.3; 95% CI 0.3 to 2.3; p=0.01)[119]. Adverse events were not significantly different. In two 
other trials of patients with unexplained cough or treatment-resistant cough, low-dose macrolide 
treatments (erythromycin 250 mg daily for 12 weeks or azithromycin 250 mg three times a week for 
8 weeks) did not provide significant benefits over placebo for objective cough frequency, cough 
severity or cough-specific quality of life[120, 121]. 
Neuromodulators
Question 6: Which cough neuromodulatory agents (pregabalin, gabapentin, tricyclics and opiates) 
should be used to treat patients with chronic cough?
We recommend a trial of low dose slow release morphine (5-10 mg bd) in adult patients with 
chronic refractory cough (strong recommendation, moderate quality evidence).
A single RCT of low dose morphine (5 to 10 mg twice daily) in adults with chronic refractory cough 
found significant benefits over placebo in reducing cough severity (self-reported scale 0 to 9 points) 
(MD -1.96 points; 95%CI -1.09 to -2.11) and improving cough-specific quality of life (LCQ) (MD 2 
points; 95%CI 0.93 to 3.07)[27]. Common adverse effects in this clinical trial were constipation and 
drowsiness in patients receiving morphine.
We suggest a trial of gabapentin or pregabalin in adults with chronic refractory cough (conditional 
recommendation, low quality evidence).





























































A single RCT of gabapentin therapy (maximum tolerable daily dose of 1800 mg) in adults with 
chronic refractory cough found significant benefits over placebo in improving LCQ (MD 1.8 points; 
95%CI 0.56 to 3.04) and reducing cough frequency (although only of a single hour of observation) 
(MD -27.31%; 95%CI -2.87 to -51.75) and severity (VAS 0 to 100 points) (MD -12.33 points; 95%CI -
1.23 to -23.23)[122]. There is one RCT of pregabalin therapy (300 mg daily) in adult patients with 
chronic refractory cough alongside speech pathology therapy [123]. Pregabalin plus speech 
pathology therapy significantly improved cough-specific quality of life (LCQ) (MD 3.5 points; 95%CI 
1.11 to 5.89: MID: 1.3 points) and cough severity (VAS 0 to 100 points) (MD -25.1 points; 95%CI -10.6 
to -39.6) over placebo plus speech pathology therapy.  There was no significant reduction in cough 
frequency. There is no comparison between pregabalin and placebo alone. An explanation for a lack 
of effect on cough frequency is that centrally acting therapies may be altering perception of cough 
rather than having truly anti-tussive effects. They could also be affecting the intensity of coughing 
without reducing the frequency.  Dizziness, fatigue, cognitive changes, nausea, or blurred vision are 
common side effects of gabapentin and pregabalin.  A systematic review revealed that the risk of 
withdrawal due to adverse events is 2.3 times higher than placebo[124].
Agents acting directly on cough hypersensitivity rather than the treatable traits causing 
hypersensitivity is a promising strategy for future developments. Current agents have been shown to 
be effective in adults, but the side effect profile is significant and may be mitigated by the use of 
lower doses than those used to treat pain.
Cough neuromodulators, such as opioids, gabapentin or pregabalin, are not used in children, due to 
reported adverse events, possible toxicity and lack of clinical trials[125]. 
Non-pharmacological cough control therapy
Question 7: Should non-pharmacological therapy (cough control therapy) be used to treat patients 
with chronic cough?
We suggest a trial of cough control therapy in adult patients with chronic cough (conditional 
recommendation, moderate quality evidence).
Two RCTs of physiotherapy/speech and language therapy (cough control therapy) in adult patients 
with chronic refractory cough have been reported. Vertigan et al. demonstrated that the 2-month 
intervention significantly reduced subjective cough score compared to placebo treatment (self-
reported scale 2 to 10 points) (MD 2.8 points; 95% CI 1.3 to 4.0)[126]. In a multi-centre study by 
Chamberlain et al., the weekly intervention for 4 weeks showed benefits over placebo for cough-
specific quality of life (LCQ; 1.53 points; 95% CI 0.21 to 2.85) and objective cough frequency (fold 
change) (0.59; 95% CI 0.36 to 0.95), but not for VAS severity or other quality of life outcomes. The 
improvements in the intervention group were sustained up to 3 months, but not beyond. No 
adverse effects were found[127]. There are no RCTs in children. This is a complex intervention that 
requires further study to determine which components are of value. Experienced practitioners 
should undertake cough-directed physiotherapy and speech and language therapy interventions.
Antibiotics for chronic wet cough in children
Question 8: In children with chronic wet cough without with warning signs, normal chest x-ray, and 
normal spirometry and no warning signs, should a trial of antibiotics be used?





























































A trial of antibiotics is suggested in children with chronic wet cough with normal chest x-rays, normal 
spirometry and no warning signs (conditional recommendation, low quality evidence).
A single RCT of antibiotics in young children (mean age 1.9 years; IQR 0.9 to 5.1) with chronic wet 
cough (>3 weeks)[128]. A 2-week regimen of twice daily oral amoxycillin clavulanate treatment (22.5 
mg/kg/dose) was compared. Cough resolution rates (defined as >75% reduction) were significantly 
higher in children who received amoxycillin clavulanate compared with those who received placebo 
(48% vs. 16%; p=0.015). Side effects were not significantly different between two groups; however, 
mild diarrhoea was found slightly more in the in the amoxycillin clavulanate group than in the 
placebo group (5/25 vs. 2/25)[128]. 
Future directions and new drugs
As the population ages the worldwide prevalence of chronic cough increases. This is partially due to 
an increasing awareness of the problem, changing diagnostic labels, air pollution, and increased 
efforts in educating health professionals. Changes in society such as the rise in obesity will also 
predispose to a greater incidence of causal factors related to chronic cough. Our understanding of 
the pathophysiological basis of chronic cough has dramatically advanced over the past decade with 
the realisation that neuronal hypersensitivity underlies the syndrome. Desensitisation through the 
use of agonists such as capsaicin has recently shown promise as a therapeutic strategy[129]. 
However, we are still grossly ignorant of the complex interplay in the peripheral and central nervous 
system. fMRI has given us insights into the central pathways of cough and will continue to do so in 
the future. However it is the pharmacology of the peripheral afferent vagus which has given us the 
most hopeful future therapeutic developments.
Much effort was devoted in the development of blockers of the nociceptors, mainly TRP receptors, 
which are responsible for the irritant sensation leading to the tickle that precedes cough. Whilst 
effective in animal models these agents have failed in the clinic[130, 131]. The substance P 
antagonist orvepitant has shown modest efficacy in phase 2 studies. One class of drugs has however 
produced a dramatic improvement in chronic cough in phase 2 studies[132]. ATP is released during 
cell damage and acts on afferent sensory nerves through P2X3 purinergic receptors. The first 
antagonist, gefapixant, has been studied in several hundred patients with chronic cough with 
resolution in the majority. Other compounds in this class are in development and we may have the 
first effective drugs for chronic cough in over 40 years.
Research gaps and recommendations for future studies
Because chronic cough has only recently been recognised as a separate entity a major challenge is 
the promulgation of the concept of cough hypersensitivity in adults and conditions such as 
protracted bacterial bronchitis in children.  Whilst the aim of these guidelines is to further awareness 





























































we recognise the scale of the task and recommend the ERS should advocate chronic cough as a 
classification in the WHO ICD.
Very little is known of the natural history of chronic cough. We recommend observational cohort 
studies to identify: –
 The true prevalence of chronic cough in the population. 
 The demographic characteristics of this patient population. 
 The natural history of chronic cough over time. 
 The clinical and psychosocial impact of chronic cough on patients.
 The economic burden of chronic cough both to the individual and society.
The assessment of chronic cough in both the clinical and research settings needs further 
development. Current instruments to assess quality of life need refinement to be useful in routine 
clinical practice. Patient reported outcomes need to be developed and validated. There is an urgent 
need for fully automated cough recording technology that continuously monitors patients in real-
time. Such devices may help confirm the diagnosis in the clinic, allow for objective assessment of 
clinical response, and ensure the entry of the correct population into clinical studies. In addition, the 
current clinical approach is largely based on sequential therapeutic trials; thus, practical biomarkers 
need to be developed to target treatable traits and guide treatment decisions in the clinic.
There are very few studies of cough in other diseases and currently patients with the syndrome of 
chronic cough are frequently mislabelled as suffering from other conditions. Studies of the overlap 
between respiratory disease and chronic cough are urgently need, particularly in view of the 
differences in pathophysiology and treatable traits.
These guidelines were constructed with editorial independence from the ERS. Conflicts of interest 
were recorded and disclosures can be found alongside this article at erj.ersjournals.com 





























































Table 1. Table of recommendations, strength and level of evidence, and supporting remarks




Values and preferences Remarks
Question 1: Should chest CT scan be routinely performed on chronic cough patient with normal chest X-ray and physician examination?
Recommendation 1: We 
suggest that clinicians do 
not routinely perform a 
chest CT scan in patients 
with chronic cough who 
have a normal chest X-ray 
and physical examination.
Conditional Very low This recommendation places relatively 
higher value on the impact on patient 
management and outcomes including 
adverse events from radiation 
exposure. Lower value was given to 
diagnostic sensitivity and specificity.
 In chronic cough patients with normal chest X-rays 
and physical examination, rates of any positive 
findings on chest CT scan varied widely in the 
literature. However, the Task Force members 
found that these abnormalities were unlikely to 
explain cough and may not influence management 
of the patients. 
 For those patients without a clear diagnosis or a 
chronic cough that is refractory to treatment of 
associated conditions, a high-resolution CT scan of 
the chest may identify subtle interstitial lung 
disease not visible on chest X-rays, e.g. pulmonary 
fibrosis, hypersensitivity pneumonitis and 
bronchiectasis, or areas of mucus plugging, which 





























































may prompt the need for bronchoscopy for 
clearance, lavage, and culture. However, whether 
these subtle changes are the cause of the cough or 
a consequence of an underlying condition, such as 
recurrent aspiration, is unknown. 
 There is a concern about potential cancer risk from 
CT radiation exposure[89]. According to an 
estimation study[88], a projected number of 
future cancers that could be related to chest CT 
scans performed in the US was 4100 (95% 
uncertainty limits, 1900–8100) cases from 
7,100,000 scans, and the estimated rates were 
higher in children and women.
Question 2: Should FeNO/blood eosinophils be used to predict treatment response to corticosteroids/anti-leukotrienes in chronic cough?
Recommendation 2: 
Research recommendation
- Very low This recommendation places relatively 
higher value on predictability for the 
treatment response and the impact on 
the treatment decision. Lower value 
 There is a need for convenient, safe, and practical 
tests for detecting predicting anti-inflammatory 
treatment responses in chronic cough. In 
randomised controlled trials of patients with 





























































was given to diagnostic sensitivity and 
specificity. 
different respiratory conditions, FeNO or blood 
eosinophil levels were positively associated with 
anti-inflammatory treatment responses[133-135]. 
However, there is no high-quality evidence to 
guide the use of FeNO or blood eosinophil counts 
as treatment response predictors in patients with 
chronic cough. In addition, there are still no 
optimal cut-off levels determined for the use in 
chronic cough populations.
Question 3: Should anti-asthmatic drugs (anti-inflammatory or bronchodilator drugs) be used to treat patients with chronic cough?
Recommendation 3a: We 
suggest a short-term ICS 
trial (2–4 weeks) in adult 
patients with chronic cough. 
Conditional Low This recommendation is based on the 
higher value of the clinical benefits 
from ICS in some patients with 
asthmatic cough (or airway 
eosinophilic inflammation) and lower 
value on adverse events.
 Asthmatic cough (cough variant asthma and 
eosinophilic bronchitis) is a frequent phenotype of 
chronic cough. Evidence for ongoing airway 
eosinophilic inflammation can be collected by 
performing differential cell counts on samples 
from sputum induction or bronchoalveolar lavage; 
however, these tests are not available at most 
clinics. Moreover, there is no high-quality 





























































evidence for the routine use of FeNO or blood 
eosinophil counts in patients with chronic cough 
(as recommendation 2). Therefore, empirical 
therapy for asthmatic cough may be considered.
 In the literature, there is a heterogeneity in the 
efficacy of ICS in adult patients with chronic cough. 
The variability in the treatment response is likely 
primarily related to patient characteristics, 
particularly eosinophilic inflammation. 
 Available evidence suggests that a high dose of ICS 
might be more effective than a low to moderate 
dose regimen, as an empirical trial. 
 A treatment response is usually seen within 2–4 
weeks. Thus, the empirical trial should be stopped 
if there is no response within 2–4 weeks. 
 The Task Force members were concerned about 
long-term overuse of ICS in the absence of 
evidence or treatment response. They were also 





























































concerned about pneumonia in relation to 
fluticasone use in patients comorbid with COPD.
Recommendation 3b: We 
suggest a short-term ICS 
trial (2-4 weeks) in children 
with chronic dry cough. 
Conditional Low This recommendation is based on a 
higher value of the clinical benefits 
from ICS in some patients with 
asthmatic cough (or eosinophilic 
inflammation) and a lower value on 
adverse events.
 Overall remarks are the same as those in adults. 
 The empirical trial should be stopped if there is no 
response within 2-4 weeks.
Recommendation 3c: We 
suggest a short-term anti-
leukotriene trial (2–4 weeks) 
in adults with chronic cough, 
particularly in those with 
asthmatic cough.
Conditional Low This recommendation is based on 
higher value on the clinical benefits 
from anti-leukotriene in some patients 
with asthmatic cough (or airway 
eosinophilic inflammation) and lower 
value on adverse events.
 Overall remarks are similar to those for ICS. 
 Currently, clinical evidence is only available in 
specific subgroups of patients, such as cough 
variant asthma or atopic cough. Overall efficacy of 
leukotriene receptor antagonist in non-specific 
chronic cough patients is uncertain.
 The empirical trial should be stopped if there is no 
response within 2–4 weeks.
Recommendation 3d: We 
suggest a short-term trial 
Conditional Moderate This recommendation is based on 
higher value on the clinical benefits 
 There is a concern about pneumonia in relation to 
fluticasone use in patients comorbid with COPD.





























































(2–4 weeks) of ICS and long-
acting bronchodilator 
combination in adults with 
chronic cough and fixed 
airflow obstruction.
from ICS and long-acting 
bronchodilator combination in some 
patients with chronic obstructive 
pulmonary disease and a lower value 
on adverse events.
 The empirical trial should be stopped if there is no 
response within 2–4 weeks.
Question 4: Should anti-acid drugs (PPIs and H2 antagonists) be used to treat patients with chronic cough?
Recommendation 4: We 
suggest that clinicians do 
not routinely use anti-acid 
drugs in adult patients with 
chronic cough.
Conditional Low This recommendation is based on 
higher value of the clinical benefits 
from anti-acid drugs only in some 
patients with acid reflux and a lower 
value on adverse events.
 Anti-acid drugs are unlikely to be useful in 
improving cough outcomes, unless patients have 
peptic symptoms or evidence of acid reflux.
 Clinical benefits from PPI over placebo on cough 
outcomes are not significant in patients without 
acid reflux and only modest in those with acid 
reflux. These agents effectively block gastric acid 
production and relieve acid-related symptoms but 
have little effect on the number and volume of 
reflux events. Gastric acid does not appear to play 
a major role in the aetiology of chronic cough. 





























































 PPIs are mostly considered well tolerated. 
However, there is a potential concern about 
increased risks of complications, such as 
pneumonia, iron deficiency, vitamin B2 deficiency, 
small intestinal bacterial overgrowth, Clostridium 
difficile-associated diarrhoea, or bone fracture 
[118].
Question 5: Should drugs with pro-motility activity (reflux inhibitors, prokinetics and macrolides with pro-motility activity) be used to treat patients with chronic cough?
Recommendation 5:  There 
is currently insufficient 
evidence to recommend the 
routine use of macrolide 
therapy in chronic cough. A 
one month trial of 
macrolides can be 
considered in the cough of 
chronic bronchitis refractory 
to other therapy, taking into 
Conditional Low This recommendation is based on 
higher value on the clinical benefits 
from drugs with pro-motility activity 
only in some patients with chronic 
bronchitis and lower value on adverse 
events.
 Current evidence only supports the use of 
azithromycin in patients with chronic bronchitis 
phenotype. However, mechanisms of 
azithromycin in improving cough outcomes are 
suggested to include prokinetic effects[136].
 Since oesophageal dysmotility is a frequent finding 
in chronic cough patients, promotility agents such 
as metoclopramide, domperidone, and 
azithromycin might be considered, although the 
clinical trial evidence in cough is sparse.  





























































account local guidelines on 
antimicrobial stewardship.
Question 6: Which cough neuromodulatory agents (pregabalin, gabapentin, tricyclics, and opiates) should be used to treat patients with chronic cough?
Recommendation 6a: We 
recommend a trial of low 
dose morphine (5–10 mg 
bd) in adult patients with 
chronic refractory cough.
Strong Moderate This recommendation is based on a 
higher value of the clinical benefits and 
adverse events from opiates for 
chronic refractory cough.
 Agents acting directly on cough hypersensitivity 
rather than the treatable traits causing 
hypersensitivity is a promising strategy for future 
developments. Current agents have been shown 
to be effective, but the side effect profile is 
significant and may be mitigated by the use of 
lower doses than that used to treat pain.
 Clinical experience suggests that only a proportion 
of patients (approximately half) respond to 
opiates. In responders, treatment response is very 
rapid and clear (usually seen in a week). Thus, 
discontinuation is recommended if there is no 
response in 1 or 2 weeks.
 Codeine is generally not recommended (except 
where it is the only available opiate) due to inter-





























































individual genetic variability in drug metabolism 
(CYP2D6) and consequent less predictable 
treatment response and side effect profile 
particularly in children.
Recommendation 6b: We 
suggest a trial of gabapentin 
or pregabalin in adult 
patients with chronic 
refractory cough.
Conditional Low This recommendation is based on a 
higher value of the clinical benefits and 
adverse events from gabapentin in 
chronic refractory cough.
 Clinical experience suggests the response rates of 
gabapentin and pregabalin are lower than that of 
opiates, and adverse events are more common. 
Common adverse effects are blurred vision, 
disorientation, dizziness, dry mouth, fatigue, and 
nausea.
Question 7: Should non-pharmacological therapy (cough control therapy) be used to treat patients with chronic cough?
Recommendation 7: We 
suggest a trial of cough 
control therapy in adult 
patients with chronic cough. 
Conditional Moderate This recommendation is based on a 
higher value of the clinical benefits 
from cough control therapy in chronic 
refractory cough, but lower value on 
adverse events.
 Multi-component physiotherapy/speech and 
language therapy interventions may be 
considered for short-term improvement of health-
related quality of life and cough frequency in 
patients with refractory chronic cough or who 
wish an alternative to drug treatment. However, 
this is a complex intervention that requires further 





























































study to determine which components are of 
value. Thus, experienced practitioners should 
undertake cough-directed physiotherapy and 
speech and language therapy intervention. The 
pool of individuals qualified for cough control 
therapy is currently lacking in many countries and 
should be increased.
Question 8: Should a trial of antibiotics be used in children with chronic wet cough without warning signs, normal chest x ray, and normal spirometry and no warning 
signs?
Recommendation 8: We 
suggest a trial of antibiotics 
in children with chronic wet 
cough with normal chest X-
rays, normal spirometry, 
and no warning signs. 
Conditional Low This recommendation is based on 
higher value of the clinical benefit from 
antibiotics in chronic wet cough, but 
lower value on adverse events.
 Protracted bacterial bronchitis is a common 
treatable trait in children. Preferred antibacterial, 
dose, and duration of therapy is unknown.
 Signs and symptoms suggestive of specific disease 
should always be investigated.
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Cough is a vital protective reflex preventing aspiration and enhancing airway clearance. 
Pathologically excessive and protracted cough is however a common and disabling complaint 
affecting perhaps 5 to 10 percent of the adult population[1]. When severe, it causes a major 
decrement in the quality of life with comorbidity such as incontinence, cough syncope and 
dysphonia leading to social isolation, depression, and difficulties in relationships[2].
Whilst a wide range of diseases may be associated with chronic cough it has become increasingly 
clear that the majority of adult patients presenting with chronic cough as the primary complaint 
have a common clinical presentation[3]. They often complain of exquisite sensitivity to inhalation of 
environmental irritants such as perfumes, bleaches, and cold air which result in sensations of 
tickling/irritation in the throat and an urge to cough; features suggestive of heightened sensitivity of 
the neuronal pathways mediating cough[4]. There is also a unique epidemiology with two thirds of 
patients being female and the peak prevalence in their fifties and sixties. These observations have 
led to the concept of cough hypersensitivity syndrome as a diagnosis[5]. In children chronic cough 
presents in a markedly different fashion with different aetiology. They are not miniature adults[6]. 
This guideline aims to improve diagnostic accuracy and promote evidence-based therapy for both 
paediatric and adult patients in both primary and secondary care. The guideline is intended for use 
by all health care professionals looking after patients with chronic cough. The guideline has been 
developed by a multidisciplinary international panel of clinicians and scientists with a published 
record of expertise in the field. Input on patient views and preferences was sought via the European 
Lung Foundation who provided an advisory group of patient representatives who expressed their 
preferences via teleconferences, attendance at the ERS Congress, and in writing. They contributed to 
formulating and prioritising the key questions. 
Guideline scope and structure
This guideline follows the hybrid model of the ERS Guidelines Working Group and Science Council[7], 
which combines the scientific rigor of the GRADE framework for key questions of uncertainty with a 
narrative component to reflect the expert consensus of the guideline task force. The narrative covers 
clinically important aspects of chronic cough while the eight key questions systematically explore the 
evidence in areas of clinically important controversy.  
Full details of the methodological process and the analysis of the individual questions can be found 
in the online supplement. Table 1 provides a summary of the eight questions (two diagnostic and six 
therapeutic questions), the level of evidence, and the recommendations arising from the systematic 
review. All other propositions should be regarded as narrative statements.





























































Definition of chronic cough
To define a chronic cough on the basis of longevity is clearly an arbitrary paradigm. Early studies 
used three months based on the MRC definition of chronic bronchitis[8]. More recent guidelines 
have adopted eight weeks in adults[9] and four weeks in children[10]. Inclusion criteria for studies of 
novel antitussives require a cough refractory to treatment to be present for over a year. Whilst some 
patients cough on a daily basis over many years for others the disease has a relapsing and remitting 
course making a definition based purely on a temporal basis difficult to sustain. The diagnosis of 
chronic cough should be made on a global clinical assessment taking into account the other features 
of the phenotypes of cough detailed below. The failure to recognise that the patient is suffering 
from the syndrome of chronic cough may lead to misdiagnosis with the patient labelled as suffering 
from recurrent chest infections, treatment resistant asthma, or exacerbations of COPD.
The commonly used definition of chronic cough in children is 4 weeks, although cough in children 
lasting 3 to 8 weeks has been termed prolonged acute cough[10, 11]. Irrespective of the exact 
duration, chronic cough in children is different from that in adults due to differences in the airway 
morphology, a higher degree of vulnerability to noxious insults, reduced control of the cough reflex 
and differences in maturation of the neurological and immunological system in the different 
paediatric age groups[6]. Chronic cough in children is best seen as a symptom of an underlying 
disease. 
Epidemiology
Cough is a common medical problem and the socioeconomic burden is substantial[12]. However, 
there is no precise data on the burden of chronic cough, probably because chronic cough was 
previously perceived not as a clinical entity but as the consequent symptom from other respiratory 
conditions. There is no agreed definition of chronic cough for use in epidemiological studies[8]. 
A meta-analysis estimated the global prevalence of chronic cough in the general adult population as 
about 10%[1]. It was more prevalent in Europe, America and Oceania than in Asia and Africa. 
Notably, the prevalence of chronic cough in adults is associated with a number of characteristics [13-
16]. In a recent international survey of 10,032 adult patients attending specialist cough clinics, two-
thirds were females and the most common age for presentation was in the sixth decade [3]. The 
distinct demographic pattern is thought to be related to sex differences in central processing of 
cough sensation. The most commonly associated conditions are irritable bowel syndrome, obesity 
and a variety of neuropathic syndromes. Iatrogenic chronic cough from drug treatments is 
frequently unrecognised.
About 35 % of preschool children report cough at any given time in a month[17]; however, so far, no 
studies have systematically compared the prevalence of chronic cough in children worldwide. 
Reports of chronic cough in populations vary between 1% in India[18], 9% in Eastern Europe[19] and 
5-12 % in China with increases in areas with higher air pollution[20]. Subjective perception and 





























































parental reporting of symptoms further biases prevalence reports[21]. Studies comparing 
prevalence rates worldwide are warranted.
Impact on patients
Chronic cough is highly disruptive to the individual affected and those around them. The most 
common reasons why patients with cough seek medical attention include concern about a serious 
underlying illness, vomiting, exhaustion, sleep disruption, social embarrassment, difficulty speaking 
on the telephone, urinary incontinence and annoyance to family, friends and workmates[22].
The consequence of chronic cough is a wide range of complications of coughing[23].  Most impactful 
on Health-Related Quality of Life (HRQOL) are stress urinary incontinence, interference with speech 
and depression[24].  However, there are many others that can be equally bothersome, such as 
syncope. Individuals report, on average, eight adverse symptoms associated with cough[22].  
Stress urinary incontinence is particularly impactful, as cough affects females disproportionately 
compared to males. Female patients with cough and urinary incontinence have worse HRQOL 
compared to those without incontinence[24].  In a quarter of patients, the incontinence is severe but 
rarely discussed. Thus incontinence should be enquired about during a consultation. 
The impact of cough can be assessed and quantified formally with validated HRQOL tools, such as 
the Leicester Cough Questionnaire (LCQ) or the Cough-specific Quality of Life Questionnaire 
(CQLQ)[25, 26]. A strength of cough HRQOL tools is that they can be used to demonstrate the 
efficacy of anti-tussive therapy that is clinically meaningful. In the clinic simply asking “score your 
cough out of 10” is perhaps the easiest subjective measure of treatment success[27] and should be 
asked at each consultation.
In children, the caregiver’s worries about the underlying reason for the cough are a major driver to 
seek medical attention[28]. Paediatric cough is best considered as a symptom of an underlying 
disease. Therefore, the burden of disease is influenced by the quality of the health care system as 
well as health care independent factors such as age range[29-31], gender, and indoor and outdoor 
air pollution[32].
Aetiology and mechanisms
Cough is a vital protective reflex preventing aspiration into the lung. Patients with a poor cough 
reflex such as those who suffer from neurological conditions succumb to recurrent episodes of 
aspiration[33] frequently misdiagnosed as “chest infections”. Cough is a vagal reflex evoked by 
stimulation of afferents carried by the tenth cranial nerve, with their receptive fields primarily in the 
larynx and conducting airways, but also potentially in the alveolar septa and parenchyma of the lung 
(e.g. pulmonary embolism, heart failure, altitude sickness), the pharynx and oesophagus, and even 





























































the ear, with vagal afferents projecting to the auricular canal from the superior vagal (jugular) 
ganglia (Arnolds reflex)[34].
Noxious stimuli (e.g. gastric fluid, protons, cigarette smoke, particulates, hyper or hypotonicity) are 
detected through receptors and ion channels (e.g. TRPV1, TRPA1, TRPV4, ASIC, P2X3) localized to 
vagal afferent nerve terminations in the airways mucosa[35]. The vagal afferent nerves regulating 
cough are polymodal i.e. responding to a variety of different chemical and mechanical stimuli. 
Cellular stress releasing ATP appears to be an important stimulus[36]. Afferent neuronal traffic is 
relayed via vagal axons to the brainstem via at are least two different biochemical pathways[37]. 
Cortical influences modulate the reflex, with women having a greater area of the somatosensory 
cortex devoted to cough. The system is characterised by marked redundancy, plasticity and 
adaption. The neurobiology of cough has recently been comprehensively reviewed[38].
Cough may be caused by excessive stimulation of a normal cough reflex such as occurs following 
inhalation of a foreign body or noxious vapours. However, most patients presenting with a chronic 
cough have features of cough reflex hypersensitivity, responding to exposure to low levels of 
thermal, chemical, or mechanical stimulation[5]. The cough hypersensitivity syndrome has been 
adopted as an overarching diagnosis with the different phenotypes dependent on the type and 
location of the inflammation seen.  Both central and peripheral mechanisms have been postulated 
for cough reflex hypersensitivity[39].
The aetiological mechanisms for cough hypersensitivity remain controversial and are dealt with in 
greater depth below. In the airways, T2 inflammation occurs in approximately a quarter of patients 
although this may be through stimulation of the innate immune system rather than atopy[40]. This 
gives rise to the phenotypes of cough variant asthma and eosinophilic bronchitis[41]. Reflux, 
particularly nonacid gaseous airway reflux, and oesophageal dysmotility are common features[42]. 
Central mechanisms for cough hypersensitivity have also been postulated, with circumstantial 
supportive evidence generated using fMRI[43]. It is suggested that there is an underlying 
neuropathic process responsible for cough hypersensitivity[44], a view that is supported by the 
development of cough in certain forms of hereditary somatosensory neuropathy[45].
Phenotypes of chronic cough
Asthmatic Cough / Eosinophilic Bronchitis
Asthma is a clinical diagnosis. There is no agreed single diagnostic test to diagnose or exclude asthma 
and because of its heterogeneous presentation opinions differ on how to describe the syndrome in 
patients with chronic cough. Eosinophilic inflammation may be a useful biomarker of asthmatic 
cough and may have utility in directing therapeutics. All adults and children with chronic cough may 
be assessed for eosinophilic inflammation. Sputum eosinophilia is perhaps the most accurate 
indicator, but is not routinely available, time-consuming, and requires expert interpretation. Exhaled 
nitric oxide can be used as a surrogate marker of eosinophilic airway inflammation and steroid 
responsiveness in classic asthma, but its role in asthma and chronic cough is questioned below. A 
meta-analysis of observational studies showed exhaled nitric oxide to have a relatively high 
specificity of 0.85 in predicting asthma among adult patients with chronic cough[46]; however, there 





























































is still no consensus on the cut-off level for the diagnosis. Blood eosinophilia is a simple and readily 
available measure, but is characterised by diurnal and seasonal variability[47] so multiple 
assessments should be made[48]. An eosinophil count of greater than 0.3 cells/µL may be taken to 
indicate eosinophilic airway inflammation[49, 50].
Three subgroups of asthmatic cough have been recognised. Classic asthma is characterised by 
airflow variability and bronchial hyperresponsiveness. Spirometry is thus an obligatory investigation. 
Cough variant asthma (CVA) ) was originally described as those patients with asthma and cough as 
the sole symptom and where treatment with bronchodilators improved coughing 
 [51]. Opinions vary as to whether this should be sought by performing bronchial provocation test. 
Some centres see this as an important part of the workup, whereas others find it adds little to the 
patient pathway. The third form of asthmatic cough is eosinophilic bronchitis (EB) without 
bronchoconstriction or hyperresponsiveness. The lack of these latter two features has been 
suggested to indicate that EB is a separate condition – Non-Asthmatic Eosinophilic Bronchitis[52]. 
However, in chronic cough communication with patients and other health care professionals may be 
enhanced if it is considered as part of an asthmatic spectrum, particularly as all three subgroups can 
respond to anti-inflammatory asthma therapy. The vital importance of establishing or refuting the 
diagnosis of asthmatic cough lies in the therapeutics (discussed in questions below) as it may be 
considered as a treatable trait. 
Reflux cough
The role of reflux, oesophageal dysmotility, and aspiration in chronic cough is controversial.  Its 
prevalence has been estimated from 0 to almost 100%.  Early studies using the criteria of acid reflux 
found a low incidence and poor temporal relationship[53]. A systematic review[54] found no 
significant benefits over placebo of PPIs in patients without acid reflux and only modest benefits 
even in patients with acid reflux. It was suggested that non-acid reflux, both liquid and gaseous, may 
be an aetiological factor[55].  However no technology reliably detects such reflux and the diagnosis 
relies on the clinical history supported by validated questionnaires such as the Hull Airway Reflux 
Questionnaire (HARQ)[56] (see issc.info for multi lingual versions) or Reflux Symptom Index[57].  The 
picture is complicated by the observation that there is a high prevalence of oesophageal dysmotility 
in patients with chronic cough[42] and thus oesophago-pharyngeal reflux rather than GORD/GERD 
may be the problem.  
Many of the signs and symptoms associated with chronic cough are explicable by reflux and 
aspiration.  Voice change, nasal symptoms and dysgeusia are common[58].  Frequent “chest 
infections” bronchitis, and even frank bronchiectasis may be the consequence rather than the cause 
of cough through repeated aspiration. Unsurprisingly following aspiration of contents from the GI 
tract there is an inflammatory response.  This might be neutrophilic or eosinophilic giving rise to 
asthmatic cough and mucus hypersecretion[59].
Postnasal drip syndrome/Upper airways cough syndrome





























































The 2006 American College of Chest Physicians (ACCP) cough management guidelines suggested the 
term upper airways cough syndrome (UACS) to describe the variety of signs and symptoms 
previously referred to by other synonyms including postnasal drip syndrome, rhinitis and 
rhinosinusitis[60]. The revised nomenclature however did not resolve ongoing controversy regarding 
the existence of this syndrome and the mechanism(s) by which it may induce chronic cough.
 A first-generation antihistamine and decongestant were recommended as the treatment, in the 
absence of adequate randomised controlled trial (RCT) evidence.  The first-generation 
antihistamines however are thought to be antitussive through their action as centrally penetrant 
anticholinergics[61].
However UACS could be accepted as an aetiology of chronic cough in some patients by acting as a 
trigger for cough hypersensitivity although the mechanism remains obscure. The absence of 
evidence for localised treatment might suggest that upper airway symptoms merely reflect 
generalised airway inflammation consequent to asthma or airway reflux.
Iatrogenic cough
Chronic cough occurs in approximately 15% of patients taking angiotensin-converting enzyme 
inhibitors (ACEI). ACEI increases the sensitivity of the cough reflex in most subjects[62] and it is 
probable that additional factors are required to produce clinical impact. Since the reflex is reset 
there may be no close temporal relation to drug administration or withdrawal and the cough[63]. No 
patient with a cough or who develops one should be given ACEI. Angiotensin II antagonists do not 
affect the cough reflex.
Drugs such as bisphosphonates or calcium channel antagonists may worsen pre-existing reflux 
disease causing increased cough. Prostanoid eye drops such as latanoprost may descend the lacrimal 
duct irritating the pharynx[64].
Chronic cough in children
Chronic cough in children differs from that in adults in terms of common aetiologies and 
management and is increasingly defined as cough that lasts more than 4 weeks. Regardless of 
setting and age, children with chronic cough should be evaluated carefully using children-specific 
protocols[65]. 
During childhood, the respiratory tract and nervous system undergo a series of anatomical and 
physiological maturation processes that influence the cough reflex. Additionally, immunological 
responses undergo developmental and memorial processes that make infection and congenital 
abnormalities the predominant causes of cough in children[66]. Thus, tracheomalacia, protracted 
bacterial bronchitis (PBB), and bronchiectasis occur, in addition to common aetiologies such as 
asthma and post-infectious cough[67]. PBB is not a new entity and PBB-like conditions were being 
reported in the 1980s[68]. An ERS task force has recently advanced a reliable definition of PBB for 
day-to-day clinical practice when all three of the following criteria are fulfilled: 1) Presence of 





























































continuous chronic (>4 weeks’ duration) wet or productive cough; 2) absence of symptoms or signs 
(i.e. specific cough pointers) suggestive of other causes of wet or productive cough; and 3) cough 
resolved following a 2–4-week course of an appropriate oral antibiotic[69]. PBB may be a precursor 
of bronchiectasis[70]. 
Initial assessment for chronic cough in children includes a detailed history and thorough physical 
examination to identify possible specific causes due to an underlying disease.  A sudden onset of 
cough in an otherwise healthy preschool child may suggest foreign body aspiration and requires 
bronchoscopy.  A chest x-ray as well as spirometry in collaborative children is essential. If specific 
cause for the chronic cough is suspected, further investigations are necessary. In case no specific 
pointers are detected and chest x-ray and spirometry are normal then the guideline panel 
considered that another period of observation of up to four weeks was indicated.  In case of 
persistence of cough differentiate between dry and wet cough[71].  Exposure to airborne irritants 
(e.g. tobacco exposure, combustions, traffic related exposure etc.), allergen exposure or 
postinfectious cough may be a reason for dry chronic cough. In case of wet cough, sputum cultures 
should be attempted.
Habit/tic cough is another aetiology found particularly in children, manifesting the core clinical 
features of tics including suppressibility, distractibility, suggestibility, variability, and the presence of 
a premonitory sensation whether the cough is single or one of many tic. The formerly called 
psychosomatic cough should now be labelled somatic cough disorder and this diagnosis should only 
be made after an extensive evaluation that includes ruling out tic disorders and uncommon causes 
of chronic cough[72].
Psycho-morbidity is present in all patients with chronic cough with a variety of aetiologies, and tends 
to decrease following successful treatment[73]. There are limited criteria for the diagnosis of 
psychogenic (or somatic) cough and features of psychogenic cough reported in the literature are not 
unique to psychogenic cough[72]. Somatic cough disorder has been commonly used to describe 
cough without obvious aetiology. However, recent research has revealed neurobiological 
phenomena are responsible for psychogenic cough[43]. The presence of depression and/or anxiety 
cannot be used to diagnose psychogenic cough because, as in adults, patients with a persistently 
troublesome chronic cough can develop these psychologic symptoms when their coughs remain 
untreatable. Non-pharmacological trials of hypnosis or suggestion therapy or combinations of 
reassurance, counselling, or referral to a psychologist and/or psychiatrist have been suggested in 
management, but such strategies lack an evidence base.
Chronic refractory cough
A proportion of patients with chronic cough, particularly among adults, have persistent cough 
despite thorough investigation and treatment according to published practice guidelines. Terms such 
as idiopathic chronic cough, unexplained chronic cough and chronic refractory cough have been 
utilized to describe this clinical condition[74]. Successful trials of drugs with neuromodulatory effects 
such as opiates, gabapentin, and P2X3 antagonists suggest that aberrant neurophysiology is likely to 
underlying this condition. Here the term chronic refractory cough is used to indicate that the cough 
is refractory to conventional treatment of cough-associated conditions or traits.





























































Chronic cough in other diseases
Most chronic respiratory disease is associated with cough.  Physical distortion of the airway such as 
occurs in lung cancer or the bronchorrhea of cystic fibrosis and chronic bronchitis produces cough by 
mechanical effects.  However cough hypersensitivity through cell damage and inflammation 
underlies much of the increased cough seen in other pathologies.  The different pathological 
processes in individual conditions contribute to the disease specific, heterogeneous, aetiology of 
cough in other lung disease.
As an example, cough in interstitial lung diseases (ILDs) is common with a prevalence of 30 to 90%. 
Patients with ILD often respond poorly to general anti-tussive therapy. In an open label study of 
idiopathic pulmonary fibrosis (IPF) pirfenidone reduced 24-hr objective cough counts and improved 
cough-related QoL[75]. Reformulated sodium cromoglicate improved 24-hr objective cough by 31% 
in patient with IPF whereas there was no effect in chronic idiopathic cough[76]. It seems likely that 
each individual respiratory condition will have its own profile dependent on the tussigenic factors 
expressed in that disease. 
Chronic cough, tobacco and nicotine
Smoking is the major remediable cause of chronic cough and is inextricably linked to chronic 
obstructive pulmonary disease (COPD). Epidemiological studies have demonstrated a relationship 
between cumulative smoking exposure and chronic cough[77]. Furthermore, smoking history and 
current cigarette consumption are predictors of objectively-measured cough frequency[78]. A 
natural inference therefore would be to ascribe a protussive effect to tobacco smoke and its 
components. Research in otherwise healthy smokers and nonsmokers, however, has provided 
additional insights, some of which contradict general assumption.
Multiple studies of otherwise healthy smokers have demonstrated suppressed cough reflex 
sensitivity to inhaled capsaicin[79, 80]. The development of electronic cigarettes (e-cigs) provided a 
mechanism of non-combustible delivery of nicotine to the lungs. One tobacco cigarette equivalent 
induced significant suppression of cough reflex sensitivity[81]. These data are consistent with 
previous clinical observations of transient increase in cough within the first month after smoking 
cessation[82]. All patients should quit smoking and they should be warned there may be a transient 
increase in coughing. For those unable to quit because of excessive coughing e-cigs may be a 
supportive therapy[83].
Assessing cough in the clinic
Initial assessment





























































The history, examination, and investigations for patients with chronic cough are performed to 
exclude treatable traits of the disease for which directed therapy can be offered.  The guideline 
panel placed higher value on control of any on-going pathology such as reflux or airway eosinophilia 
before currently available neuro-modulatory treatments are considered. A detailed history and 
examination should be directed to exclude malignancy, infection, foreign body inhalation or the use 
of an angiotensin converting enzyme (ACE) inhibitor. The impact of cough should be assessed either 
by recording simple measures such a cough score out of 10 or VAS or by more detailed, validated 
measures of cough quality of life (LCQ or CQLQ).  Validated questionnaires may help to detect 
features of airway reflux (HARQ and RSI) and airway hypersensitivity[84]. 
Initial evaluation should include spirometry and a recent chest x-ray (CXR) (Good Practice 
Statement). 
Chest CT
Question 1: Should chest CT scan be routinely performed on chronic cough patients with normal 
chest X-ray and physical examination?
We suggest that clinicians do not routinely perform a chest CT scan in patients with chronic cough 
who have normal chest x-ray and physical examination (conditional recommendation, very low 
quality evidence).
Some prospective and retrospective cohorts identified CT findings in a range of 6.5% to 58% of 
patients with cough and normal CXR; however the causal relationship was either not specified or 
considered as unlikely related to cough [85-87]. There is a concern about potential cancer risk from 
CT radiation exposure [88, 89]. Thus the potential radiation risk needs to be weighed against 
possible diagnostic yields, particularly in susceptible populations such as children and females.
Further investigations to identify treatable traits in chronic cough
Further investigations for asthma, EB, reflux and oesophageal dysmotility, and rhinosinusitis should 
be considered depending on the clinical history. 
Asthma and eosinophilic inflammation
Objective evidence of classic asthmatic cough conventionally requires some evidence of variable 
airflow obstruction such as peak flow variability, or reversibility to salbutamol of more than 12-15%. 
However, these investigations have a very low negative predictive value particularly in patients with 
normal lung function[86].  Further investigation of bronchial hyper-responsiveness (BHR) using 
either methacholine or histamine inhalational challenge is advocated by some although its utility in 
diagnosis is questioned. Evidence for ongoing airway eosinophilic inflammation can be sought by 
performing differential cell counts on samples from sputum induction or bronchoalveolar lavage. In 
such cases, elevated eosinophils (>3%) in the airways in the absence of BHR would suggests EB, 
which has been reported in up to 13% of patients attending cough clinics[41]. However, most 
centres do not have such facilities available, hence a non-invasive alternative is the use of fractional 
exhaled nitric oxide (FeNO) in breath or blood eosinophilia as a surrogate marker to assess airway 
eosinophilia. The clinical usefulness of FeNO or blood eosinophils in aiding diagnosis or predicting 
treatment response in patients with chronic cough has not yet been systematically evaluated[90]. 
Question 2: Should FeNO/blood eosinophils be used to predict treatment response to 
corticosteroids/anti-leukotrienes in chronic cough?





























































There is a need for convenient and practical tests for predicting anti-inflammatory treatment 
responses in patients with chronic cough. However, there is a still lack of quality evidence. Placebo-
controlled trials are warranted to assess their utility and also consensus is required on threshold 
levels in patients with chronic cough. 
One RCT [91] in adult non-smoking patients with chronic cough shows that baseline FeNO levels 
(greater than 30ppb or lower than 20 ppb) did not predict response to anti-leukotrienes. Cough 
frequency and quality of life were similar between high and low FeNO groups at the end of 
treatment. Observational studies suggested that non-responders to ICS may have significant lower 
levels of FeNO at baseline [92, 93], but the findings were not consistent[94]. Randomised placebo-
controlled trials are required to validate the utility or otherwise of FeNO as a predictor of treatment 
response in chronic cough patients.  Currently, there is no study examining the predictive utility of 
blood eosinophils in patients with chronic cough. 
Given the uncertainty of diagnostic testing, a therapeutic trial may be indicated for asthmatic cough. 
In adults oral prednisolone for one week may cause a dramatic decrease in cough[95]. Inhaled 
corticosteroids (ICS) may be used when oral is contraindicated and is preferable in children.  
However it may be less effective since inflammation in CVA and EB is located in different parts of the 
airway from that seen in classic asthma[96], and may be driven by other pathways such as the innate 
immune system[97]. This also may explain the greater efficacy of systemic leukotriene antagonists 
such as montelukast in asthmatic cough[98].
Reflux and dysmotility
In the absence of peptic symptoms 24-hour pH monitoring for the investigation of reflux disease is 
not helpful. However abnormal oesophageal physiology is very common in patients with chronic 
cough and may be detected with poor sensitivity by a barium swallow. More accurately, high 
resolution oesophageal manometry provides diagnostic information as to the site and mechanism of 
dysmotility in the majority of patients[42].
The upper airways
In patients who report upper airway symptoms fibre optic laryngoscopy may be performed. The 
larynx is commonly found to be red and inflamed. However, the test has poor sensitivity and 
specificity. In select patients, laryngoscopy may be useful in identifying inducible laryngeal 
obstruction (ILO) associated with cough, and this may help plan the need for future cough control 
therapy[99]. Rhinoscopy may be helpful in identifying polyps and clearing mucus from blocked 
sinuses in patients with recurrent sinus and nasal inflammation, but routine laryngoscopy, 
rhinoscopy or CT sinuses is not advised as nasal findings are not directly associated with cough[100, 
101].
Chronic cough in children
Chronic cough in children should be approached using paediatric-specific cough management 
protocols or algorithms and basing the management on the aetiology of the cough. The most 
common recognized aetiologies for chronic cough in children are post-infectious or natural 
resolution, asthma and PBB.  Refer to the flow diagram on page x.





























































Treatment of chronic cough
Even after a thorough clinical assessment it may be impossible to identify which of the treatable 
traits is most likely to underlie the patient’s chronic cough. Individuals may vary in their response to 
the different modalities of treatment. The guideline panel considered that it was preferable to 
undertake sequential therapeutic trials of each agent in turn and if no responses were observed 
therapy should be stopped. The length of the trial depends on the pharmacology. Response to 
morphine occurs within one week. ICS may take a month. If successful, the guideline panel believes 
that treatment may be continued for several months to allow for resolution of neuronal 
hypersensitivity. Treatment may be then withdrawn to determine whether remission has occurred.  
The reader is referred to table 1 for commentary on the recommendations below. 
Anti-asthmatic drugs
Question 3:  Should anti-asthmatic drugs (anti-inflammatory or bronchodilator drugs) be used to 
treat patients with chronic cough?
We suggest a short-term ICS trial (2-4 weeks) in adult patients with chronic cough (conditional 
recommendation, low quality evidence).
Ten RCTs were identified for chronic cough, but with considerable heterogeneity in patient 
characteristics, intervention, measured outcomes and treatments responses. Two studies of chronic 
cough patients (unselected by airway hyper-responsiveness or sputum eosinophilia) found 
significant benefits from a 2-week high dose ICS treatment over placebo in reducing cough 
severity[102] and subjective cough frequency. However, in a study of patients with chronic cough 
and at least one additional respiratory symptom but with normal lung function, an 8-week medium 
dose ICS treatment did not produce a significant improvement in cough severity score over placebo. 
In two studies of patients with non-asthmatic chronic cough (defined by negative methacholine 
airway-hyper-responsiveness), ICS treatment was not superior to placebo in improving cough 
outcomes[103, 104]. In studies of patients with chronic bronchitis or chronic obstructive pulmonary 
disease (COPD), ICS treatment did not significantly improve subjective cough scores compared to 
placebo[105-108]. 
Although the original definition of CVA demonstrated improvement of coughing in a small number of 
asthmatic subjects with bronchodilator therapy, we do not recommend the use of a lone 
bronchodilator therapy as maintenance treatment for cough in asthmatic patients. The current GINA 
2019 guideline recommend the use of low dose ICS-formoterol or low dose ICS. Effectiveness of 
these treatment regimes in CVA and asthmatic cough still requires further evaluation.
We suggest a short-term ICS trial in children with chronic dry cough (2-4 weeks) (conditional 
recommendation, low quality evidence). 
Two RCTs were identified. A trial of 50 children aged 1-10 years with persistent nocturnal cough 
found that there is a modest but significant benefit in objective cough frequency from a 2-week 
course of high dose ICS over placebo[109]. Another study of 43 children aged 6-17 years with 
recurrent cough (two episodes of cough, each lasting two weeks in the past 12 months) found no 





























































significant effects of ICS in cough outcomes at 4-5 weeks; there was no association between ICS 
treatment response and airway hyper-responsiveness in hypertonic saline challenge[110].
We suggest a short-term anti-leukotriene trial (2-4 weeks) in adult patients with chronic cough, 
particularly in those with asthmatic cough (conditional recommendation, low quality evidence).
Three RCTs were identified. Two clinical trials[111, 112] of adults with cough variant asthma (defined 
by clinical history, absence of other common diseases, and presence of methacholine hyper-
responsiveness) found significant benefits of oral anti-leukotriene (for 2-4 weeks) over placebo in 
subjective cough frequency or severity scores. However, a single trial of adults with atopic cough 
(defined as chronic cough with increased capsaicin cough sensitivity and atopic constitution but 
without bronchial hyper-responsiveness) did not find any significant benefits of 2-weeks 
montelukast over placebo in subjective cough score[113]. Adverse drug event was reported in one 
study, without any significant event related to the treatment[112]. There are no trials conducted in 
unselected chronic cough patients.
No RCTs are available for children.  Mild, transient neuropsychiatric adverse events are common 
(>10%) in children[114].
We suggest a short-term trial (2-4 weeks) of ICS and long-acting bronchodilator combination in 
adults with chronic cough and fixed airflow obstruction (conditional recommendation, moderate 
quality evidence).
A single RCT[108] of COPD patients with chronic bronchitis, smoking history and at least one episode 
of COPD symptom exacerbation in the previous year found that the combination of 50 μg salmeterol 
and 500 μg fluticasone twice daily produced a significant improvement in cough severity score 
compared to placebo (scale: 0-4) (mean difference: −0.09; 95% CI: −0.17 to −0.01), whereas 
salmeterol or fluticasone monotherapy did not. The treatment was well-tolerated, except for an 
increased incidence of oropharyngeal candidiasis (8% in the combination treatment group vs. 2% in 
the placebo group).
Anti-acids
Question 4: Should anti-acid drugs (PPIs and H2 antagonists) be used to treat patients with chronic 
cough?
We suggest that clinicians do not routinely prescribe anti-acid drugs in adult patients with chronic 
cough (conditional recommendation, low quality evidence).
Anti-acid drugs are unlikely to be useful in improving cough outcomes, unless patients have peptic 
symptoms or evidence of acid reflux. Systematic reviews have found no significant benefits from PPI 
over placebo in adult patients without acid reflux and possible modest effect in those with acid 
reflux [54]. Faruqi et al. found no significant benefits of esomeprazole 20 mg twice daily therapy 
over placebo in subjective cough frequency, cough severity, or cough-specific quality of life scores at 
8 weeks. There was a trend towards greater improvement in the PPI treatment arm in patients with 
dyspepsia[115]. In a study of chronic cough patients with rare or no heartburn, there were no 
benefits from a long-term high-dose PPI therapy (esomeprazole 40 mg twice daily for 12 weeks) in 





























































cough-specific quality of life or cough scores [116]. Whilst PPI is frequently considered safe 
observational studies reported potential risks of iron deficiency, vitamin B12 deficiency, 
hypomagnesemia, Clostridium difficile–associated diarrhoea, osteoporosis-related bone fracture, 
dementia, or pneumonia[117, 118].  However, direct evidence about the safety issues is lacking in 
chronic cough population. There is not enough evidence to draw a specific recommendation for PPI 
use in children.
Drugs with promotility activity
Question 5: Should drugs with promotility activity be used to treat patients with chronic cough?
 There is currently insufficient evidence to recommend the routine use of macrolide therapy in 
chronic cough. A one month trial of macrolides can be considered in the cough of chronic bronchitis 
refractory to other therapy, taking into account local guidelines on antimicrobial stewardship.  
(conditional recommendation, low quality evidence). 
No RCTs have been undertaken with pro-motility agents, such as baclofen, metoclopramide or 
domperidone, in patients with chronic cough. There are three RCTs with macrolides with pro-
motility activity in adult patients with chronic cough. One study of patients with COPD GOLD stage ≥ 
2 and chronic productive cough demonstrated a significant benefit of a 12-week low dose 
azithromycin (250 mg three times a week) over placebo for improving cough-specific quality of life 
(LCQ; MD 1.3; 95% CI 0.3 to 2.3; p=0.01)[119]. Adverse events were not significantly different. In two 
other trials of patients with unexplained cough or treatment-resistant cough, low-dose macrolide 
treatments (erythromycin 250 mg daily for 12 weeks or azithromycin 250 mg three times a week for 
8 weeks) did not provide significant benefits over placebo for objective cough frequency, cough 
severity or cough-specific quality of life[120, 121]. 
Neuromodulators
Question 6: Which cough neuromodulatory agents (pregabalin, gabapentin, tricyclics and opiates) 
should be used to treat patients with chronic cough?
We recommend a trial of low dose slow release morphine (5-10 mg bd) in adult patients with 
chronic refractory cough (strong recommendation, moderate quality evidence).
A single RCT of low dose morphine (5 to 10 mg twice daily) in adults with chronic refractory cough 
found significant benefits over placebo in reducing cough severity (self-reported scale 0 to 9 points) 
(MD -1.96 points; 95%CI -1.09 to -2.11) and improving cough-specific quality of life (LCQ) (MD 2 
points; 95%CI 0.93 to 3.07)[27]. Common adverse effects in this clinical trial were constipation and 
drowsiness in patients receiving morphine.
We suggest a trial of gabapentin or pregabalin in adults with chronic refractory cough (conditional 
recommendation, low quality evidence).
A single RCT of gabapentin therapy (maximum tolerable daily dose of 1800 mg) in adults with 
chronic refractory cough found significant benefits over placebo in improving LCQ (MD 1.8 points; 
95%CI 0.56 to 3.04) and reducing cough frequency (although only of a single hour of observation) 
(MD -27.31%; 95%CI -2.87 to -51.75) and severity (VAS 0 to 100 points) (MD -12.33 points; 95%CI -
1.23 to -23.23)[122]. There is one RCT of pregabalin therapy (300 mg daily) in adult patients with 





























































chronic refractory cough alongside speech pathology therapy [123]. Pregabalin plus speech 
pathology therapy significantly improved cough-specific quality of life (LCQ) (MD 3.5 points; 95%CI 
1.11 to 5.89: MID: 1.3 points) and cough severity (VAS 0 to 100 points) (MD -25.1 points; 95%CI -10.6 
to -39.6) over placebo plus speech pathology therapy.  There was no significant reduction in cough 
frequency. There is no comparison between pregabalin and placebo alone. An explanation for a lack 
of effect on cough frequency is that centrally acting therapies may be altering perception of cough 
rather than having truly anti-tussive effects. They could also be affecting the intensity of coughing 
without reducing the frequency.  Dizziness, fatigue, cognitive changes, nausea, or blurred vision are 
common side effects of gabapentin and pregabalin.  A systematic review revealed that the risk of 
withdrawal due to adverse events is 2.3 times higher than placebo[124].
Agents acting directly on cough hypersensitivity rather than the treatable traits causing 
hypersensitivity is a promising strategy for future developments. Current agents have been shown to 
be effective in adults, but the side effect profile is significant and may be mitigated by the use of 
lower doses than those used to treat pain.
Cough neuromodulators, such as opioids, gabapentin or pregabalin, are not used in children, due to 
reported adverse events, possible toxicity and lack of clinical trials[125]. 
Non-pharmacological cough control therapy
Question 7: Should non-pharmacological therapy (cough control therapy) be used to treat patients 
with chronic cough?
We suggest a trial of cough control therapy in adult patients with chronic cough (conditional 
recommendation, moderate quality evidence).
Two RCTs of physiotherapy/speech and language therapy (cough control therapy) in adult patients 
with chronic refractory cough have been reported. Vertigan et al. demonstrated that the 2-month 
intervention significantly reduced subjective cough score compared to placebo treatment (self-
reported scale 2 to 10 points) (MD 2.8 points; 95% CI 1.3 to 4.0)[126]. In a multi-centre study by 
Chamberlain et al., the weekly intervention for 4 weeks showed benefits over placebo for cough-
specific quality of life (LCQ; 1.53 points; 95% CI 0.21 to 2.85) and objective cough frequency (fold 
change) (0.59; 95% CI 0.36 to 0.95), but not for VAS severity or other quality of life outcomes. The 
improvements in the intervention group were sustained up to 3 months, but not beyond. No 
adverse effects were found[127]. There are no RCTs in children. This is a complex intervention that 
requires further study to determine which components are of value. Experienced practitioners 
should undertake cough-directed physiotherapy and speech and language therapy interventions.
Antibiotics for chronic wet cough in children
Question 8: In children with chronic wet cough with normal chest x-ray, normal spirometry and no 
warning signs, should a trial of antibiotics be used?
A trial of antibiotics is suggested in children with chronic wet cough with normal chest x-rays, normal 
spirometry and no warning signs (conditional recommendation, low quality evidence).
A single RCT of antibiotics in young children (mean age 1.9 years; IQR 0.9 to 5.1) with chronic wet 
cough (>3 weeks)[128]. A 2-week regimen of twice daily oral amoxycillin clavulanate treatment (22.5 





























































mg/kg/dose) was compared. Cough resolution rates (defined as >75% reduction) were significantly 
higher in children who received amoxycillin clavulanate compared with those who received placebo 
(48% vs. 16%; p=0.015). Side effects were not significantly different between two groups; however, 
mild diarrhoea was found slightly more in the in the amoxycillin clavulanate group than in the 
placebo group (5/25 vs. 2/25)[128]. 
Future directions and new drugs
As the population ages the worldwide prevalence of chronic cough increases. This is partially due to 
an increasing awareness of the problem, changing diagnostic labels, air pollution, and increased 
efforts in educating health professionals. Changes in society such as the rise in obesity will also 
predispose to a greater incidence of causal factors related to chronic cough. Our understanding of 
the pathophysiological basis of chronic cough has dramatically advanced over the past decade with 
the realisation that neuronal hypersensitivity underlies the syndrome. Desensitisation through the 
use of agonists such as capsaicin has recently shown promise as a therapeutic strategy[129]. 
However, we are still grossly ignorant of the complex interplay in the peripheral and central nervous 
system. fMRI has given us insights into the central pathways of cough and will continue to do so in 
the future. However it is the pharmacology of the peripheral afferent vagus which has given us the 
most hopeful future therapeutic developments.
Much effort was devoted in the development of blockers of the nociceptors, mainly TRP receptors, 
which are responsible for the irritant sensation leading to the tickle that precedes cough. Whilst 
effective in animal models these agents have failed in the clinic[130, 131]. The substance P 
antagonist orvepitant has shown modest efficacy in phase 2 studies. One class of drugs has however 
produced a dramatic improvement in chronic cough in phase 2 studies[132]. ATP is released during 
cell damage and acts on afferent sensory nerves through P2X3 purinergic receptors. The first 
antagonist, gefapixant, has been studied in several hundred patients with chronic cough with 
resolution in the majority. Other compounds in this class are in development and we may have the 
first effective drugs for chronic cough in over 40 years.
Research gaps and recommendations for future studies
Because chronic cough has only recently been recognised as a separate entity a major challenge is 
the promulgation of the concept of cough hypersensitivity in adults and conditions such as 
protracted bacterial bronchitis in children.  Whilst the aim of these guidelines is to further awareness 
we recognise the scale of the task and recommend the ERS should advocate chronic cough as a 
classification in the WHO ICD.
Very little is known of the natural history of chronic cough. We recommend observational cohort 
studies to identify: –
 The true prevalence of chronic cough in the population. 





























































 The demographic characteristics of this patient population. 
 The natural history of chronic cough over time. 
 The clinical and psychosocial impact of chronic cough on patients.
 The economic burden of chronic cough both to the individual and society.
The assessment of chronic cough in both the clinical and research settings needs further 
development. Current instruments to assess quality of life need refinement to be useful in routine 
clinical practice. Patient reported outcomes need to be developed and validated. There is an urgent 
need for fully automated cough recording technology that continuously monitors patients in real-
time. Such devices may help confirm the diagnosis in the clinic, allow for objective assessment of 
clinical response, and ensure the entry of the correct population into clinical studies. In addition, the 
current clinical approach is largely based on sequential therapeutic trials; thus, practical biomarkers 
need to be developed to target treatable traits and guide treatment decisions in the clinic.
There are very few studies of cough in other diseases and currently patients with the syndrome of 
chronic cough are frequently mislabelled as suffering from other conditions. Studies of the overlap 
between respiratory disease and chronic cough are urgently need, particularly in view of the 
differences in pathophysiology and treatable traits.
These guidelines were constructed with editorial independence from the ERS. Conflicts of interest 
were recorded and disclosures can be found alongside this article at erj.ersjournals.com 





























































Table 1. Table of recommendations, strength and level of evidence, and supporting remarks




Values and preferences Remarks
Question 1: Should chest CT scan be routinely performed on chronic cough patient with normal chest X-ray and physician examination?
Recommendation 1: We 
suggest that clinicians do 
not routinely perform a 
chest CT scan in patients 
with chronic cough who 
have a normal chest X-ray 
and physical examination.
Conditional Very low This recommendation places relatively 
higher value on the impact on patient 
management and outcomes including 
adverse events from radiation 
exposure. Lower value was given to 
diagnostic sensitivity and specificity.
 In chronic cough patients with normal chest X-rays 
and physical examination, rates of any positive 
findings on chest CT scan varied widely in the 
literature. However, the Task Force members 
found that these abnormalities were unlikely to 
explain cough and may not influence management 
of the patients. 
 For those patients without a clear diagnosis or a 
chronic cough that is refractory to treatment of 
associated conditions, a high-resolution CT scan of 
the chest may identify subtle interstitial lung 
disease not visible on chest X-rays, e.g. pulmonary 
fibrosis, hypersensitivity pneumonitis and 
bronchiectasis, or areas of mucus plugging, which 





























































may prompt the need for bronchoscopy for 
clearance, lavage, and culture. However, whether 
these subtle changes are the cause of the cough or 
a consequence of an underlying condition, such as 
recurrent aspiration, is unknown. 
 There is a concern about potential cancer risk from 
CT radiation exposure[89]. According to an 
estimation study[88], a projected number of 
future cancers that could be related to chest CT 
scans performed in the US was 4100 (95% 
uncertainty limits, 1900–8100) cases from 
7,100,000 scans, and the estimated rates were 
higher in children and women.
Question 2: Should FeNO/blood eosinophils be used to predict treatment response to corticosteroids/anti-leukotrienes in chronic cough?
Recommendation 2: 
Research recommendation
- Very low This recommendation places relatively 
higher value on predictability for the 
treatment response and the impact on 
the treatment decision. Lower value 
 There is a need for convenient, safe, and practical 
tests for detecting predicting anti-inflammatory 
treatment responses in chronic cough. In 
randomised controlled trials of patients with 





























































was given to diagnostic sensitivity and 
specificity. 
different respiratory conditions, FeNO or blood 
eosinophil levels were positively associated with 
anti-inflammatory treatment responses[133-135]. 
However, there is no high-quality evidence to 
guide the use of FeNO or blood eosinophil counts 
as treatment response predictors in patients with 
chronic cough. In addition, there are still no 
optimal cut-off levels determined for the use in 
chronic cough populations.
Question 3: Should anti-asthmatic drugs (anti-inflammatory or bronchodilator drugs) be used to treat patients with chronic cough?
Recommendation 3a: We 
suggest a short-term ICS 
trial (2–4 weeks) in adult 
patients with chronic cough. 
Conditional Low This recommendation is based on the 
higher value of the clinical benefits 
from ICS in some patients with 
asthmatic cough (or airway 
eosinophilic inflammation) and lower 
value on adverse events.
 Asthmatic cough (cough variant asthma and 
eosinophilic bronchitis) is a frequent phenotype of 
chronic cough. Evidence for ongoing airway 
eosinophilic inflammation can be collected by 
performing differential cell counts on samples 
from sputum induction or bronchoalveolar lavage; 
however, these tests are not available at most 
clinics. Moreover, there is no high-quality 





























































evidence for the routine use of FeNO or blood 
eosinophil counts in patients with chronic cough 
(as recommendation 2). Therefore, empirical 
therapy for asthmatic cough may be considered.
 In the literature, there is a heterogeneity in the 
efficacy of ICS in adult patients with chronic cough. 
The variability in the treatment response is likely 
primarily related to patient characteristics, 
particularly eosinophilic inflammation. 
 Available evidence suggests that a high dose of ICS 
might be more effective than a low to moderate 
dose regimen, as an empirical trial. 
 A treatment response is usually seen within 2–4 
weeks. Thus, the empirical trial should be stopped 
if there is no response within 2–4 weeks. 
 The Task Force members were concerned about 
long-term overuse of ICS in the absence of 
evidence or treatment response. They were also 





























































concerned about pneumonia in relation to 
fluticasone use in patients comorbid with COPD.
Recommendation 3b: We 
suggest a short-term ICS 
trial (2-4 weeks) in children 
with chronic dry cough. 
Conditional Low This recommendation is based on a 
higher value of the clinical benefits 
from ICS in some patients with 
asthmatic cough (or eosinophilic 
inflammation) and a lower value on 
adverse events.
 Overall remarks are the same as those in adults. 
 The empirical trial should be stopped if there is no 
response within 2-4 weeks.
Recommendation 3c: We 
suggest a short-term anti-
leukotriene trial (2–4 weeks) 
in adults with chronic cough, 
particularly in those with 
asthmatic cough.
Conditional Low This recommendation is based on 
higher value on the clinical benefits 
from anti-leukotriene in some patients 
with asthmatic cough (or airway 
eosinophilic inflammation) and lower 
value on adverse events.
 Overall remarks are similar to those for ICS. 
 Currently, clinical evidence is only available in 
specific subgroups of patients, such as cough 
variant asthma or atopic cough. Overall efficacy of 
leukotriene receptor antagonist in non-specific 
chronic cough patients is uncertain.
 The empirical trial should be stopped if there is no 
response within 2–4 weeks.
Recommendation 3d: We 
suggest a short-term trial 
Conditional Moderate This recommendation is based on 
higher value on the clinical benefits 
 There is a concern about pneumonia in relation to 
fluticasone use in patients comorbid with COPD.





























































(2–4 weeks) of ICS and long-
acting bronchodilator 
combination in adults with 
chronic cough and fixed 
airflow obstruction.
from ICS and long-acting 
bronchodilator combination in some 
patients with chronic obstructive 
pulmonary disease and a lower value 
on adverse events.
 The empirical trial should be stopped if there is no 
response within 2–4 weeks.
Question 4: Should anti-acid drugs (PPIs and H2 antagonists) be used to treat patients with chronic cough?
Recommendation 4: We 
suggest that clinicians do 
not routinely use anti-acid 
drugs in adult patients with 
chronic cough.
Conditional Low This recommendation is based on 
higher value of the clinical benefits 
from anti-acid drugs only in some 
patients with acid reflux and a lower 
value on adverse events.
 Anti-acid drugs are unlikely to be useful in 
improving cough outcomes, unless patients have 
peptic symptoms or evidence of acid reflux.
 Clinical benefits from PPI over placebo on cough 
outcomes are not significant in patients without 
acid reflux and only modest in those with acid 
reflux. These agents effectively block gastric acid 
production and relieve acid-related symptoms but 
have little effect on the number and volume of 
reflux events. Gastric acid does not appear to play 
a major role in the aetiology of chronic cough. 





























































 PPIs are mostly considered well tolerated. 
However, there is a potential concern about 
increased risks of complications, such as 
pneumonia, iron deficiency, vitamin B2 deficiency, 
small intestinal bacterial overgrowth, Clostridium 
difficile-associated diarrhoea, or bone fracture 
[118].
Question 5: Should drugs with pro-motility activity (reflux inhibitors, prokinetics and macrolides with pro-motility activity) be used to treat patients with chronic cough?
Recommendation 5:  There 
is currently insufficient 
evidence to recommend the 
routine use of macrolide 
therapy in chronic cough. A 
one month trial of 
macrolides can be 
considered in the cough of 
chronic bronchitis refractory 
to other therapy, taking into 
Conditional Low This recommendation is based on 
higher value on the clinical benefits 
from drugs with pro-motility activity 
only in some patients with chronic 
bronchitis and lower value on adverse 
events.
 Current evidence only supports the use of 
azithromycin in patients with chronic bronchitis 
phenotype. However, mechanisms of 
azithromycin in improving cough outcomes are 
suggested to include prokinetic effects[136].
 Since oesophageal dysmotility is a frequent finding 
in chronic cough patients, promotility agents such 
as metoclopramide, domperidone, and 
azithromycin might be considered, although the 
clinical trial evidence in cough is sparse.  





























































account local guidelines on 
antimicrobial stewardship.
Question 6: Which cough neuromodulatory agents (pregabalin, gabapentin, tricyclics, and opiates) should be used to treat patients with chronic cough?
Recommendation 6a: We 
recommend a trial of low 
dose morphine (5–10 mg 
bd) in adult patients with 
chronic refractory cough.
Strong Moderate This recommendation is based on a 
higher value of the clinical benefits and 
adverse events from opiates for 
chronic refractory cough.
 Agents acting directly on cough hypersensitivity 
rather than the treatable traits causing 
hypersensitivity is a promising strategy for future 
developments. Current agents have been shown 
to be effective, but the side effect profile is 
significant and may be mitigated by the use of 
lower doses than that used to treat pain.
 Clinical experience suggests that only a proportion 
of patients (approximately half) respond to 
opiates. In responders, treatment response is very 
rapid and clear (usually seen in a week). Thus, 
discontinuation is recommended if there is no 
response in 1 or 2 weeks.
 Codeine is generally not recommended (except 
where it is the only available opiate) due to inter-





























































individual genetic variability in drug metabolism 
(CYP2D6) and consequent less predictable 
treatment response and side effect profile 
particularly in children.
Recommendation 6b: We 
suggest a trial of gabapentin 
or pregabalin in adult 
patients with chronic 
refractory cough.
Conditional Low This recommendation is based on a 
higher value of the clinical benefits and 
adverse events from gabapentin in 
chronic refractory cough.
 Clinical experience suggests the response rates of 
gabapentin and pregabalin are lower than that of 
opiates, and adverse events are more common. 
Common adverse effects are blurred vision, 
disorientation, dizziness, dry mouth, fatigue, and 
nausea.
Question 7: Should non-pharmacological therapy (cough control therapy) be used to treat patients with chronic cough?
Recommendation 7: We 
suggest a trial of cough 
control therapy in adult 
patients with chronic cough. 
Conditional Moderate This recommendation is based on a 
higher value of the clinical benefits 
from cough control therapy in chronic 
refractory cough, but lower value on 
adverse events.
 Multi-component physiotherapy/speech and 
language therapy interventions may be 
considered for short-term improvement of health-
related quality of life and cough frequency in 
patients with refractory chronic cough or who 
wish an alternative to drug treatment. However, 
this is a complex intervention that requires further 





























































study to determine which components are of 
value. Thus, experienced practitioners should 
undertake cough-directed physiotherapy and 
speech and language therapy intervention. The 
pool of individuals qualified for cough control 
therapy is currently lacking in many countries and 
should be increased.
Question 8: Should a trial of antibiotics be used in children with chronic wet cough with normal chest x ray, normal spirometry and no warning signs?
Recommendation 8: We 
suggest a trial of antibiotics 
in children with chronic wet 
cough with normal chest X-
rays, normal spirometry, 
and no warning signs. 
Conditional Low This recommendation is based on 
higher value of the clinical benefit from 
antibiotics in chronic wet cough, but 
lower value on adverse events.
 Protracted bacterial bronchitis is a common 
treatable trait in children. Preferred antibacterial, 
dose, and duration of therapy is unknown.
 Signs and symptoms suggestive of specific disease 
should always be investigated.
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Cough assessment in adults
History taking and physical examination on presentation
 Cough duration
 Cough impact and triggers
 Family history
 Cough score (using VAS or verbal out of 10)
 HARQ
 Associated symptoms: throat, chest, GI
 Risk factors: ACE inhibitor, smoking, sleep apnoea
 Physical examination: throat, chest, ear
Routine evaluation
 Chest X-ray
 Pulmonary function test
 ?FeNO
 ?Blood count for eosinophils
Initial management
 Stop risk factors
 Initiate corticosteroids (oral or inhaled) or LTRA, particularly when FeNO or blood eosinophils high
 Initiate PPI only when peptic symptoms or evidence of acid reflux are present
Follow up assessment for cough
 Cough score (using VAS or 0 – 10)
 Associated symptoms
Improvement
 Continue for 3/12 and 
attempt withdrawal
No improvement
 consider low dose opiate
 consider promotility agent
 consider gabapentin
 consider pregabalin
 consider cough control therapy
Additional evaluation where indicated
 High resolution oesophageal manometry



































































Cough assessment flow chart in children
Detailed history1
Clinical presentation of cough2
Physical examination
Identify symptoms and signs suggestive for specific 
disease 4,5
Perform chest X-ray
Perform spirometry >5 years (collaborative children)
Symptom and signs of specific 
disease present 4,5
Specific pointers identified
Symptom and signs of specific 
disease absent
Specific pointers not identified
Investigate and treat accordingly Wet cough Dry cough































































Rule out precedent infection
Wet cough Dry cough
Attempt sputum culture
Treat with antibiotics as for PBB 

















Follow for 4 weeks
Spontaneous 
regression
Persistent 4 – 8 week trial 
with ICS
Resolution Follow up for 
recurrence



































































1. See - Reference 11
2. Clinical presentation of cough: How and when the cough started, time-course of cough, nature and quality of cough, symptoms associated 
with cough, triggers of cough, diurnal and nocturnal variations, cough associated with indoor and outdoor irritants.
3. See – Reference 69
4. Symptoms and signs of specific diseases: chest pain, history suggestive of inhaled foreign body, dyspnoea, exertional dyspnoea, 
haemoptysis, failure to thrive, feeding difficulties (including choking/vomiting), cardiac or neurodevelopmental abnormalities, recurrent 
sinopulmonary infections, immunodeficiency, epidemiological risk factors for exposure to tuberculosis, signs of respiratory distress, digital 
clubbing, chest wall deformity, auscultatory crackles, chest radiographic changes (other than perihilar changes).
5. Specific conditions and diseases: cystic fibrosis, primary ciliary dyskinesia, immune deficiency, tuberculosis, aspiration syndromes, 
tracheobronchomalacia, somatic and tic cough, bronchiectasis, children's interstitial lung disease, upper airway syndrome, asthma, ACE-
inhibitor induced cough.
6. Testing for allergy not to be routinely performed, should be undertaken in presence of features and signs of allergy






























































ERS guidelines on the diagnosis and treatment of chronic cough in adults and children
Online-Only Supplement Part 1.
1. Methods
Scope and purpose
The purpose of these guidelines is to provide guidance for the diagnosis and treatment of chronic 
cough in adults and children. The guidelines aim to improve diagnostic accuracy and promote 
evidence-based therapy for paediatric and adult patients in primary and secondary care. The 
guidelines are intended for use by all healthcare professionals treating patients with chronic 
cough. 
Panel composition
The Task Force (TF) chairs (A.H. Morice and E. Millqvist) led all aspects of project 
management and selected the TF members. The TF consisted of a multidisciplinary international 
panel of clinicians and scientists with a published record of expertise in the field, a junior 
member, and methodologists. European Respiratory Society (ERS) methodologists (T. Tonia and 
D. Rigau) provided expertise in guideline development following the Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE) approach. The 
methodologists coordinated and guided TF members throughout the entire process of conducting 
systematic reviews, generating recommendations, and ensuring methodological robustness, 
according to the GRADE approach. Input on patient views and preferences was sought via the 
European Lung Foundation, which provided an advisory group of patient representatives who 






























































expressed their preferences via teleconferences, attendance at the ERS Congress, and in writing. 
They contributed to formulating and prioritising the key questions. 
Formulating clinical questions
The TF members compiled a list of issues that they considered important and relevant to the 
management of chronic cough. The questions were rephrased by the methodologists using the 
Population, Intervention, Comparator and Outcomes (PICO) format. Discussion and consensus 
among the chairs and TF members was used to decide the eight questions of clinical uncertainty 
that would be addressed in the guidelines.
Outcome importance rating
After choosing the eight PICO questions, the TF identified outcomes that they considered 
relevant to each question. The following outcomes were considered for the PICO questions on 
treatment: cough frequency, cough severity, cough-specific quality of life, cough-related 
complications, specific impact of cough (on self-esteem, sleep, fatigue, depression, social 
isolation), tussive response to cough challenge, and adverse events. Sensitivity/specificity, 
association to the treatment response, change in the treatment decision, and adverse events were 
considered for the PICO questions on diagnostics. Then, all TF members including the patient 
representatives rated the importance of each outcome using a scale from 1–9: a rating of 1–3 to 
outcomes of low importance; 4–6 to outcomes important; and 7–9 to outcomes critically 
important for decision-making. A teleconference was convened during which the ratings were 
discussed, and some additional outcomes were rated. At the conclusion of the teleconference, all 
outcomes were categorised as “not important,” “important,” or “critical” for decision-making 
during development of the guidelines.































































The methodology group performed a full systematic review of the literature for each PICO 
question to identify and summarise the current evidence about the effects of diagnostics or 
therapeutics on cough outcomes. A systematic search was also conducted to collect information 
about patients’ values and preferences. Pubmed MEDLINE, Embase, and Cochrane Central 
Register of Controlled Trials databases were searched for relevant articles from inception until 
August 2017, and updated in June 2018. The search strategy was constructed with professional 
assistance from a methodologist (H.J. Kim, Institute for Evidence-based Medicine and 
Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea). 
Manual searches were performed for cross-referenced articles. 
Selection criteria
Study eligibility was assessed using pre-defined criteria for each PICO question. Common 
eligibility criteria for inclusion were: 1) a population with chronic cough as the main complaint 
regardless of their underlying conditions (chronic cough defined as cough lasting > 8 weeks in 
adults and > 4 weeks in children), 2) intervention (or investigation) and/or comparison relevant 
to each PICO question, and 3) outcomes related to cough. The population criteria were based on 
the recent ERS Task Force report, which views chronic cough as a clinical syndrome presenting 
as cough hypersensitivity [1]. Thus, studies of specific chronic cough conditions, such as cough 
variant asthma, eosinophilic bronchitis, chronic bronchitis in chronic obstructive pulmonary 
disease, and chronic wet cough, were also considered. Only full-text publications were 
considered. Only randomised placebo-controlled trials were considered for the treatment efficacy 
for PICO questions, because placebo or period effects are substantial in cough. Cross-over trials 






























































were considered for inclusion depending on the availability of parallel trials and the 
pharmacology of drugs. Randomised controlled trials (RCTs) and observational studies were 
considered for diagnostic questions. There was no language restriction in the selection criteria.
Study selection
The relevancy of the retrieved studies was determined by at least two independent reviewers per 
PICO questions, according to the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses guidelines. Briefly, the titles and abstracts of initially retrieved studies were screened 
and the full texts were reviewed for potentially relevant studies. Reasons for full-text exclusion 
were specified. Disagreements between reviewers were resolved by discussion and consensus 
within the committee. 
Evidence synthesis
Study characteristics, type of participants, interventions (or investigations), the outcomes 
measured, and results were extracted from each study. If the data were amenable to pooling, 
effects were estimated via meta-analysis using Review Manager (version 5.3; The Nordic 
Cochrane Centre, Copenhagen, Denmark). The random effects model was primarily utilised for 
the meta-analyses, unless otherwise specified. Dichotomous outcomes are reported as odds ratios 
and continuous outcomes are reported as mean differences or standardised mean differences 
(SMD), unless otherwise specified. To facilitate understanding of the SMD, we used an 
interpretation of the effect size following Cohen’s criteria [2]: small, SMD = 0.2; moderate, 
SMD = 0.5; and large, SMD = 0.8. 
The methodologists appraised the quality of the evidence using the GRADE approach. The 
methodologists used the GRADEpro tool (McMaster University, Hamilton, ON, Canada) to 






























































develop evidence profiles that summarised the findings for each outcome and the rationale for 
the quality of the evidence appraisal. Thresholds for clinically important changes were based on 
published literature when available, but also relied on the clinical experience of the TF members, 
as many of the previous outcomes were not validated.
Formulating and grading the recommendations
The evidence profiles were sent to the TF members for review. Using an iterative process 
conducted face to face, via teleconference, and via email, consensus recommendations were 
formulated based on the following considerations: the balance of desirable (benefits) and 
undesirable consequences (burden, adverse effects and cost) of the intervention (or investigation), 
quality of the evidence, patient values and preferences, and feasibility.
The quality of the evidence was rated for outcomes of interest in each PICO question according 
to the GRADE approach. Briefly, the evidence supported by RCTs was considered high quality, 
while that of observational studies was considered low quality. Five factors were considered for 
possible down-rating of a study (risk of bias, inconsistency, indirectness, imprecision, and 
publication bias) and three factors for possible up-rating (large effects, dose response, and all 
plausible residual confounders). Then, the committee members determined the direction and 
strength of the recommendations based on the following considerations: balance of benefits and 
undesirable consequences of intervention (or investigation), quality of evidence, patient values 
and preferences, and feasibility.
Briefly, one of two grades (strong or conditional) was assigned to describe the strength of the 
recommendations. The criterion for a strong recommendation was evidence that the desirable 
effects clearly outweighed the undesirable effects (or vice versa). The criterion for a conditional 






























































recommendation was evidence that the desirable effects likely or slightly outweighed the 
undesirable effects (or vice versa). Two classifications were used to indicate the direction of the 
recommendations (for or against) of a specific treatment or test.































































1 Morice AH, Millqvist E, Belvisi MG, et al. Expert opinion on the cough hypersensitivity 
syndrome in respiratory medicine. Eur Respir J 2014; 44: 1132-1148.
2 Cohen J. Statistical power analysis for the behavioral sciences. Routledge, 2013.





























































ERS guidelines on the diagnosis and treatment of chronic cough in adults and children
Online-Only Supplement Part 2.
2. Research Protocols 
Research Protocol, Question 1
Question Should chest CT be routinely performed on chronic cough patient with normal chest X-ray 
and physical examination?
Objective To examine the diagnostic utility of chest CT in chronic cough patients with normal chest 
X-rays and physical examination
Criteria Randomised trials or observational studies on the diagnostic utility of chest CT in in chronic 
cough patients with normal chest X-rays and physical examination
Population Chronic cough patients with normal chest X-ray and physical examination
Investigation Chest CT scan
Comparison None
Outcomes  Change in treatment decision (important)
 Sensitivity and specificity (important)
 Direct adverse events (important)
Search strategy Chronic cough populations (regardless of underlying conditions) AND chest CT
Source: Pubmed/Medline, Embase and Cochrane Controlled Register of Trials (CENTRAL)
Study type: Randomised trial or observational study
Year: From inception to 2018 June
Language: Not restricted
Research Protocol, Question 2





























































Question Should FeNO/blood eosinophils be used to predict treatment response to 
corticosteroids/anti-leukotrienes in chronic cough?
Objective To examine the utility of FeNO and blood eosinophils to predict treatment response to 
corticosteroids and anti-leukotrienes in chronic cough patients 
Criteria Randomised trials or observational studies on the utility of FeNO and blood eosinophils to 
predict treatment response to corticosteroids and anti-leukotrienes in chronic cough patients
Population Patients with chronic cough as the main complaint regardless of their underlying conditions
Investigation FeNO or blood eosinophils
Comparison None
Outcomes  Association with treatment response (important)
 Change in treatment decision (important)
 Sensitivity and specificity (important)
Search strategy Chronic cough populations (regardless of underlying conditions) AND FeNO/blood 
eosinophils AND corticosteroids/anti-leukotrienes
Source: Pubmed/Medline, Embase and Cochrane Controlled Register of Trials (CENTRAL)
Study type: Randomised trial or observational study
Year: From inception to 2018 June
Language: Not restricted
Research Protocol, Question 3
Question Should anti-asthmatic drugs (anti-inflammatory or bronchodilator drugs) be used to treat 
patients with chronic cough?
Objective To compare anti-asthmatic drugs (inhaled or systemic corticosteroids, inhaled 
bronchodilators, or anti-leukotrienes) to placebo for improving cough outcomes in chronic 
cough patients





























































Criteria Randomised placebo-controlled trials comparing anti-asthmatic drugs (inhaled or systemic 
corticosteroids, inhaled bronchodilators, or anti-leukotrienes) with placebo in adults or 
children with chronic cough as the main complaint (regardless of underlying conditions)
Population Patients with chronic cough as the main complaint regardless of their underlying conditions
Intervention Inhaled or systemic corticosteroids, inhaled bronchodilators, or anti-leukotrienes
Comparison Placebo
Outcomes  Cough frequency (critical)
 Cough severity VAS (critical)
 Cough-specific quality-of-life questionnaire (critical)
 Cough severity symptom score (important)
 Generic quality-of-life questionnaire (important)
 Incontinence (important)
 Impact of cough on self-esteem, sleep, fatigue, depression, social isolation etc. 
(important)
 Tussive response to cough challenge (important)
 Treatment specific adverse events (important)
Search strategy Chronic cough populations (regardless of underlying conditions) AND anti-asthmatic drugs 
(inhaled or systemic corticosteroids, inhaled bronchodilators, or anti-leukotrienes)
Source: Pubmed/Medline, Embase and Cochrane Controlled Register of Trials (CENTRAL)
Study type: Randomised placebo-controlled trial
Year: From inception to 2018 June
Language: Not restricted
Research Protocol, Question 4





























































Question Should anti-acid drugs (PPIs and H2 antagonists) be used to treat patients with chronic 
cough?
Objective To compare anti-acid drugs (PPIs and H2 antagonists) to placebo for improving cough 
outcomes in chronic cough patients
Criteria Randomised placebo-controlled trials comparing anti-acid drugs (PPIs and H2 antagonists) 
with placebo in adults or children with chronic cough as the main complaint (regardless of 
underlying conditions)
Population Patients with chronic cough as the main complaint regardless of their underlying conditions
Intervention PPIs or H2 antagonists
Comparison Placebo
Outcomes  Cough frequency (critical)
 Cough severity VAS (critical)
 Cough-specific quality-of-life questionnaire (critical)
 Cough severity symptom score (important)
 Generic quality-of-life questionnaire (important)
 Incontinence (important)
 Impact of cough on self-esteem, sleep, fatigue, depression, social isolation etc. 
(important)
 Tussive response to cough challenge (important)
 Treatment specific adverse events (important)
Search strategy Chronic cough populations (regardless of underlying conditions) AND anti-acid drugs (PPIs 
and H2 antagonists) 
Source: Pubmed/Medline, Embase and Cochrane Controlled Register of Trials (CENTRAL)
Study type: Randomised placebo-controlled trial
Year: From inception to 2018 June
Language: Not restricted





























































Research Protocol, Question 5
Question Should drugs with pro-motility activity (reflux inhibitors, prokinetics, or macrolides with 
pro-motility activity) be used to treat patients with chronic cough?
Objective To compare drugs with pro-motility activity (reflux inhibitors, prokinetics, or macrolides 
with pro-motility activity) to placebo for improving cough outcomes in chronic cough 
patients
Criteria Randomised placebo-controlled trials comparing drugs with pro-motility activity (reflux 
inhibitors, prokinetics, or macrolides with pro-motility activity) with placebo in adults or 
children with chronic cough as the main complaint (regardless of underlying conditions)
Population Patients with chronic cough as the main complaint regardless of their underlying conditions
Intervention Reflux inhibitors, prokinetics, or macrolides with pro-motility activity
Comparison Placebo
Outcomes  Cough frequency (critical)
 Cough severity VAS (critical)
 Cough-specific quality-of-life questionnaire (critical)
 Cough severity symptom score (important)
 Generic quality-of-life questionnaire (important)
 Incontinence (important)
 Impact of cough on self-esteem, sleep, fatigue, depression, social isolation etc. 
(important)
 Tussive response to cough challenge (important)
 Treatment specific adverse events (important)
Search strategy Chronic cough populations (regardless of underlying conditions) AND drugs with pro-
motility activity (reflux inhibitors, prokinetics, or macrolides with pro-motility activity)
Source: Pubmed/Medline, Embase and Cochrane Controlled Register of Trials (CENTRAL)





























































Study type: Randomised placebo-controlled trial
Year: From inception to 2018 June
Language: Not restricted
Research Protocol, Question 6
Question Which cough neuromodulatory agents (pregabalin, gabapentin, tricyclics, and opiates) 
should be used to treat patients with chronic cough?
Objective To compare cough neuromodulatory agents (pregabalin, gabapentin, tricyclics, and opiates) 
to placebo for improving cough outcomes in adults with chronic cough
Criteria Randomised placebo-controlled trials comparing cough neuromodulatory agents 
(pregabalin, gabapentin, tricyclics, and opiates) with placebo in adults with chronic cough 
as the main complaint (regardless of underlying conditions)
Population Adult with chronic cough as the main complaint regardless of their underlying conditions
Intervention Pregabalin, gabapentin, tricyclics, or opiates
Comparison Placebo
Outcomes  Cough frequency (critical)
 Cough severity VAS (critical)
 Cough-specific quality-of-life questionnaire (critical)
 Treatment specific adverse events (critical)
 Cough severity symptom score (important)
 Generic quality-of-life questionnaire (important)
 Incontinence (important)
 Impact of cough on self-esteem, sleep, fatigue, depression, social isolation etc. 
(important)
 Tussive response to cough challenge (important)





























































Search strategy Chronic cough populations (regardless of underlying conditions) AND cough 
neuromodulatory agents (pregabalin, gabapentin, tricyclics, and opiates)
Source: Pubmed/Medline, Embase and Cochrane Controlled Register of Trials (CENTRAL)
Study type: Randomised placebo-controlled trial
Year: From inception to 2018 June
Language: Not restricted
Research Protocol, Question 7
Question Should non-pharmacological therapy (cough control therapy) be used to treat patients with 
chronic cough?
Objective To compare non-pharmacological therapy (cough control therapy) to placebo for improving 
cough outcomes in chronic cough patients
Criteria Randomised placebo-controlled trials comparing non-pharmacological therapy (cough 
control therapy) with placebo in adults or children with chronic cough as the main complaint 
(regardless of underlying conditions)
Population Patients with chronic cough as the main complaint regardless of their underlying conditions
Intervention Cough control therapy
Comparison Placebo
Outcomes  Cough frequency (critical)
 Cough severity VAS (critical)
 Cough-specific quality-of-life questionnaire (critical)
 Cough severity symptom score (important)
 Generic quality-of-life questionnaire (important)
 Incontinence (important)





























































 Impact of cough on self-esteem, sleep, fatigue, depression, social isolation etc. 
(important)
 Tussive response to cough challenge (important)
Search strategy Chronic cough populations (regardless of underlying conditions) AND non-
pharmacological therapy (cough control therapy)
Source: Pubmed/Medline, Embase and Cochrane Controlled Register of Trials (CENTRAL)
Study type: Randomised placebo-controlled trial
Year: From inception to 2018 June
Language: Not restricted
Research Protocol, Question 8
Question Should a trial of antibiotics be used in children with chronic wet cough without  warning 
signs, normal chest x ray and, normal spirometry and no warning signs?
Objective To compare a trial of antibiotics to placebo for improving cough outcomes in children with 
chronic cough 
Criteria Randomised placebo-controlled trials comparing a trial of antibiotics with placebo in 
children with chronic wet cough with normal chest X-rays, normal spirometry and no 
warning signschronic cough as the main complaint (regardless of underlying conditions)
Population Children with chronic wet cough with normal chest X-rays, normal spirometry and no 
warning signs
Intervention Antibiotics (amoxicillin, clavulanate, erythromycin or clarithromycin)
Comparison Placebo
Outcomes  Cough frequency (critical)
 Cough severity VAS (critical)
 Cough-specific quality-of-life questionnaire (critical)





























































 Cough severity symptom score (important)
 Generic quality-of-life questionnaire (important)
 Incontinence (important)
 Impact of cough on self-esteem, sleep, fatigue, depression, social isolation etc. 
(important)
 Treatment specific adverse events (important)
 Tussive response to cough challenge (important)
Search strategy Chronic wet cough or bronchitis populations (regardless of underlying conditions) AND a 
trial of antibiotics (amoxicillin, clavulanate, erythromycin or clarithromycin)
Source: Pubmed/Medline, Embase and Cochrane Controlled Register of Trials (CENTRAL)
Study type: Randomised placebo-controlled trial
Year: From inception to 2018 June
Language: Not restricted





























































3. Electronic search strategies
Question 1: Should chest CT be routinely performed on chronic cough patient with normal chest X-ray and 
physical examination?
Last search: June 2018
Pubmed MEDLINE
#1. ("Cough"[Mesh] OR cough[TIAB] OR coughing[TIAB] OR coughs[TIAB] OR "Bronchitis"[Mesh:NoExp] OR 
"Bronchitis, Chronic"[Mesh] OR bronchitis[TIAB] OR bronchitic[TIAB]) 
#2. (chronic[TIAB] OR persistent[TIAB] OR longstanding[TIAB] OR long-standing[TIAB] OR longterm[TIAB] 
OR long-term[TIAB] OR uncontrolled[TIAB] OR “poorly controlled” [TIAB] OR lingering[TIAB] OR 
nagging[TIAB] OR resistant[TIAB] OR refractory[TIAB] OR unexplained[TIAB] OR idiopathic[TIAB] OR 
frequent[TIAB]) 
#3. #1 AND #2 
#4. "Tomography, X-Ray Computed"[Mesh] OR ct[TIAB] OR "computed tomography"[TIAB] OR "computed 
tomogram"[TIAB] OR "computerized tomography"[TIAB] OR “computerised tomography”[TIAB] OR “computed 
X-ray tomography”[TIAB] OR "computer assisted tomography"[TIAB] OR "computerized axial 
tomography"[TIAB] OR “computerised axial tomography”[TIAB] 
#5. #3 AND #4 
#6. #5 NOT (animals[Mesh Term] NOT (humans[Mesh Term] AND animals[Mesh Term])) 
Embase
#1. 'coughing'/exp OR cough:ab,ti OR coughing:ab,ti OR coughs:ab,ti OR 'bronchitis'/de OR 'chronic bronchitis'/exp 
OR 'laryngotracheobronchitis'/exp OR 'tracheobronchitis'/exp OR bronchitis:ab,ti OR bronchitic:ab,ti 
#2. chronic:ab,ti OR persistent:ab,ti OR longstanding:ab,ti OR 'long standing':ab,ti OR longterm:ab,ti OR 'long 
term':ab,ti OR uncontrolled:ab,ti OR 'poorly controlled':ab,ti OR lingering:ab,ti OR nagging:ab,ti OR resistant:ab,ti 
OR refractory:ab,ti OR unexplained:ab,ti OR idiopathic:ab,ti OR frequent:ab,ti = 3417568
#3. #1 AND #2 
#4. 'computer assisted tomography'/exp OR ct:ab,ti OR "computed tomography":ab,ti OR "computed 
tomogram":ab,ti OR "computerized tomography":ab,ti OR “computerised tomography”:ab,ti OR “computed X-ray 
tomography”:ab,ti OR "computer assisted tomography":ab,ti OR "computerized axial tomography":ab,ti OR 
“computerised axial tomography”:ab,ti 
#5. #3 AND #4 
#6. #5 NOT ('animal experiment'/de OR 'animal model'/de OR 'in vitro study'/de OR 'nonhuman'/de) 
Cochrane library
#1. MeSH descriptor: [Cough] explode all trees 
#2. cough:ti,ab,kw (Word variations have been searched) 





























































#3. MeSH descriptor: [Bronchitis] this term only 
#4. MeSH descriptor: [Bronchitis, Chronic] explode all trees 
#5. bronchitis:ti,ab,kw (Word variations have been searched) 
#6. #1 OR #2 OR #3 OR #4 OR #5 
#7. chronic or persistent or longstanding or long-standing or longterm or long-term or uncontrolled or "poorly 
controlled" or lingering or nagging or resistant or refractory or unexplained or idiopathic or frequent:ti,ab,kw (Word 
variations have been searched) 
#8. #6 AND #7 
#9. MeSH descriptor: [Tomography, X-Ray Computed] explode all trees 
#10. ct or "computed tomography" or "computed tomogram" or "computerized tomography" or "computerised 
tomography" or "computed X-ray tomography" or "computer assisted tomography" or "computerized axial 
tomography" or "computerised axial tomography":ti,ab,kw (Word variations have been searched) 
#11. #9 OR #10 
#12. #8 AND #11 
#13. #12 in Trials 
Question 2: Should FeNO/blood eosinophils be used to predict treatment response to corticosteroids/anti-
leukotrienes in chronic cough?
Last search: June 2018
Pubmed MEDLINE
#1. ((("Cough"[Mesh]) OR (cough[TIAB] OR coughing[TIAB] OR coughs[TIAB])) OR 
(("Bronchitis"[Mesh:NoExp]) OR "Bronchitis, Chronic"[Mesh])) OR (bronchitis[TIAB] OR bronchitic[TIAB])
#2. "Adrenal Cortex Hormones"[Mesh:NoExp] OR "Glucocorticoids"[Mesh] OR 
"Hydroxycorticosteroids"[Mesh:NoExp] OR "Steroids"[Mesh:NoExp] OR "Beclomethasone"[Mesh] OR 
"Betamethasone"[Mesh] OR "Budesonide"[Mesh] OR "Fluticasone"[Mesh] OR "Mometasone Furoate"[Mesh] OR 
"Triamcinolone"[Mesh] OR "ciclesonide" [Supplementary Concept] OR "flunisolide" [Supplementary Concept] OR 
"Prednisolone"[Mesh] OR "Prednisone"[Mesh] OR "Dexamethasone"[Mesh] OR "Cortisone"[Mesh] OR 
"Hydrocortisone"[Mesh] OR "Leukotriene Antagonists"[Mesh] OR "montelukast" [Supplementary Concept] OR 
"pranlukast" [Supplementary Concept] OR "zafirlukast" [Supplementary Concept]
#3. (glucocorticoid[TIAB] OR glucocorticoids[TIAB] OR corticosteroid[TIAB] OR corticosteroids[TIAB] OR 
steroid[TIAB] OR steroids[TIAB]) OR beclomethasone[TIAB] OR betamethasone[TIAB] OR budesonide[TIAB] 
OR fluticasone[TIAB] OR mometasone[TIAB] OR triamcinolone[TIAB] OR ciclesonide[TIAB] OR 





























































flunisolide[TIAB] OR prednisolone[TIAB] OR prednisone[TIAB] OR methylprednisolone[TIAB] OR 
dexamethasone[TIAB] OR cortisone[TIAB] OR hydrocortisone[TIAB] OR montelukast[TIAB] OR 
pranlukast[TIAB] OR zafirlukast[TIAB] OR leukotriene[TIAB] OR leukotrienes[TIAB] OR leukotrien[TIAB] OR 
leucotriene[TIAB] OR leucotrienes[TIAB] OR leucotrien[TIAB] OR anti-leukotriene[TIAB] OR anti-
leukotrienes[TIAB] OR anti-leukotrien[TIAB] OR anti-leucotriene[TIAB] OR anti-leucotrienes[TIAB] OR anti-
leucotrien[TIAB]
#4. "Nitric Oxide"[Mesh] OR "Eosinophils"[Mesh] OR "Biomarkers"[Mesh] OR "Sensitivity and 
Specificity"[Mesh]
#5. "nitric oxide"[TIAB] OR eno[TIAB] OR feno[TIAB] OR eosinophil[TIAB] OR eosinophils[TIAB] OR 
eosinophilic[TIAB] OR biomarker[TIAB] OR biomarkers[TIAB] OR predict[TIAB] OR predictive[TIAB] OR 
predictable[TIAB] OR predictability[TIAB] OR predicted[TIAB] OR predicts[TIAB] OR predictor[TIAB] OR 
predictors[TIAB] OR sensitivity[TIAB] OR sensitive[TIAB] OR sensitivities[TIAB] specificity[TIAB] OR 
specific[TIAB] OR specificities[TIAB] OR accuracy[TIAB] OR accurate[TIAB] OR accuracies[TIAB] OR 
“diagnostic value”[TIAB] OR “diagnostic test value”[TIAB] OR “diagnostic utility”[TIAB] OR “diagnostic test 
utility”[TIAB]
#6. #2 OR #3
#7. #4 OR #5
#8. #1 AND #6 AND #7
#9. #8 NOT ("review"[Publication Type] OR "review literature as topic"[MeSH Terms])
Embase
#1. 'coughing'/exp OR cough:ab,ti OR coughing:ab,ti OR coughs:ab,ti OR 'bronchitis'/de OR 'chronic bronchitis'/exp 
OR 'laryngotracheobronchitis'/exp OR 'tracheobronchitis'/exp OR bronchitis:ab,ti OR bronchitic:ab,ti
#2. 'corticosteroid'/de OR 'glucocorticoid'/de OR 'hydroxycorticosteroid'/exp OR 'steroid'/de OR 'beclometasone'/exp 
OR 'betamethasone'/exp OR 'budesonide'/exp OR 'fluticasone'/exp OR 'mometasone furoate'/exp OR 
'triamcinolone'/exp OR 'ciclesonide'/exp OR 'flunisolide'/exp OR 'prednisolone'/exp OR 'prednisone'/exp OR 
'methylprednisolone'/exp OR 'dexamethasone'/exp OR 'cortisone'/exp OR 'hydrocortisone'/exp OR 'leukotriene 
receptor blocking agent'/de OR 'montelukast'/exp OR 'pranlukast'/exp OR 'zafirlukast'/exp
#3. corticosteroid:ab,ti OR corticosteroids:ab,ti OR glucocorticoid:ab,ti OR glucocorticoids:ab,ti OR steroid:ab,ti 
OR steroids:ab,ti OR beclomethasone:ab,ti OR betamethasone:ab,ti OR budesonide:ab,ti OR fluticasone:ab,ti OR 
mometasone:ab,ti OR triamcinolone:ab,ti OR ciclesonide:ab,ti OR flunisolide:ab,ti OR prednisolone:ab,ti OR 
prednisone:ab,ti OR methylprednisolone:ab,ti OR dexamethasone:ab,ti OR cortisone:ab,ti OR hydrocortisone:ab,ti 





























































OR montelukast:ab,ti OR pranlukast:ab,ti OR zafirlukast:ab,ti OR leukotriene:ab,ti OR leukotrienes:ab,ti OR 
leukotrien:ab,ti OR leucotriene:ab,ti OR leucotrienes:ab,ti OR leucotrien:ab,ti OR 'anti leukotriene':ab,ti OR 'anti 
leukotrienes':ab,ti OR 'anti leukotrien':ab,ti OR 'anti leucotriene':ab,ti OR 'anti leucotrienes':ab,ti OR 'anti 
leucotrien':ab,ti
#4. 'nitric oxide'/exp OR 'eosinophil'/exp OR 'biological marker'/exp OR 'pharmacological biomarker'/exp OR 
'sensitivity and specificity'/exp OR 'predictive value'/exp OR 'diagnostic accuracy'/exp OR 'diagnostic test accuracy 
study'/exp OR 'diagnostic value'/exp
#5. 'nitric oxide':ab,ti OR eno:ab,ti OR feno:ab,ti OR eosinophil:ab,ti OR eosinophils:ab,ti OR eosinophilic:ab,ti OR 
biomarker:ab,ti OR biomarkers:ab,ti OR predict:ab,ti OR predictive:ab,ti OR predictable:ab,ti OR predictability:ab,ti 
OR predicted:ab,ti OR predicts:ab,ti OR predictor:ab,ti OR predictors:ab,ti OR sensitivity:ab,ti OR sensitive:ab,ti 
OR sensitivities:ab,ti OR specificity:ab,ti OR specific:ab,ti OR specificities:ab,ti OR accuracy:ab,ti OR 
accurate:ab,ti OR accuracies:ab,ti OR 'diagnostic value':ab,ti OR 'diagnostic test value':ab,ti OR 'diagnostic 
utility':ab,ti OR 'diagnostic test utility':ab,ti
#6. #2 OR #3
#7. #4 OR #5
#8. #1 AND #6 AND #7
#9. #8 NOT ('conference review'/it OR 'review'/it)
Cochrane Library
#1. MeSH descriptor: [Cough] explode all trees
#2. cough:ti,ab,kw (Word variations have been searched) 
#3. MeSH descriptor: [Bronchitis] this term only 
#4. MeSH descriptor: [Bronchitis, Chronic] explode all trees 
#5. bronchitis:ti,ab,kw (Word variations have been searched) 
#6. #1 OR #2 OR #3 OR #4 OR #5 
#7. MeSH descriptor: [Adrenal Cortex Hormones] this term only
#8. MeSH descriptor: [Glucocorticoids] explode all trees
#9. MeSH descriptor: [Hydroxycorticosteroids] this term only
#10. MeSH descriptor: [Beclomethasone] explode all trees
#11. MeSH descriptor: [Beclomethasone] explode all trees





























































#12. MeSH descriptor: [Betamethasone] explode all trees
#13. MeSH descriptor: [Budesonide] explode all trees
#14. MeSH descriptor: [Fluticasone] explode all trees
#15. MeSH descriptor: [Mometasone Furoate] explode all trees
#16. MeSH descriptor: [Triamcinolone] explode all trees
#17. MeSH descriptor: [Prednisolone] explode all trees
#18. MeSH descriptor: [Prednisone] explode all trees
#19. MeSH descriptor: [Dexamethasone] explode all trees
#20. MeSH descriptor: [Cortisone] explode all trees
#21. MeSH descriptor: [Hydrocortisone] explode all trees
#22. MeSH descriptor: [Leukotriene Antagonists] explode all trees
#23. glucocorticoid or glucocorticoids or corticosteroid or corticosteroids or steroid or steroids or beclomethasone or 
betamethasone or budesonide or fluticasone or mometasone or triamcinolone or ciclesonide or flunisolide or 
prednisolone or prednisone or methylprednisolone or dexamethasone or cortisone or hydrocortisone or montelukast 
or pranlukast or zafirlukast or leukotriene or leukotrienes or leukotrien or leucotriene or leucotrienes or leucotrien or 
anti-leukotriene or anti-leukotrienes or anti-leukotrien or anti-leucotriene or anti-leucotrienes or anti-
leucotrien:ti,ab,kw (Word variations have been searched)
#24. #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or 
#23
#25. MeSH descriptor: [Nitric Oxide] explode all trees
#26. MeSH descriptor: [Eosinophils] explode all trees
#27. MeSH descriptor: [Biomarkers] explode all trees
#28. MeSH descriptor: [Sensitivity and Specificity] explode all trees
#29. "nitric oxide" or eno or feno or eosinophil or eosinophils or eosinophilic or biomarker or biomarkers or predict 
or predictive or predictable or predictability or predicted or predicts or predictor or predictors or sensitivity or 
sensitive or sensitivities specificity or specific or specificities or accuracy or accurate or accuracies or "diagnostic 
value" or "diagnostic test value" or "diagnostic utility" or "diagnostic test utility":ti,ab,kw (Word variations have 
been searched)
#29. #25 or #26 or #27 or #28 or #29
#30. #6 and #24 and #29 
#31. #30 in Trials 
Question 3: Should anti-asthmatic drugs (anti-inflammatory or bronchodilator drugs) be used to treat patients 
with chronic cough?





























































Last search: June 2018
Pubmed MEDLINE
#1. ((("Cough"[Mesh]) OR (cough[TIAB] OR coughing[TIAB] OR coughs[TIAB])) OR 
(("Bronchitis"[Mesh:NoExp]) OR "Bronchitis, Chronic"[Mesh])) OR (bronchitis[TIAB] OR bronchitic[TIAB]) 
#2.  "Beclomethasone"[Mesh] OR "Betamethasone"[Mesh] OR "Budesonide"[Mesh] OR "Fluticasone"[Mesh] OR 
"Mometasone Furoate"[Mesh] OR "Triamcinolone"[Mesh] OR "ciclesonide" [Supplementary Concept] OR 
"flunisolide" [Supplementary Concept] OR "Prednisolone"[Mesh] OR "Prednisone"[Mesh] OR 
"Dexamethasone"[Mesh] OR "Cortisone"[Mesh] OR "Hydrocortisone"[Mesh] OR "Leukotriene 
Antagonists"[Mesh] OR "montelukast" [Supplementary Concept] OR "pranlukast" [Supplementary Concept] OR 
"zafirlukast" [Supplementary Concept]  
#3. "Adrenergic beta-2 Receptor Agonists"[Mesh] OR "Formoterol Fumarate"[Mesh] OR 
"vilanterol"[Supplementary Concept] OR "Salmeterol Xinafoate"[Mesh] OR "indacaterol"[Supplementary Concept] 
OR "olodaterol"[Supplementary Concept] OR "Albuterol"[Mesh] OR "tulobuterol"[Supplementary Concept] OR 
"Terbutaline"[Mesh] OR “Cholinergic Antagonists"[Mesh:NoExp] OR "Muscarinic Antagonists"[Mesh] OR 
"Ipratropium"[Mesh] OR "Glycopyrrolate"[Mesh] OR "Tiotropium Bromide"[Mesh] OR "aclidinium 
bromide"[Supplementary Concept] OR "GSK573719"[Supplementary Concept] 
#4. beclomethasone[TIAB] OR betamethasone[TIAB] OR budesonide[TIAB] OR fluticasone[TIAB] OR 
mometasone[TIAB] OR triamcinolone[TIAB] OR ciclesonide[TIAB] OR flunisolide[TIAB] OR 
prednisolone[TIAB] OR prednisone[TIAB] OR methylprednisolone[TIAB] OR dexamethasone[TIAB] OR 
cortisone[TIAB] OR hydrocortisone[TIAB] OR montelukast[TIAB] OR pranlukast[TIAB] OR zafirlukast[TIAB] 
#5. formoterol[TIAB] OR vilanterol[TIAB] OR salmeterol[TIAB] OR indacaterol[TIAB] OR olodaterol[TIAB] OR 
albuterol[TIAB] OR salbutamol[TIAB] OR levalbuterol[TIAB] OR tulobuterol[TIAB] OR terbutaline[TIAB] OR 
ipratropium[TIAB] OR glycopyrrolate[TIAB] OR tiotropium[TIAB] OR aclidinium[TIAB] OR 
umeclidinium[TIAB] 
#6. #2-5/OR 
#7. #1 AND #6 
#8. (groups[tiab] OR trial[TIAB] OR randomly[TIAB] OR "drug therapy"[SH] OR placebo[TIAB] OR 
randomized[TIAB] OR "controlled clinical trial"[PT] OR "randomized controlled trial"[PT]) NOT (animals[MH] 
NOT (humans[MH] AND animals[MH])) 
#9. #7 AND #8 
Embase
#1. 'coughing'/exp OR cough:ab,ti OR coughing:ab,ti OR coughs:ab,ti OR 'bronchitis'/de OR 'chronic bronchitis'/exp 
OR 'laryngotracheobronchitis'/exp OR 'tracheobronchitis'/exp OR bronchitis:ab,ti OR bronchitic:ab,ti 
#2. 'beclometasone'/exp OR 'betamethasone'/exp OR 'budesonide'/exp OR 'fluticasone'/exp OR 'mometasone 
furoate'/exp OR 'triamcinolone'/exp OR 'ciclesonide'/exp OR 'flunisolide'/exp OR 'prednisolone'/exp OR 
'prednisone'/exp OR 'methylprednisolone'/exp OR 'dexamethasone'/exp OR 'cortisone'/exp OR 'hydrocortisone'/exp 
OR 'leukotriene receptor blocking agent'/de OR 'montelukast'/exp OR 'pranlukast'/exp OR 'zafirlukast'/exp 
#3. 'beta 2 adrenergic receptor stimulating agent'/exp OR 'formoterol'/exp OR 'vilanterol'/exp OR 'salmeterol'/exp 
OR 'indacaterol'/exp OR 'olodaterol'/exp OR 'salbutamol'/exp OR 'tulobuterol'/exp OR 'terbutaline'/exp OR 





























































'cholinergic receptor blocking agent'/de OR 'muscarinic receptor blocking agent'/de OR 'ipratropium bromide'/exp 
OR 'glycopyrronium'/exp OR 'tiotropium bromide'/exp OR 'aclidinium bromide'/exp OR 'umeclidinium'/exp 
#4. beclomethasone:ab,ti OR betamethasone:ab,ti OR budesonide:ab,ti OR fluticasone:ab,ti OR mometasone:ab,ti 
OR triamcinolone:ab,ti OR ciclesonide:ab,ti OR flunisolide:ab,ti OR prednisolone:ab,ti OR prednisone:ab,ti OR 
methylprednisolone:ab,ti OR dexamethasone:ab,ti OR cortisone:ab,ti OR hydrocortisone:ab,ti OR montelukast:ab,ti 
OR pranlukast:ab,ti OR zafirlukast:ab,ti 
#5. formoterol:ab,ti OR vilanterol:ab,ti OR salmeterol:ab,ti OR indacaterol:ab,ti OR olodaterol:ab,ti OR 
albuterol:ab,ti OR salbutamol:ab,ti OR levalbuterol:ab,ti OR tulobuterol:ab,ti OR terbutaline:ab,ti OR 
ipratropium:ab,ti OR glycopyrrolate:ab,ti OR tiotropium:ab,ti OR aclidinium:ab,ti OR umeclidinium:ab,ti 
#6. #2 OR #3 OR #4 OR #5 
#7. #1 AND #6 
#8. 'crossover procedure'/exp OR 'double blind procedure'/exp OR 'randomized controlled trial'/exp OR 'single blind 
procedure'/exp OR random* OR factorial* OR crossover* OR 'cross over' OR 'cross-over' OR placebo* OR (doubl* 
AND blind*) OR (singl* AND blind*) OR assign* OR allocat* OR volunteer*
#9. #7 AND #8 
Cochrane library
#1. MeSH descriptor: [Cough] explode all trees 
#2. cough:ti,ab,kw (Word variations have been searched) 
#3. MeSH descriptor: [Bronchitis] this term only 
#4. MeSH descriptor: [Bronchitis, Chronic] explode all trees 
#5. bronchitis:ti,ab,kw (Word variations have been searched) 
#6. #1 OR #2 OR #3 OR #4 OR #5 
#7. MeSH descriptor: [Beclomethasone] explode all trees
#8. MeSH descriptor: [Betamethasone] explode all trees
#9. MeSH descriptor: [Budesonide] explode all trees
#10. MeSH descriptor: [Fluticasone] explode all trees
#11. MeSH descriptor: [Mometasone Furoate] explode all trees
#12. MeSH descriptor: [Triamcinolone] explode all trees
#13. MeSH descriptor: [Prednisolone] explode all trees
#14. MeSH descriptor: [Prednisone] explode all trees
#15. MeSH descriptor: [Dexamethasone] explode all trees
#16. MeSH descriptor: [Cortisone] explode all trees





























































#17. MeSH descriptor: [Hydrocortisone] explode all trees
#18. MeSH descriptor: [Leukotriene Antagonists] explode all trees
#19. beclomethasone or betamethasone or budesonide or fluticasone or mometasone or triamcinolone or ciclesonide 
or flunisolide or prednisolone or prednisone or methylprednisolone or dexamethasone or cortisone or hydrocortisone 
or montelukast or pranlukast or zafirlukast:ti,ab,kw (Word variations have been searched)
#20. MeSH descriptor: [Adrenergic beta-2 Receptor Agonists] explode all trees
#21. MeSH descriptor: [Formoterol Fumarate] explode all trees
#22. MeSH descriptor: [Salmeterol Xinafoate] explode all trees
#23. MeSH descriptor: [Albuterol] explode all trees
#24. MeSH descriptor: [Terbutaline] explode all trees
#25. MeSH descriptor: [Cholinergic Antagonists] this term only
#26. MeSH descriptor: [Muscarinic Antagonists] explode all trees
#27. MeSH descriptor: [Ipratropium] explode all trees
#28. MeSH descriptor: [Glycopyrrolate] explode all trees
#29. MeSH descriptor: [Tiotropium Bromide] explode all trees
#30. formoterol or vilanterol or salmeterol or indacaterol or olodaterol or albuterol or salbutamol or levalbuterol or 
tulobuterol or terbutaline or ipratropium or glycopyrrolate or tiotropium or aclidinium or umeclidinium:ti,ab,kw 
(Word variations have been searched)
#31. #7-30/OR 
#32. #6 AND #31 
#33. #32 in Trials 
Question 4: Should anti-acid drugs (PPIs and H2 antagonists) be used to treat patients with chronic cough?
Last search: June 2018
Pubmed MEDLINE
#1. "Cough"[Mesh] 
#2. cough[TIAB] OR coughing[TIAB] OR coughs[TIAB] 
#3. ("Bronchitis"[Mesh:NoExp]) OR "Bronchitis, Chronic"[Mesh] 
#4. bronchitis[TIAB] OR bronchitic[TIAB] 
#5. #1 OR #2 OR #3 OR #4 
#6. "Proton Pump Inhibitors"[Mesh] OR "Proton Pump Inhibitors" [Pharmacological Action] 





























































#7. "proton pump inhibitor"[TIAB] OR "proton pump inhibitors"[TIAB] OR ppi[TIAB] OR omeprazole[TIAB] OR 
esomeprazole[TIAB] OR lansoprazole[TIAB] OR dexlansoprazole[TIAB] OR pantoprazole[TIAB] OR 
rabeprazole[TIAB] OR timoprazole[TIAB] 
#8. #6 OR #7 
#9. "Histamine H2 Antagonists"[Mesh] OR "Histamine H2 Antagonists"[Pharmacological Action] 
#10. “H2 receptor blockaders”[TIAB] OR “H2 receptor blockader”[TIAB] OR “H2 receptor blockade”[TIAB] OR 
“H2 receptor blockers”[TIAB] OR “H2 receptor blocking”[TIAB] OR “H2 receptor blockers”[TIAB] OR “H2 
receptor blocker”[TIAB] OR “H2 receptor antagonists”[TIAB] OR “H2 receptor antagonist”[TIAB] OR “H2 
blockaders”[TIAB] OR “H2 blockader”[TIAB] OR "h2 blockade"[TIAB] OR “H2 blocking”[TIAB] OR “H2 
blockers”[TIAB] OR “H2 blocker”[TIAB] OR “H2 antagonists”[TIAB] OR “H2 antagonist”[TIAB] OR (H2[TIAB] 
AND antihistamin*[TIAB]) OR (H2[TIAB] AND anti-histamin*[TIAB]) OR h2ra[TIAB] OR cimetidine[TIAB] 
OR famotidine[TIAB] OR lafutidine[TIAB] OR nizatidine[TIAB] OR ranitidine[TIAB] OR roxatidine[TIAB] 
#11. #9 OR #10 
#12. #8 OR #11 
#13. #5 AND #12 
#14. (groups[tiab] OR trial[TIAB] OR randomly[TIAB] OR "drug therapy"[SH] OR placebo[TIAB] OR 
randomized[TIAB] OR "controlled clinical trial"[PT] OR "randomized controlled trial"[PT]) NOT (animals[MH] 
NOT (humans[MH] AND animals[MH])) 
#15. #13 AND #14 
Embase
#1. 'coughing'/exp 
#2. cough:ab,ti OR coughing:ab,ti OR coughs:ab,ti 
#3. 'bronchitis'/de OR 'chronic bronchitis'/exp OR 'laryngotracheobronchitis'/exp OR 'tracheobronchitis'/exp 
#4. bronchitis:ab,ti OR bronchitic:ab,ti 
#5. #1 OR #2 OR #3 OR #4 
#6. 'proton pump inhibitor'/exp 
#7. 'proton pump inhibitor':ab,ti OR 'proton pump inhibitors':ab,ti OR ppi:ab,ti OR omeprazole:ab,ti OR 
esomeprazole:ab,ti OR lansoprazole:ab,ti OR dexlansoprazole:ab,ti OR pantoprazole:ab,ti OR rabeprazole:ab,ti OR 
timoprazole:ab,ti 
#8. 'histamine h2 receptor antagonist'/exp 
#9. 'h2 receptor blockaders':ab,ti OR 'h2 receptor blockader':ab,ti OR 'h2 receptor blockade':ab,ti OR 'h2 receptor 
blocking':ab,ti OR 'h2 receptor blockers':ab,ti OR 'h2 receptor blocker':ab,ti OR 'h2 receptor antagonists':ab,ti OR 
'h2 receptor antagonist':ab,ti OR 'h2 blockaders':ab,ti OR 'h2 blockader':ab,ti OR 'h2 blockade':ab,ti OR 'h2 
blocking':ab,ti OR 'h2 blockers':ab,ti OR 'h2 blocker':ab,ti OR 'h2 antagonists':ab,ti OR 'h2 antagonist':ab,ti OR 
(h2:ab,ti AND antihistamin*:ab,ti) OR (h2:ab,ti AND 'anti histamin*':ab,ti) OR h2ra:ab,ti OR cimetidine:ab,ti OR 
famotidine:ab,ti OR lafutidine:ab,ti OR nizatidine:ab,ti OR ranitidine:ab,ti OR roxatidine:ab,ti 
#10. #6 OR #7 





























































#11. #8 OR #9 
#12. #10 OR #11 
#13. #5 AND #12 
#14. 'crossover procedure'/exp OR 'double blind procedure'/exp OR 'randomized controlled trial'/exp OR 'single 
blind procedure'/exp OR random* OR factorial* OR crossover* OR 'cross over' OR 'cross-over' OR placebo* OR 
(doubl* AND blind*) OR (singl* AND blind*) OR assign* OR allocat* OR volunteer* 
#15. #13 AND #14 
Cochrane library
#1. MeSH descriptor: [Cough] explode all trees 
#2. cough:ti,ab,kw (Word variations have been searched) 
#3. MeSH descriptor: [Bronchitis] this term only 
#4. MeSH descriptor: [Bronchitis, Chronic] explode all trees 
#5. bronchitis:ti,ab,kw (Word variations have been searched) 
#6. #1 OR #2 OR #3 OR #4 OR #5 
#7. MeSH descriptor: [Proton Pump Inhibitors] explode all trees 
#8. 'proton pump inhibitor' or 'proton pump inhibitors' or ppi or omeprazole or esomeprazole or lansoprazole or 
dexlansoprazole or pantoprazole or rabeprazole or timoprazole:ti,ab,kw (Word variations have been searched) 
#9. MeSH descriptor: [Histamine H2 Antagonists] explode all trees 
#10. "H2 receptor blockaders" or "H2 receptor blockader" or "H2 receptor blockade" or "H2 receptor blockers" or 
"H2 receptor blocking" or "H2 receptor blockers" or "H2 receptor blocker" or "H2 receptor antagonists" or "H2 
receptor antagonist" or "H2 blockaders" or "H2 blockader" or "h2 blockade" or "H2 blocking" or "H2 blockers" or 
"H2 blocker" or "H2 antagonists" or "H2 antagonist" or (H2 and antihistamin*) or (H2 and anti-histamin*) or h2ra 
or cimetidine or famotidine or lafutidine or nizatidine or ranitidine or roxatidine:ti,ab,kw (Word variations have been 
searched) 
#11. #7 OR #8 
#12. #9 OR #10 
#13. #11 OR #12 
#14. #13 in Trials 
Question 5: Should drugs with pro-motility activity (reflux inhibitors, prokinetics and macrolides with pro-
motility activity) be used to treat patients with chronic cough?
Last search: June 2018






























































#1. ((("Cough"[Mesh]) OR (cough[TIAB] OR coughing[TIAB] OR coughs[TIAB])) OR 
(("Bronchitis"[Mesh:NoExp]) OR "Bronchitis, Chronic"[Mesh])) OR (bronchitis[TIAB] OR bronchitic[TIAB]) 
#2. "Metoclopramide"[Mesh] OR Metoclopramide[TIAB] OR Metaclopramide[TIAB] OR Metoclopromide[TIAB] 
OR Maxolon[TIAB] OR Primperan[TIAB] OR Reglan[TIAB] OR Cerucal[TIAB] 
#3. "Domperidone"[Mesh] OR Domperidone[TIAB] OR Domperidon[TIAB] OR Motilium[TIAB] 
#4. "Baclofen"[Mesh] OR Baclofen[TIAB] OR Baclophen[TIAB] 
#5. "Macrolides"[Mesh:NoExp] OR Macrolides[TIAB] OR Macrolide[TIAB] OR "Erythromycin"[Mesh] OR 
Erythromycin[TIAB] OR Monomycin[TIAB] OR Mitemcinal[TIAB] OR Azithromycin[TIAB] OR 
Azythromycin[TIAB] OR Zithromax[TIAB] OR Sumamed[TIAB] OR Clarithromycin[TIAB] OR Biaxin[TIAB] 
OR Ketolides[TIAB] OR Roxithromycin[TIAB] OR Rulide[TIAB] OR Rulid[TIAB] OR "Troleandomycin"[Mesh] 
OR Troleandomycin[TIAB] OR Triacetyloleandomycin[TIAB] OR Telithromycin[TIAB] OR Ketek[TIAB] 
#6. #2 OR #3 OR #4 OR #5 
#7. #1 AND #6 
#8. (groups[tiab] OR trial[TIAB] OR randomly[TIAB] OR "drug therapy"[SH] OR placebo[TIAB] OR 
randomized[TIAB] OR "controlled clinical trial"[PT] OR "randomized controlled trial"[PT]) NOT (animals[MH] 
NOT (humans[MH] AND animals[MH])) 
#9. #7 AND #8 
Embase
#1. 'coughing'/exp OR cough:ab,ti OR coughing:ab,ti OR coughs:ab,ti OR 'bronchitis'/de OR 'chronic bronchitis'/exp 
OR 'laryngotracheobronchitis'/exp OR 'tracheobronchitis'/exp OR bronchitis:ab,ti OR bronchitic:ab,ti 
#2. 'metoclopramide'/exp OR metoclopramide:ab,ti OR metaclopramide:ab,ti OR metoclopromide:ab,ti OR 
maxolon:ab,ti OR primperan:ab,ti OR reglan:ab,ti OR cerucal:ab,ti 
#3. 'domperidone'/exp OR domperidone:ab,ti OR domperidon:ab,ti OR motilium:ab,ti 
#4. 'macrolide'/de OR 'erythromycin'/exp OR 'mitemcinal'/exp OR 'erythromycin derivative'/exp OR 
'azithromycin'/exp OR 'clarithromycin'/exp OR 'telithromycin'/exp OR 'roxithromycin'/exp OR 'troleandomycin'/exp 
OR macrolides:ab,ti OR macrolide:ab,ti OR erythromycin:ab,ti OR monomycin:ab,ti OR mitemcinal:ab,ti OR 
azithromycin:ab,ti OR azythromycin:ab,ti OR zithromax:ab,ti OR sumamed:ab,ti OR clarithromycin:ab,ti OR 
biaxin:ab,ti OR ketolides:ab,ti OR roxithromycin:ab,ti OR rulide:ab,ti OR rulid:ab,ti OR troleandomycin:ab,ti OR 
triacetyloleandomycin:ab,ti OR telithromycin:ab,ti OR ketek:ab,ti 
#5. #2 OR #3 OR #4 
#6. #1 AND #5 
#7. 'crossover procedure'/exp OR 'double blind procedure'/exp OR 'randomized controlled trial'/exp OR 'single blind 
procedure'/exp OR random* OR factorial* OR crossover* OR 'cross over' OR 'cross-over' OR placebo* OR (doubl* 
AND blind*) OR (singl* AND blind*) OR assign* OR allocat* OR volunteer* 





























































#8. #6 AND #7 
Cochrane library
#1. MeSH descriptor: [Cough] explode all trees 
#2. cough:ti,ab,kw (Word variations have been searched) 
#3. MeSH descriptor: [Bronchitis] this term only 
#4. MeSH descriptor: [Bronchitis, Chronic] explode all trees 
#5. bronchitis:ti,ab,kw (Word variations have been searched) 
#6. #1 OR #2 OR #3 OR #4 OR #5 
#7. MeSH descriptor: [Metoclopramide] explode all trees 
#8. Metoclopramide or Metaclopramide or Metoclopromide or Maxolon or Primperan or Reglan or Cerucal:ti,ab,kw 
(Word variations have been searched) 
#9. MeSH descriptor: [Domperidone] explode all trees 
#10. Domperidone or Domperidon or Motilium:ti,ab,kw (Word variations have been searched) 
#11. MeSH descriptor: [Baclofen] explode all trees 
#12. Baclofen or Baclophen:ti,ab,kw (Word variations have been searched) 
#13. MeSH descriptor: [Macrolides] this term only 
#14. MeSH descriptor: [Erythromycin] explode all trees 
#15. MeSH descriptor: [Troleandomycin] explode all trees 
#16. Macrolides or Macrolide or Erythromycin or Monomycin or Mitemcinal or Azithromycin or Azythromycin or 
Zithromax or Sumamed or Clarithromycin or Biaxin or Ketolides or Roxithromycin or Rulide or Rulid or 
Troleandomycin or Triacetyloleandomycin or Telithromycin or Ketek:ti,ab,kw (Word variations have been 
searched) 
#17. #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 
#18. #6 and #17 
#19. #18 in Trials 
Question 6: Which cough neuromodulatory agents (pregabalin, gabapentin, tricyclics, and opiates) should be 
used to treat patients with chronic cough?
Last search: June 2018






























































#1. ((("Cough"[Mesh]) OR (cough[TIAB] OR coughing[TIAB] OR coughs[TIAB])) OR 
(("Bronchitis"[Mesh:NoExp]) OR "Bronchitis, Chronic"[Mesh])) OR (bronchitis[TIAB] OR bronchitic[TIAB]) 
#2. "Pregabalin"[Mesh] OR Pregabalin[TIAB] OR Lyrica[TIAB] 
#3. "gabapentin" [Supplementary Concept] OR Gabapentin[TIAB] OR Neurontin[TIAB] 
#4. "Antidepressive Agents, Tricyclic"[Mesh] OR (tricyclic[TIAB] AND (antidepressant[TIAB] OR 
antidepressants[TIAB] OR antidepressive[TIAB])) OR "Amitriptyline"[Mesh] OR Amitriptyline[TIAB] OR 
Amitriptylin[TIAB] OR Amitriptiline[TIAB] OR Amitriptilin[TIAB] OR Elavil[TIAB] OR "Clomipramine"[Mesh] 
OR Clomipramine[TIAB] OR Chlomipramine[TIAB] OR Chlorimipramine[TIAB] OR Anafranil[TIAB] OR 
Cyclobenzaprine[TIAB] OR Flexeril[TIAB] OR "Desipramine"[Mesh] OR Desipramine[TIAB] OR 
Desmethylimipramine[TIAB] OR Demethylimipramine[TIAB] OR Norpramin[TIAB] OR Pertofrane[TIAB] OR 
Desmethyldoxepin[TIAB] OR Dibenzepin[TIAB] OR Noveril[TIAB] OR "Dothiepin"[Mesh] OR Dothiepin[TIAB] 
OR Dosulepin[TIAB] OR Prothiaden[TIAB] OR "Doxepin"[Mesh] OR Doxepin[TIAB] OR Sinequan[TIAB] OR 
"Imipramine"[Mesh] OR Imipramine[TIAB] OR Melipramine[TIAB] OR Tofranil[TIAB] OR "Iprindole"[Mesh] 
OR Iprindole[TIAB] OR "Lofepramine"[Mesh] OR Lofepramine[TIAB]  OR Melitracene[TIAB] OR 
Metapramine[TIAB] OR Mirtazapine[TIAB] OR Remeron[TIAB] OR "Nortriptyline"[Mesh] OR 
Nortriptyline[TIAB] OR Nortriptylin[TIAB] OR Nortriptiline[TIAB] OR Nortriptilin[TIAB] OR Aventyl[TIAB] 
OR Sensival[TIAB] OR Noxiptilin[TIAB] OR "Opipramol"[Mesh] OR Opipramol[TIAB] OR insidon[TIAB] OR 
"Protriptyline"[Mesh] OR Protriptyline[TIAB] OR Tianeptine[TIAB] OR "Trimipramine"[Mesh] OR 
Trimipramine[TIAB] OR Surmontil[TIAB] 
#5. "Analgesics, Opioid"[Mesh] OR "Opium"[Mesh] OR "Opiate Alkaloids"[Mesh:NoExp] OR opioid[TIAB] OR 
opioids[TIAB] OR opium[TIAB] OR opiate[TIAB] OR opiates[TIAB] OR "Morphine"[Mesh] OR 
Morphine[TIAB] OR morphia[TIAB] OR "Codeine"[Mesh] OR codeine[TIAB] OR "pholcodine" [Supplementary 
Concept] OR pholcodine[TIAB] 
#6. #2 OR #3 OR #4 OR #5 
#7. #1 AND #6 
#8. (groups[tiab] OR trial[TIAB] OR randomly[TIAB] OR "drug therapy"[SH] OR placebo[TIAB] OR 
randomized[TIAB] OR "controlled clinical trial"[PT] OR "randomized controlled trial"[PT]) NOT (animals[MH] 
NOT (humans[MH] AND animals[MH])) 
#9. #7 AND #8 
Embase
#1. 'coughing'/exp OR cough:ab,ti OR coughing:ab,ti OR coughs:ab,ti OR 'bronchitis'/de OR 'chronic bronchitis'/exp 
OR 'laryngotracheobronchitis'/exp OR 'tracheobronchitis'/exp OR bronchitis:ab,ti OR bronchitic:ab,ti 
#2. 'pregabalin'/exp OR pregabalin:ab,ti OR lyrica:ab,ti 
#3. 'gabapentin'/exp OR gabapentin:ab,ti OR neurontin:ab,ti 
#4. 'tricyclic antidepressant agent'/exp OR (tricyclic:ab,ti AND (antidepressant:ab,ti OR antidepressants:ab,ti OR 
antidepressive:ab,ti)) OR amitriptyline:ab,ti OR amitriptylin:ab,ti OR amitriptiline:ab,ti OR amitriptilin:ab,ti OR 
elavil:ab,ti OR clomipramine:ab,ti OR chlomipramine:ab,ti OR chlorimipramine:ab,ti OR anafranil:ab,ti OR 
cyclobenzaprine:ab,ti OR flexeril:ab,ti OR desipramine:ab,ti OR desmethylimipramine:ab,ti OR 
demethylimipramine:ab,ti OR norpramin:ab,ti OR pertofrane:ab,ti OR desmethyldoxepin:ab,ti OR dibenzepin:ab,ti 





























































OR noveril:ab,ti OR dothiepin:ab,ti OR dosulepin:ab,ti OR prothiaden:ab,ti OR doxepin:ab,ti OR sinequan:ab,ti OR 
imipramine:ab,ti OR melipramine:ab,ti OR tofranil:ab,ti OR iprindole:ab,ti OR lofepramine:ab,ti OR 
melitracene:ab,ti OR metapramine:ab,ti OR mirtazapine:ab,ti OR remeron:ab,ti OR nortriptyline:ab,ti OR 
nortriptylin:ab,ti OR nortriptiline:ab,ti OR nortriptilin:ab,ti OR aventyl:ab,ti OR sensival:ab,ti OR noxiptilin:ab,ti 
OR opipramol:ab,ti OR insidon:ab,ti OR protriptyline:ab,ti OR tianeptine:ab,ti OR trimipramine:ab,ti OR 
surmontil:ab,ti 
#5. 'opiate'/exp OR 'opiate agonist'/de OR 'codeine'/exp OR 'morphine'/exp OR 'pholcodine'/exp OR opioid:ab,ti OR 
opioids:ab,ti OR opium:ab,ti OR opiate:ab,ti OR opiates:ab,ti OR morphine:ab,ti OR morphia:ab,ti OR codeine:ab,ti 
OR pholcodine:ab,ti 
#6. #2 or #3 or #4 or #5 
#7. #1 AND #6 
#8. 'crossover procedure'/exp OR 'double blind procedure'/exp OR 'randomized controlled trial'/exp OR 'single blind 
procedure'/exp OR random* OR factorial* OR crossover* OR 'cross over' OR 'cross-over' OR placebo* OR (doubl* 
AND blind*) OR (singl* AND blind*) OR assign* OR allocat* OR volunteer* 
#9. #7 AND #8 
Cochrane library
#1. MeSH descriptor: [Cough] explode all trees 
#2. cough:ti,ab,kw (Word variations have been searched) 
#3. MeSH descriptor: [Bronchitis] this term only 
#4. MeSH descriptor: [Bronchitis, Chronic] explode all trees 
#5. bronchitis:ti,ab,kw (Word variations have been searched) 
#6. #1 OR #2 OR #3 OR #4 OR #5 
#7. MeSH descriptor: [Pregabalin] explode all trees 
#8. MeSH descriptor: [Antidepressive Agents, Tricyclic] explode all trees 
#9. MeSH descriptor: [Amitriptyline] explode all trees 
#10. MeSH descriptor: [Clomipramine] explode all trees 
#11. MeSH descriptor: [Desipramine] explode all trees 
#12. MeSH descriptor: [Dothiepin] explode all trees 
#13. MeSH descriptor: [Doxepin] explode all trees 
#14. MeSH descriptor: [Imipramine] explode all trees 
#15. MeSH descriptor: [Iprindole] explode all trees 
#16. MeSH descriptor: [Lofepramine] explode all trees 
#17. MeSH descriptor: [Nortriptyline] explode all trees 
#18. MeSH descriptor: [Opipramol] explode all trees 





























































#19. MeSH descriptor: [Protriptyline] explode all trees 
#20. MeSH descriptor: [Trimipramine] explode all trees 
#21. MeSH descriptor: [Analgesics, Opioid] explode all trees 
#22. MeSH descriptor: [Opium] explode all trees 
#23. MeSH descriptor: [Opiate Alkaloids] this term only 
#24. MeSH descriptor: [Morphine] explode all trees 
#25. MeSH descriptor: [Codeine] explode all trees 
#26. pregabalin or lyrica:ti,ab,kw (Word variations have been searched) 
#27. gabapentin or neurontin:ti,ab,kw (Word variations have been searched) 
#28. (tricyclic and (antidepressant or antidepressants or antidepressive)) or Amitriptyline or Amitriptylin or 
Amitriptiline or Amitriptilin or Elavil or Clomipramine or Chlomipramine or Chlorimipramine or Anafranil or 
Cyclobenzaprine or Flexeril or Desipramine or Desmethylimipramine or Demethylimipramine or Norpramin or 
Pertofrane or Desmethyldoxepin or Dibenzepin or Noveril or Dothiepin or Dosulepin or Prothiaden or Doxepin or 
Sinequan or Imipramine or Melipramine or Tofranil or Iprindole or Lofepramine or Melitracene or Metapramine or 
Mirtazapine or Remeron or Nortriptyline or Nortriptylin or Nortriptiline or Nortriptilin or Aventyl or Sensival or 
Noxiptilin or Opipramol or insidon or Protriptyline or Tianeptine or Trimipramine or Surmontil:ti,ab,kw (Word 
variations have been searched) 
#29. opioid or opioids or opium or opiate or opiates or Morphine or morphia or codeine or pholcodine:ti,ab,kw 
(Word variations have been searched) 
#30. #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or 
#23 or #24 or #25 or #26 or #27 or #28 or #29 
#32. #6 and #30 
#33. #32 in Trials 
Question 7: Should non-pharmacological therapy (cough control therapy) be used to treat patients with chronic 
cough?
Last search: June 2018
Pubmed MEDLINE
#1. ((("Cough"[Mesh]) OR (cough[TIAB] OR coughing[TIAB] OR coughs[TIAB])) OR 
(("Bronchitis"[Mesh:NoExp]) OR "Bronchitis, Chronic"[Mesh])) OR (bronchitis[TIAB] OR bronchitic[TIAB]) 
#2. "Rehabilitation of Speech and Language Disorders"[Mesh] OR "Speech-Language Pathology"[Mesh] OR 
"Physical Therapy Modalities"[Mesh] OR (“speech pathology”[TIAB] OR “speech therapy”[TIAB] OR “speech 
therapist”[TIAB] OR “speech pathologist”[TIAB] OR “speech rehabilitation”[TIAB] OR “speech disorder”[TIAB] 
OR “language pathology”[TIAB] OR “language therapy”[TIAB] OR “language therapist”[TIAB] OR “language 
pathologist”[TIAB] OR “language rehabilitation”[TIAB] OR physiotherapy[TIAB] OR physiotherapist[TIAB] OR 
“physical therapy”[TIAB] OR “physical therapist”[TIAB] OR neurophysiotherapy[TIAB] OR 
neurophysiotherapist[TIAB]) 





























































#3. #1 AND #2 
#4. (groups[tiab] OR trial[TIAB] OR randomly[TIAB] OR "drug therapy"[SH] OR placebo[TIAB] OR 
randomized[TIAB] OR "controlled clinical trial"[PT] OR "randomized controlled trial"[PT]) NOT (animals[MH] 
NOT (humans[MH] AND animals[MH])) 
#5. #3 AND #4 
Embase
#1. 'coughing'/exp OR cough:ab,ti OR coughing:ab,ti OR coughs:ab,ti OR 'bronchitis'/de OR 'chronic bronchitis'/exp 
OR 'laryngotracheobronchitis'/exp OR 'tracheobronchitis'/exp OR bronchitis:ab,ti OR bronchitic:ab,ti 
#2. 'speech and language rehabilitation'/exp OR 'speech language pathologist'/exp OR 'speech disorder'/exp OR 
'physiotherapy'/exp OR ‘speech pathology’:ab,ti OR ‘speech therapy’:ab,ti OR ‘speech therapist’:ab,ti OR ‘speech 
pathologist’:ab,ti OR ‘speech rehabilitation’:ab,ti OR ‘speech disorder’:ab,ti OR ‘language pathology’:ab,ti OR 
‘language therapy’:ab,ti OR ‘language therapist’:ab,ti OR ‘language pathologist’:ab,ti OR ‘language 
rehabilitation’:ab,ti OR physiotherapy:ab,ti OR physiotherapist:ab,ti OR ‘physical therapy’:ab,ti OR ‘physical 
therapist’:ab,ti OR neurophysiotherapy:ab,ti OR neurophysiotherapist:ab,ti 
#3. #1 AND #2 
#4. 'crossover procedure'/exp OR 'double blind procedure'/exp OR 'randomized controlled trial'/exp OR 'single blind 
procedure'/exp OR random* OR factorial* OR crossover* OR 'cross over' OR 'cross-over' OR placebo* OR (doubl* 
AND blind*) OR (singl* AND blind*) OR assign* OR allocat* OR volunteer* 
#5. #3 AND #4 
Cochrane library
#1. MeSH descriptor: [Cough] explode all trees 
#2. cough:ti,ab,kw (Word variations have been searched) 
#3. MeSH descriptor: [Bronchitis] this term only 
#4. MeSH descriptor: [Bronchitis, Chronic] explode all trees 
#5. bronchitis:ti,ab,kw (Word variations have been searched) 
#6. #1 OR #2 OR #3 OR #4 OR #5 
#7. MeSH descriptor: [Rehabilitation of Speech and Language Disorders] explode all trees 
#8. MeSH descriptor: [Speech-Language Pathology] explode all trees 
#9. MeSH descriptor: [Physical Therapy Modalities] explode all trees 
#10. "speech pathology" or "speech therapy" or "speech therapist" or "speech pathologist" or "speech rehabilitation" 
or "speech disorder" or "language pathology" or "language therapy" or "language therapist" or "language 
pathologist" or "language rehabilitation" or physiotherapy or physiotherapist or "physical therapy" or "physical 
therapist" or neurophysiotherapy or neurophysiotherapist:ti,ab,kw (Word variations have been searched) 
#11. #7 OR #8 OR #9 OR #10 





























































#12. #6 AND #11 
#13. #12 in Trials 
Question 8: Should a trial of antibiotics be used in children with chronic wet cough without warning signs, 
normal chest x ray and, normal spirometry and no warning signs?
Last search: June 2018
Pubmed MEDLINE
#1. ((("Cough"[Mesh]) OR (cough[TIAB] OR coughing[TIAB] OR coughs[TIAB])) OR 
(("Bronchitis"[Mesh:NoExp]) OR "Bronchitis, Chronic"[Mesh])) OR (bronchitis[TIAB] OR bronchitic[TIAB]) 
#2. "Amoxicillin"[Mesh] OR "Clavulanic Acids"[Mesh] OR "Erythromycin"[Mesh:NoExp] OR 
"Clarithromycin"[Mesh] 
#3. amoxicillin[TIAb] OR amoxycillin[TIAB] OR clavulanate[TIAB] OR “clavulanic acids”[TIAB] OR “clavulanic 
acid”[TIAB] OR augmentin[TIAB] OR co-amoxiclav[TIAB] OR coamoxiclav[TIAB] OR erythromycin[TIAB] OR 
clarithromycin[TIAB] 
#4. #2 OR #3 
#5. #1 AND #4 
#6. (groups[tiab] OR trial[TIAB] OR randomly[TIAB] OR "drug therapy"[SH] OR placebo[TIAB] OR 
randomized[TIAB] OR "controlled clinical trial"[PT] OR "randomized controlled trial"[PT]) NOT (animals[MH] 
NOT (humans[MH] AND animals[MH])) 
#7. #5 AND #6 
Embase
#1. 'coughing'/exp OR cough:ab,ti OR coughing:ab,ti OR coughs:ab,ti OR 'bronchitis'/de OR 'chronic bronchitis'/exp 
OR 'laryngotracheobronchitis'/exp OR 'tracheobronchitis'/exp OR bronchitis:ab,ti OR bronchitic:ab,ti 
#2. 'amoxicillin'/exp OR 'clavulanic acid'/exp OR 'amoxicillin plus clavulanic acid'/exp OR 'erythromycin'/exp OR 
'clarithromycin'/exp 
#3. amoxicillin:ab,ti OR amoxycillin:ab,ti OR clavulanate:ab,ti OR 'clavulanic acids':ab,ti OR 'clavulanic acid':ab,ti 
OR augmentin:ab,ti OR 'co amoxiclav':ab,ti OR coamoxiclav:ab,ti OR erythromycin:ab,ti OR clarithromycin:ab,ti 
#4. #2 OR #3 
#5. #1 AND #4 
#6. 'crossover procedure'/exp OR 'double blind procedure'/exp OR 'randomized controlled trial'/exp OR 'single blind 
procedure'/exp OR random* OR factorial* OR crossover* OR 'cross over' OR 'cross-over' OR placebo* OR (doubl* 
AND blind*) OR (singl* AND blind*) OR assign* OR allocat* OR volunteer*
#7. #5 AND #6 






























































#1. MeSH descriptor: [Cough] explode all trees 
#2. cough:ti,ab,kw (Word variations have been searched) 
#3. MeSH descriptor: [Bronchitis] this term only 
#4. MeSH descriptor: [Bronchitis, Chronic] explode all trees 
#5. bronchitis:ti,ab,kw (Word variations have been searched) 
#6. #1 OR #2 OR #3 OR #4 OR #5 
#7. MeSH descriptor: [Amoxicillin] explode all trees
#8. MeSH descriptor: [Clavulanic Acids] explode all trees
#15. MeSH descriptor: [Erythromycin] this term only
#16. MeSH descriptor: [Clarithromycin] explode all trees
#22. amoxicillin or amoxycillin or clavulanate or "clavulanic acids" or "clavulanic acid" or augmentin or co-
amoxiclav or coamoxiclav or erythromycin or clarithromycin:ti,ab,kw (Word variations have been searched)
#23. #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22
#24. #6 AND #23 
#25. #24 in Trials 





























































4. PRIMSA flow diagrams
Question 1: Should chest CT be routinely performed on chronic cough patient with normal chest X-ray and 
physical examination?
Last search: June 2018





























































Question 2: Should FeNO/blood eosinophils be used to predict treatment response to corticosteroids/anti-
leukotrienes in chronic cough?
Last search: June 2018





























































Question 3: Should anti-asthmatic drugs (anti-inflammatory or bronchodilator drugs) be used to treat patients 
with chronic cough?
Last search: June 2018





























































Question 4: Should anti-acid drugs (PPIs and H2 antagonists) be used to treat patients with chronic cough?
Last search: June 2018





























































Question 5: Should drugs with pro-motility activity (reflux inhibitors, prokinetics and macrolides with pro-
motility activity) be used to treat patients with chronic cough?
Last search: June 2018





























































Question 6: Which cough neuromodulatory agents (pregabalin, gabapentin, tricyclics, and opiates) should be 
used to treat patients with chronic cough?
Last search: June 2018





























































Question 7: Should non-pharmacological therapy (cough control therapy) be used to treat patients with chronic 
cough?
Last search: June 2018





























































Question 8: Should a trial of antibiotics be used in children with chronic wet cough without warning signs, 
normal chest x ray and, normal spirometry and no warning signs?
Last search: June 2018





























































5. Evidence GRADE profiles
Question 1: Should chest CT be routinely performed on chronic cough patient with normal chest X-ray and physical examination?












4 1,2,3,4 Observational serious a serious b serious c serious d none Prospective study: 
- Kastelik 2005: 3 out of 46 (6.5%) CT findings despite normal 
chest X-rays (specific findings were not described; causal 
relationship of each finding was not specified)
Retrospective studies: 
- McGarvey 1998: 20 out of 34 (58%) CT findings despite normal 
chest X-rays (specific findings were not described; causal 
relationship of each finding was not specified)
- Barnes 2004: 9 out of 21 (43%) CT findings despite normal chest 
X-rays (none were likely to explain cough)
- Truba 2018: 21 out of 59 (36%) CT findings despite normal chest 





CI: Confidence interval; MD: Mean difference; RR: Risk ratio; HR: Hazard Ratio
Explanations
a. In most of studies CT scan was only performed in a subgroup of patients (about half of them)
b. Rate of positive findings varied broadly (from 6.5% to 58%)
c. Diagnostic yield / diagnostic accuracy are indirect findings of the effectiveness of CT scan on patients' important outcomes
d. Specific findings o causal relationship not described or not likely to explain the cough, the impact on final patient management and outcomes in comparison to not 
performing CT is not known.
References
1. Kastelik JA, Aziz I, Ojoo JC, Thompson RH, Redington AE, Morice AH. Investigation and management of chronic cough using a probability-based algorithm. Eur Respir J. 
2005 Feb;25(2):235-43.
2. Barnes TW, Afessa B, Swanson KL, Lim KG. The clinical utility of flexible bronchoscopy in the evaluation of chronic cough. Chest. 2004 Jul;126(1):268-72.
3. Truba O, Rybka A, Klimowicz K, Grabczak EM, Żukowska M, Dąbrowska M, Krenke R. Is a normal chest radiograph sufficient to exclude pulmonary abnormalities 
potentially associated with chronic cough? Adv Respir Med. 2018;86(3).
4. McGarvey LP, Heaney LG, Lawson JT, Johnston BT, Scally CM, Ennis M, Shepherd DR, MacMahon J. Evaluation and outcome of patients with chronic non-productive 
cough using a comprehensive diagnostic protocol. Thorax. 1998 Sep;53(9):738-43.





























































Question 2: Should FeNO/blood eosinophils be used to predict treatment response to corticosteroids/anti-leukotrienes in chronic cough?
Summary of finding table including GRADE assessment (GRADE Evidence Profile) - ANTI-LEUKOTRIENES

















Cough frequency: 24-hours cough count at 2 weeks




not serious not serious serious b none 24-hours cough count at 2 weeks decreased in both groups (low and high FeNO at 
baseline) without differences between them:




Cough frequency: 24-hours cough count at 4 weeks




not serious not serious serious b none 24-hours cough count at 4 weeks decreased in both groups (low and high FeNO at 
baseline) without differences between them:

































































Quality of life specific questionnaires – LCQ (Leicester Cough Questionnaire). Range 3 to 21 points; higher scores indicate better quality of life. MID is estimated to be 1.3 points; Follow up: 2 weeks
1 1 randomised 
trials 
serious a not serious not serious serious b none LCQ score at 2 weeks improved in both groups (low and high FeNO at baseline) without differences 
between them:




Quality of life specific questionnaires – LCQ (Leicester Cough Questionnaire). Range 3 to 21 points; higher scores indicate better quality of life. MID is estimated to be 1.3 points; Follow up: 4 weeks
1 1 randomised 
trials 
serious a not serious not serious serious b none LCQ score at 4 weeks improved in both groups (low and high FeNO at baseline) without differences 
between them:






a. Patients with low FeNO levels (<20ppb) received montelukast 10 mg (28 days); patients with high FeNO levels (>30ppb) were randomised to receive prednisolone+montelukast or 
montelukast 10 mg (28 days). Only patients receiving montelukast were considered in the analysis, thus one arm was not randomised. Baseline characteristics were not similar 
between groups (higher percentage of females in low FeNO levels) 
b. Very limited sample size, wide 95%CI making difficult to detect subgroup differences. 
References
1. Sadeghi MH, Wright CE,Hart S,Crooks M,Morice A.. Phenotyping patients with chronic cough: evaluating the ability to predict the response to anti-inflammatory therapy.. 
Ann Allergy Asthma Immunol; 2018. 





























































Question 2: Should FeNO/blood eosinophils be used to predict treatment response to corticosteroids/anti-leukotrienes in chronic cough?
Summary of finding table including GRADE assessment (GRADE Evidence Profile) - CORTICOSTEROIDS















FeNO levels (follow up: range 4 weeks to 24 weeks; assessed with: difference between responders and non responders)




not serious a very serious 
b,c
serious d none 113 86 - MD 23.31 ppb fewer




CI: Confidence interval; MD: Mean difference
Explanations
a. Although the analysis shows significant variability among effect estimates one study (Prieto 2009) contributes to most of the heterogeneity. This study assessed treatment 
response using he most objective score (>50% reduction in daily cough symptom score) 
b. Studies show considerable heterogeneity in definition of 'high' versus 'low' FeNO (thresholds range from 16.3 to 38.0 ppb); ICS prescribing criteria, dose, and duration; and 
definition of treatment response
c. Indirect measure for predictive value of FeNO
d. Lower 95%CI (-7.27 ppb) probably does not allow discriminate populations and is not clinically meaningful. 
References
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2. Prieto L, Ferrer A,Ponce S,Palop J,Marin J.. Exhaled nitric oxide measurement is not useful for predicting the response to inhaled corticosteroids in subjects with chronic cough. 
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Question 3: Should anti-asthmatic drugs (anti-inflammatory or bronchodilator drugs) be used to treat patients with chronic cough?
Summary of finding table including GRADE assessment (GRADE Evidence Profile) - LTRA













Cough severity and frequency 'combined': mean change at 2 weeks in cough score from baseline (patient completed score: 0 [no cough] - 10 [cough as bad as it has ever been1 or as bad as at the first 
visit2])




serious b serious c very serious d none 16 27 - MD 3.10 lower




Cough frequency (number of coughs/day): mean change at 1 week of daily cough frequency from baseline; assessed with: recorded objectively with an audio cough meter. 
1 3 randomised 
trials 
not serious not serious not serious very serious d none 6 8 - MD 29.63 lower




Cough frequency (number of coughs/day): mean change at 4 week of daily cough frequency from baseline; assessed with: recorded objectively with an audio cough meter.
1 3 randomised 
trials 
not serious not serious not serious serious e none 6 8 - MD 144.06 lower




Improvement in quality of life (not further specified)
1 3 randomised 
trials 






547 more per 1.000




Any adverse events: (any adverse or unusual experiences) documented by patients on a diary card at each visit (0.97 to 7.23)
1 3 randomised 
trials 







CI: confidence interval; CVA: cough-variant asthma; LTRA: leukotriene receptor antagonist; MD: mean difference; RD: risk difference; RR: risk ratio.
Explanations
a. Very high risk of selection bias and probably lack of blinding in one study. 
b. Confidence intervals show only minimal overlap and high I² (i.e., the proportion of the variation in point estimates due to ‘among-study differences’ 
is large). 
c. Regarding the population of interest, the study population also includes patients with CVA and chronic atopic cough. 
d. Low number of patients and  95% CI consistent with the possibility for benefit and the possibility of harm (dichotomous outcome) 
e. Very low number of patients 
f. Low number of patients and no events in both groups.
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Summary of finding table including GRADE assessment (GRADE Evidence Profile) – BRONCHODILATORS, ADULT POPULATION













Cough severity: mean cough score at 52 weeks (patient completed daily score: 0 [no cough] - 3 [severe cough], recording of the previous 24 h before visit at week 52)
1 1 randomised 
trials 
not serious not serious not serious serious a none 361 372 - MD 0.08 lower




Day-time cough severity: at 3 weeks; assessed with different scales. Rules of thumb exist for interpreting SMDs: 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect
2 2,3 randomised 
trials 
not serious serious b not serious serious a none 43 43 - SMD 1.63 lower




Night-time cough severity: at 3 weeks; assessed with different scales. Rules of thumb exist for interpreting SMDs: 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect
2 2,3 randomised 
trials 
not serious serious b not serious serious a none 43 43 - SMD 0.98 lower




Generic Quality of life questionnaires - St. George's Respiratory Questionnaire (SGRQ). At 52 weeks. Scores range from 0 to 100, with higher scores indicating more limitations. MID: Based on empirical data 
and interviews with patients, a mean change score of 4 units is associated with slightly efficacious treatment, 8 units for moderately efficacious change and 12 units for very efficacious treatment
1 1 randomised 
trials 
not serious not serious not serious serious a none 361 372 - MD 2.70 lower




Night interruptions: mean change from baseline
1 1 randomised 
trials 
not serious not serious not serious serious a none 361 372 - MD 0.07 less




Skin bruises: number of bruises on the volar side of the forearm with a diameter >5 cm
1 1 randomised 
trials 






7 Fewer per 1.000




Any adverse events: (treatment related adverse events) (0.97 to 7.23)
1 1 randomised 
trials 






12 Fewer per 1.000




CI: confidence interval; MD: mean difference; SMD: standardized mean difference; RR: risk ratio.
Explanations





























































a. 95% CI was consistent with the possibility of improving and the possibility of worsening symptoms or no effect (continuous outcome). 
b. Confidence intervals show no overlap and high I² (i.e., the proportion of the variation in point estimates due to ‘among-study differences’ is large).
References
4. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a 
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5. Ellul-Micallef R. Effect of terbutaline sulphate in chronic "allergic" cough. British medical journal (Clinical research ed). 1983;287(6397):940-943.
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infection. Respiratory medicine. 1992;86(5):425-29





























































Summary of finding table including GRADE assessment (GRADE Evidence Profile) – BRONCHODILATORS, CHILDREN POPULATION













Cough severity – parent assessment: at 5-7days of treatment; assessed with VAS; Range 0 to 10 points; higher scores indicate better higher severity.
1 1 randomised 
trials 
not serious not serious not serious very serious a none 22 21 - MD 0.4 lower




Cough severity – parent assessment: at 5-7days of treatment; assessed with VAS; Range 0 to 10 points; higher scores indicate better higher severity.
1 1 randomised 
trials 
not serious not serious not serious very serious a none 22 21 - MD 0.3 higher




Response to treatment ("treatment success") defined as a ≥70% reduction in cough frequency at 5-7-days.
1 1 randomised 
trials 






36 Fewer per 1.000




CI: confidence interval; MD: mean difference; RR: risk ratio.
Explanations
a. Confidence intervals show no overlap and high I² (i.e., the proportion of the variation in point estimates due to ‘among-study differences’ is large).
References
1. Chang AB, Phelan PD, Carlin JB, Sawyer SM, Robertson CF. A randomised, placebo controlled trial of inhaled salbutamol and beclomethasone 
for recurrent cough. Archives of disease in childhood. 1998;79(1):6-11.





























































Summary of finding table including GRADE assessment (GRADE Evidence Profile) – ICS, Adults













Cough severity at 2 weeks– patient with chronic cough; assessed with VAS; Range 0 to 100 points; higher scores indicate better higher severity.
2 5,6 randomised 
trials 
not serious not serious not serious serious d none 111 109 - MD 8.42 lower




Cough frequency at 2 weeks– patient with chronic cough; assessed with patient completed score: 0 [no cough] - 4 [constant cough].
1 2 randomised 
trials 
serious a not serious not serious serious f none 20 44 - MD 1 lower




Cough severity – patient with chronic cough: mean cough symptom score up to 8 weeks. Assessed with: different scales. Rules of thumb exist for interpreting SMDs: 0.2 represents a small effect, 0.5 a 
moderate effect, and 0.8 a large effect.
3 1,2,3 randomised 
trials 
serious a serious b serious c serious d none 104 128 - SMD 0.28 lower




Cough severity – patient with chronic bronchitis: mean change in daily cough score (patient completed) from baseline (at 12 weeks): 0 (none), 1 (few coughs every day), 2 (repeated cough attacks, but only in 
the morning or during the day), 3 (persistent cough attacks during the night and day)
1 4 randomised 
trials 
not serious not serious serious e very serious f none 18 18 - MD 0.03 lower




Night interruptions– patient with chronic cough: mean change from baseline
1 2 randomised 
trials 
serious a not serious not serious very serious f none 20 44 - MD 0.31 less




Any adverse events– patient with chronic cough (0.97 to 7.23)
3 2,3,6 randomised 
trials 






27 more per 1.000




Any adverse events– patient with chronic bronchitis (0.97 to 7.23)














Major adverse events– patient with chronic cough (0.97 to 7.23)










































































2 2,3 randomised 
trials 






11 fewer per 1.000




CI: confidence interval; ICS: inhaled corticosteroids; SMD: standardized mean difference; MD: mean difference; RD: risk difference; 
RR: risk ratio.
Explanations
a. High risk of selective reporting. 
b. High I² (i.e., the proportion of the variation in point estimates due to ‘among-study differences’ is large, I² >50%).
c. Patients with airway symptoms suggestive of asthma, without fulfilling the functional criteria of asthma included.
d. 95% CI was consistent with the possibility of improving and the possibility of worsening symptoms or no effect. 
e. All patients in the study were smokers with bronchitis.
f. Small number of patients; 95% CI was consistent with the possibility of improving and the possibility of worsening symptoms or no effect.
g. Very high risk of selection bias.
h. Small number of patients and events; 95% CI was consistent with the possibility of large benefit or large harm.
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Summary of finding table including GRADE assessment (GRADE Evidence Profile) – ICS, COPD POPULATION













Cough severity: mean cough score at 52 weeks (patient completed daily score: 0 [no cough] - 3 [severe cough], recording of the previous 24 h before visit at week 52)
1 1 randomised 
trials 
not serious not serious not serious serious a none 361 374 - MD 0.06 lower




Generic Quality of life questionnaires - St. George's Respiratory Questionnaire (SGRQ). At 52 weeks. Scores range from 0 to 100, with higher scores indicating more limitations. MID: Based on empirical data 
and interviews with patients, a mean change score of 4 units is associated with slightly efficacious treatment, 8 units for moderately efficacious change and 12 units for very efficacious treatment
1 1 randomised 
trials 
not serious not serious not serious serious a none 361 374 - MD 3.50 lower




Night interruptions: mean change from baseline
1 1 randomised 
trials 
not serious not serious not serious serious a none 361 374 - MD 0.56 less




Skin bruises: number of bruises on the volar side of the forearm with a diameter >5 cm
1 1 randomised 
trials 






9 more per 1.000




Response to treatment ('treatment success'): at 24 weeks; defined as: no cough symptoms
1 2 randomised 
trials 






104 more per 1.000




Exacerbations: number of patients with exacerbations up to 52 weeks.
2 1,2 randomised 
trials 






36 fewer per 1.000




Any adverse events: up to 52 weeks (0.97 to 7.23)
2 1,2 randomised 
trials 






32 more per 1.000




CI: confidence interval; MD: mean difference; RR: risk ratio.
Explanations
c. 95% CI was consistent with the possibility of improving and the possibility of worsening symptoms or no effect (continuous outcome). 
d. confidence intervals show only minimal overlap and high I² (i.e., the proportion of the variation in point estimates due to ‘among-study differences’ is large, 
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Summary of finding table including GRADE assessment (GRADE Evidence Profile) – BRONCHODILATORS +ICS















Cough severity: mean cough score at 52 weeks (patient completed daily score: 0 [no cough] - 3 [severe cough], recording of the previous 24 h before visit at week 52)
1 1 randomised 
trials 
not serious not serious serious a serious b none 361 358 - MD 0.09 lower




Generic Quality of life questionnaires - St. George's Respiratory Questionnaire (SGRQ). At 52 weeks. Scores range from 0 to 100, with higher scores indicating more limitations. MID: Based on empirical data 
and interviews with patients, a mean change score of 4 units is associated with slightly efficacious treatment, 8 units for moderately efficacious change and 12 units for very efficacious treatment
1 1 randomised 
trials 
not serious not serious not serious serious a none 361 358 - MD 2.20 lower




Night interruptions: mean change from baseline
1 1 randomised 
trials 
not serious not serious not serious serious a none 361 358 - MD 0.00 less




Skin bruises: number of bruises on the volar side of the forearm with a diameter >5 cm
1 1 randomised 
trials 






20 more per 1.000




Any adverse events: (treatment related adverse events) (0.97 to 7.23)
1 1 randomised 
trials 






27 Fewer per 1.000




CI: confidence interval; MD: mean difference; SMD: standardized mean difference; RR: risk ratio.
Explanations
a. Duration of intervention was 
b. 95% CI was consistent with the possibility of improving and the possibility of worsening symptoms or no effect (continuous outcome). 
References
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randomised controlled trial. Lancet (London, England). 2003;361(9356):449-456.





























































Summary of finding table including GRADE assessment (GRADE Evidence Profile) – ICS, Children














Nocturnal cough frequency: mean change from baseline (objectively recorded) - At nights 15/16
1 1 randomise
d trials 
serious a not serious not serious serious b none 26 24 - MD 60 lower
(85.45 lower to 34.55 lower) 
⨁⨁◯◯
LOW 
Cough severity: mean change from baseline (VAS score averaged over 1 week, at 4-5 weeks) - Parent completed
1 2 randomise
d trials 
serious a not serious not serious serious c none 22 21 - MD 0.6 higher
(0.6 lower to 1.8 higher) 
⨁⨁◯◯
LOW 
Cough severity: mean change from baseline (VAS score averaged over 1 week, at 4-5 weeks) - Child completed
1 2 randomise
d trials 
serious a not serious not serious serious c none 22 21 - MD 0.6 higher
(0.53 lower to 1.73 higher) 
⨁⨁◯◯
LOW 
Response to treatment ('treatment succes') - Defined as a ≥75% reduction in nocturnal cough frequencys (at nights 15/16)
1 1 randomise
d trials 
serious a not serious not serious serious d none 17/26 
(65.4%) 
8/24 (33.3%) RR 1.96
(1.04 to 3.69) 
320 more per 1,000
(from 13 more to 897 more) 
⨁⨁◯◯
LOW 
Response to treatment ('treatment succes') - Defined as a ≥70% reduction in 24 h cough frequency (at 4/5 weeks)
1 2 randomise
d trials 




14/21 (66.7%) RR 0.82
(0.50 to 1.33) 
120 fewer per 1,000




CI: Confidence interval; MD: Mean difference; RR: Risk ratio
Explanations
a. Potential risk of carry-over effect, uncertainties in missinbg data and randomisation. 
b. 95% CI was consistent with the possibility of improving and the possibility of no effect. 
c. 95% CI was consistent with the possibility of worsening symptoms or no effect. 





























































d. Low number of events and patients included 
e. 95%CI was consistent with appreciable benefit or harm 
References
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2. Chang AB, Phelan PD, Carlin JB, Sawyer SM, Robertson CF. A randomised, placebo controlled trial of inhaled salbutamol and beclomethasone for recurrent cough. Arch Dis Child. 1998 
Jul;79(1):6-11.





























































Question 4: Should anti-acid drugs (PPIs and H2 antagonists) be used to treat patients with chronic cough?
Summary of finding table including GRADE assessment (GRADE Evidence Profile) - Adults
















Cough severity (different scales). Rules of thumb exist for interpreting SMDs: 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect
4 1,2,3,4 randomised 
trials 
serious a serious b not serious serious c none 74 63 - SMD 0.63 lower




Cough frequency (different scales). Rules of thumb exist for interpreting SMDs: 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect
2 2,3 randomised 
trials 
serious d not serious not serious serious c none 46 43 - SMD 0.18 lower




Quality of life specific questionnaires (different scales). Rules of thumb exist for interpreting SMDs: 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect
3 2,3,4 randomised 
trials 
serious e not serious not serious serious c none 65 51 - SMD 0.72 SD lower




Tussive response to cough challenge. Assessed with: Citric acid cough challenge
1 2 randomised 
trials 
not serious not serious Serious f serious g none There were no differences between treatment and placebo groups in the 
change from baseline concentration on inhaled citric acid (to trigger 






3 2,3,4 randomised 
trials 
serious e not serious not serious serious h none 3 RCTs reported few adverse events with a similar incidence between 
intervention and placebo group. Faruqi: treatment 4/24 (17%) versus 
placebo 2/25 (8%) respiratory tract infection; Shaheen: no serious 
events/withdrawns in both groups; Park: treatment 2/19 (11%, both from 


































































CI: Confidence interval; SMD: Standardised mean difference
Explanations
a. 3 studies: non-validated subjective outcome measures; 1 study (Kiljander) no description on the number of dropouts according to treatment group or period; 1 study (Park): high 
drop-out rate (30%); 1 study (Park): significant different baseline characteristics and different dropout rates between groups 
b. Heterogeneity: Tau² = 0.41; Chi² = 11.70, df = 3 (P = 0.008); I² = 74% 
c. SMD >0.5 and <0.8 representing a moderate difference 
d. All studies: non-validated subjective outcome measures 
e. 1 study (Park): high drop-out rate (30%); 1 study (Park): significant different baseline characteristics and different dropout rates between groups 
f. Indirect (surrogate) measure of efficacy  
g. single study with small sample size
h. Low number of patients and events 
References
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Randomised clinical trial: high-dose acid suppression for chronic cough - a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011 Jan;33(2):225-34.
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10;12(10):e0185397





























































Summary of finding table including GRADE assessment (GRADE Evidence Profile) - Children
















Daytime cough frequency. Assessed with : episodes/day
1 1 randomised 
trials 
serious a not serious not serious Very serious b none 4 4 - MD 2.70 fewer




Night-time cough frequency. Assessed with : episodes/night
1 1 randomised 
trials 
serious a not serious not serious Very serious b none 4 4 - MD 0.20 fewer














a. non-validated subjective outcome measures; observer bias; unknown number of dropouts in treatment group 
b. small groups (n=4) 
References
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Question 5: Should drugs with pro-motility activity (reflux inhibitors, prokinetics and macrolides with pro-motility activity) be used to treat patients with 
chronic cough?
Summary of finding table including GRADE assessment (GRADE Evidence Profile)














Quality of life specific questionnaires – LCQ (Leicester Cough Questionnaire). Range 3 to 21 points; higher scores indicate better quality of life. MID is estimated to be 1.3 points
3 1,2,3 randomised 
trials 
not serious not serious serious a serious b none 74 77 - MD 1.27 higher




Cough severity (VAS or severity score). Rules of thumb exist for interpreting SMDs: 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect
2 1,3 randomised 
trials 
not serious not serious not serious serious b none 36 36 - SMD 0.42 lower




Cough frequency at 12 weeks (number of coughs/24h)
1 1 randomised 
trials 
not serious not serious c not serious serious d none Mean difference in fold change 1.1 (95% CI 0.7 to 1.5) ⨁⨁⨁◯
MODERATE
CRITICAL 
Capsaicin C2 at 12 weeks
1 randomised 
trials 
not serious not serious d serious e serious d none Mean difference in fold change 0.7 (95% CI 0.4 to 1.3) ⨁⨁◯◯
LOW
IMPORTANT 
Capsaicin C5 at 12 weeks
1 randomised 
trials 
not serious not serious d serious e serious d none Mean difference in fold change 1.3 (95% CI 0.9 to 2.0) ⨁⨁◯◯
LOW
IMPORTANT 
Generic Quality of life questionnaires - St. George's Respiratory Questionnaire (SGRQ). Scores range from 0 to 100, with higher scores indicating more limitations. MID: Based on empirical data and 
interviews with patients, a mean change score of 4 units is associated with slightly efficacious treatment, 8 units for moderately efficacious change and 12 units for very efficacious treatment
1 randomised 
trials 
not serious not serious d serious a serious b none Mean difference in fold change -7.5 (95% CI -12.5 to -2.5) ⨁⨁◯◯
LOW
IMPORTANT 
Adverse events - Gastrointestinal











































































2 2,3 randomised 
trials 





(0.50 to 3.09) 
35 more per 1,000




Adverse events - Respiratory
2 2,3 randomised 
trials 
not serious not serious not serious serious g none 8/58 (13.8%) 13/58 
(22.4%) 
OR 0.56
(0.21 to 1.46) 
85 fewer per 1,000




Adverse events - CNS
1 3 randomised 
trials 
not serious not serious c not serious very serious d none 1/21 (4.8%) 0/21 (0.0%) OR 3.15




Adverse events - Musculoskeletal
1 3 randomised 
trials 
not serious not serious c not serious very serious d none 0/21 (0.0%) 3/21 
(14.3%) 
OR 0.12
(0.01 to 2.54) 
123 fewer per 1,000





Adverse events - Cardiovascular
1 2,3 randomised 
trials 
not serious not serious c not serious very serious d none 2/37 (5.4%) 1/37 (2.7%) OR 2.06
(0.18 to 23.72) 
27 more per 1,000




CI: Confidence interval; MD: Mean difference; SMD: Standardised mean difference; OR: Odds ratio
Explanations
a. Largest study includes patients with COPD and chronic cough 
b. Low number of patients included. 95%CI includes a clinically important / large benefit and meaningless difference.
c. Single study
d. Small study, probably not powered to detect differences. 
e. Indirect measure of efficacy
f. Variability (heterogeneity) among effects estimates
g. Very low number of events, 95%CI indicates large benefit or harm. 
References
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3. Hodgson, D., et al. (2016). "The Effects of Azithromycin in Treatment-Resistant Cough: A Randomized, Double-Blind, Placebo-Controlled Trial." Chest149(4): 1052-1060





























































Question 6: Which cough neuromodulatory agents (pregabalin, gabapentin, tricyclics, and opiates) should be used to treat patients with chronic 
cough?
Summary of finding table including GRADE assessment (GRADE Evidence Profile) - OPIATES











Quality of life specific questionnaires – LCQ (Leicester Cough Questionnaire). Follow-up: 4 weeks. Range 3 to 21 points; higher scores indicate better quality of life. MID is estimated to be 1.3 points
1 1 randomised 
trials 
not serious not serious a not serious serious b none 27 27 - MD 2 higher




Cough severity score. Follow-up: 4 weeks. Range 0 to 9 points; higher scores indicate more severity; assessed with: Diary
1 1 randomised 
trials 
not serious not serious a not serious serious c none 27 27 - MD 1.6 lower




Tussive response to cough challenge. Follow up: 4 weeks; assessed with: Citric acid cough challenge.
1 1 randomised 
trials 
not serious not serious a serious d not serious none 27 27 - MD 93 higher





Adverse event - constipation
1 1 randomised 
trials 
not serious not serious a not serious very serious e none 40% in treatment group (11 patients) ⨁⨁◯◯
LOW
CRITICAL 
Adverse event – drowsiness
1 1 randomised 
trials 
not serious not serious a not serious very serious e none 25% in treatment group (7 patients) ⨁⨁◯◯
LOW
CRITICAL 
CI: Confidence interval; MD: Mean difference
Explanations
a. Single study
b. Low number of patients included. 95%CI includes a clinically important / large benefit and meaningless difference





























































c. Low number of patients included. Lower 95%CI does not exclude a meaningless difference
d. Indirect (surrogate) measure of efficacy  
e. No information on control group. Frequency based on very limited number of patients and events. The expected frequency of this adverse events in no-treatment is zero 
however it is not clear that these figures reflect an accurate measure.
References
1. Morice AH1, Menon MS, Mulrennan SA, Everett CF, Wright C, Jackson J, Thompson R. Opiate therapy in chronic cough. Am J Respir Crit Care Med. 2007 Feb 
15;175(4):312-5.





























































Question 6: Which cough neuromodulatory agents (pregabalin, gabapentin, tricyclics, and opiates) should be used to treat patients with chronic 
cough?
Summary of finding table including GRADE assessment (GRADE Evidence Profile) - GABAPENTIN













Quality of life specific questionnaires – LCQ (Leicester Cough Questionnaire). Follow-up: 8 weeks on treatment. Range 3 to 21 points; higher scores indicate better quality of life. MID is estimated to be 
1.3 points
1 1 randomised 
trials 
not serious not serious a not serious serious b none 32 30 - MD 1.8 higher




Cough frequency at 8 weeks of treatment (number of coughs/h)
1 1 randomised 
trials 
not serious not serious a not serious serious c none 32 30 - MD 27.31 lower




Cough severity at 8 weeks of treatment; assessed with VAS; Range 0 to 100 points; higher scores indicate better higher severity.
1 1 randomised 
trials 
not serious not serious a not serious serious c none 32 30 - MD 12.23 lower




Capsaicin C5 at 8 weeks of treatment
1 1 randomised 
trials 
not serious not serious a serious d serious e none 32 30 - MD 3.12 lower





1 1 randomised 
trials 





(1.46 to 14.07) 
331 more per 1,000




Adverse event - Blurred vision
1 1 randomised 
trials 
not serious not serious not serious very serious f none 1/32 (3.1%) 0/30 (0.0%) OR 2.90




Adverse event - Depression 










































































1 1 randomised 
trials 
not serious not serious not serious very serious f none 0/32 (0.0%) 1/30 (3.3%) OR 0.30
(0.01 to 7.72) 
23 fewer per 1,000




Adverse event - Disorientation 
1 1 randomised 
trials 






Adverse event - Dizziness 
1 1 randomised 
trials 
not serious not serious not serious very serious f none 3/32 (9.4%) 1/30 (3.3%) OR 3.00
(0.29 to 30.56) 
60 more per 1,000




Adverse event - Dry mouth 
1 1 randomised 
trials 
not serious not serious not serious very serious f none 2/32 (6.3%) 1/30 (3.3%) OR 1.93
(0.17 to 22.50) 
29 more per 1,000




Adverse event - Fatigue 
1 1 randomised 
trials 
not serious not serious not serious very serious f none 3/32 (9.4%) 1/30 (3.3%) OR 3.00
(0.29 to 30.56) 
60 more per 1,000




Adverse event - Headache 
1 1 randomised 
trials 
not serious not serious not serious very serious f none 1/32 (3.1%) 0/30 (0.0%) OR 2.90




Adverse event - Memory loss 
1 1 randomised 
trials 
not serious not serious not serious very serious f none 1/32 (3.1%) 0/30 (0.0%) OR 2.90




Adverse event - Nausea, stomach pain 










































































1 1 randomised 
trials 
not serious not serious not serious very serious f none 4/32 (12.5%) 2/30 (6.7%) OR 2.00
(0.34 to 11.82) 
58 more per 1,000




CI: Confidence interval; MD: Mean difference; OR: Odds ratio
Explanations
a. Single study 
b. Low number of patients included. 95%CI includes a clinically important / large benefit and meaningless difference
c. Low number of patients included. Lower 95%CI does not exclude a meaningless difference
d. Indirect (surrogate) measure of efficacy  
e. Low number of patients included. Lower 95%CI includes both benefit or harm
f. Very low number of events.
References
1. Ryan NM1, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012 Nov 3;380(9853):1583-9.





























































Question 6: Which cough neuromodulatory agents (pregabalin, gabapentin, tricyclics, and opiates) should be used to treat patients with chronic 
cough?
Summary of finding table including GRADE assessment (GRADE Evidence Profile) - PREGABALIN

















not serious a not serious b not serious serious c none 20 20 - MD 3.5 higher




Cough frequency at 14 weeks of treatment (number of coughs/h)
1 randomised 
trials 
not serious a not serious b not serious serious d none 20 20 - MD 2.3 lower




Cough severity at 14 weeks of treatment; assessed with VAS; Range 0 to 100 points; higher scores indicate better higher severity.
1 randomised 
trials 
not serious a not serious b not serious serious c none 20 20 - MD 25.1 lower




Capsaicin C5 at 14 weeks of treatment
1 randomised 
trials 
not serious a not serious b serious e serious d none 20 20 - MD 47 lower




Adverse event - Blurred vision 
1 randomised 
trials 





(0.48 to 46.91) 
150 more per 1,000




Adverse event - Cognitive changes 
1 randomised 
trials 





(0.88 to 75.48) 
250 more per 1,000




Adverse event - Dizziness 

















































































(1.73 to 139.65) 
400 more per 1,000




Adverse event - Dry mouth 
1 randomised 
trials 





(0.18 to 25.35) 
50 more per 1,000




Adverse event - Fatigue 
1 randomised 
trials 





(0.33 to 4.73) 
51 more per 1,000




Adverse event - Headache 
1 randomised 
trials 
not serious not serious not serious very serious f none 0/20 (0.0%) 2/20 
(10.0%) 
OR 0.18
(0.01 to 4.01) 
80 fewer per 1,000




Adverse event - Weight gain 
1 randomised 
trials 





(0.67 to 60.16) 
200 more per 1,000




Adverse event - Sleep disturbance 
1 randomised 
trials 
not serious not serious not serious very serious f none 0/20 (0.0%) 2/20 
(10.0%) 
OR 0.18
(0.01 to 4.01) 
80 fewer per 1,000




Adverse event - Gastrointestinal 
1 randomised 
trials 





(0.16 to 2.43) 
100 fewer per 1,000




Adverse event - Respiratory 

















































































(0.18 to 5.67) 
0 fewer per 1,000




Adverse event - Dermatological 
1 randomised 
trials 
not serious not serious not serious very serious f none 1/20 (5.0%) 2/20 
(10.0%) 
OR 0.47
(0.04 to 5.69) 
50 fewer per 1,000




Adverse event - Fluid build-up 
1 randomised 
trials 





(0.18 to 25.35) 
50 more per 1,000




Adverse event - Tight leg and muscle cramp 
1 randomised 
trials 





(0.18 to 25.35) 
50 more per 1,000




CI: Confidence interval; MD: Mean difference; OR: Odds ratio
Explanations
a. No comparison to pregabalin or placebo alone. Mean cough duration is longer in the placebo group (151 months) than in the pregabalin group (94 months). Mean baseline 
LCQ score is higher in the placebo group (12.3) than in the pregabalin group (10.8). 
b. Single study 
c. Low number of patients included. 95%CI includes a clinically important / large benefit and meaningless difference
d. Low number of patients included. Lower 95%CI includes both benefit or harm
e. Indirect (surrogate) measure of efficacy  
f. Very low number of events
Refetrences
1. Vertigan AE, Kapela SL, Ryan NM, Birring SS, McElduff P, Gibson PG. Pregabalin and Speech Pathology Combination Therapy for Refractory Chronic Cough: A Randomized 
Controlled Trial. Chest. 2016 Mar;149(3):639-48.





























































Question 7: Should non-pharmacological therapy (cough control therapy) be used to treat patients with chronic cough?
Summary of finding table including GRADE assessment (GRADE Evidence Profile)















Cough frequency at 4 weeks of treatment (number of coughs/h)




not serious a not serious not serious b none 31 40 - MD 7 less




Cough severity at 4 weeks of treatment (assessed with different scales) Rules of thumb exist for interpreting SMDs: 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect
2 1,2 randomised 
trials 
serious c not serious not serious not serious none 74 84 - SMD 0,61 less




Cough severity at 4 weeks of treatment
2 1,2 randomised 
trials 
serious c not serious not serious not serious none Chamberlain (2017): Mean difference between groups at 4 weeks 
−9.72 (−20.80 to 1.36) P=0.084 (VAS severity). Vertigan (2006): 
Mean difference between groups at 4 weeks 8.5 (95% CI 4.7 to 14.9) 




Capsaicin C2 at 4 weeks of treatment




not serious a serious d not serious none 31 40 - MD 1.11 C2 higher





Quality of life specific questionnaires – LCQ (Leicester Cough Questionnaire). Follow-up: 4 weeks on treatment. Range 3 to 21 points; higher scores indicate better quality of life. MID is estimated to be 1.3 
points
1 1 randomised 
trials 
serious c not serious a not serious serious e none 31 40 - MD 1.53 LCQ points 
higher






















































































not serious a not serious not serious none None observed ⨁⨁⨁⨁
HIGH 
IMPORTANT
Incontinence – not measured
- CRITICAL 
CI: Confidence interval; MD: Mean difference
Explanations
a. Single study
b. Low number of patients included, most probably underpowered to detect differences. 
c. Single blinded study (patients were not aware of the intervention assignment), bias cannot be excluded for subjective outcomes
d. Indirect (surrogate) measure of efficacy  
e. Low number of patients included. 95%CI includes a clinically important / large benefit and meaningless difference
References: 
1. Chamberlain Mitchell, S. A., et al. (2017). "Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: a multicentre randomised 
control trial." Thorax 72(2): 129-136. 
2. Vertigan, A., et al. (2006) Efficacy of speech pathology management for chronic cough: a randomised placebo controlled trial of treatment efficacy. Thorax 61, 1065-1069





























































Question 8: Should a trial of antibiotics be used in children with chronic wet cough without warning signs, normal chest x ray and, normal spirometry 
and no warning signs?


















Cough resolution rate: >75% reduction in cough score after 14 days or cessation of coughing for >3 days within the trial (=treatment) period (assessed with VCD score)









(1.12 to 8.05) 
320 more per 1.000 




Change in cough score (VCD score) after 14 days (VCD cough score from 0 to 5: 0=no cough, 1=cough for one or two short periods only, 2=cough for more than two short periods, 3=frequent coughing but 
does not interfere with school and other activities, 4=frequent coughing which interferes with school and other activities, 5=cannot perform most activities due to severe coughing)




not serious seriousa seriousb none 24c 23c - MD 0.96 lowere




Adverse event: mild diarrhoea











120 more per 1.000








0 fewer per 
1.000 (from 0 
fewer to 0 
fewer)g














20 more per 
1.000 (from 9 





CI: Confidence interval; RR: Risk Ratio; MD: mean difference; VCD: verbal category descriptive cough score. 






























































a. Children in both groups were very young (median 1.9 years), therefore, the study findings don’t apply to the age group which should be addressed according to the ERS; 
additionally, chest x ray was abnormal in 15 out of 42 children; 8 children did not receive a chest x ray; an abnormal chest x ray also raises concerns about indirectness considering 
the PICO provided by the ERS; spirometry was not conducted (according to authors, measurement is not valid in children <6 years). 
b. Low number of included patients and few events. 
c. Outcome addresses change in cough score, which is not a binary outcome; therefore, no event rates can be provided.
d. Change in cough score: in the primary study data were expressed as median and interquartile range (IQR); we calculated the mean change and standard deviation according to 
the methods described in Wan 2014.5 
e. Change is in favour of the antibiotic treatment.
f. 95% CI was consistent with the possibility for benefit and the possibility of harm; additionally, (very) few events in both groups and a low number of included patients. 
g. Due to zero events in the control group, it was not possible to calculate the risk difference with antibiotics.
h. Assumed baseline risk for a low risk population. 
References
1. Marchant J, Masters I, Champion A, Petsky H, Chang A. Randomised controlled trial of amoxycillin clavulanate in children with chronic wet cough.  Thorax 2012:689-93.
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